SVM-light Version V5.01-TK-1.5
5 # kernel type
3 # kernel parameter -d 
1 # kernel parameter -g 
1 # kernel parameter -s 
1 # kernel parameter -r 
empty# kernel parameter -u 
0.4 # kernel parameter -L 
1 # kernel parameter -T 
S # kernel parameter -C 
1 # kernel parameter -F 
0 # kernel parameter -S 
0.400000 # kernel parameter -M 
3 # kernel parameter -N 
S # kernel parameter -V 
S # kernel parameter -W 
0 # kernel parameter -U 
4332 # highest feature index 
510 # number of training documents 
396 # number of support vectors plus 1 
0.93076819 # threshold b, each following line is a SV (starting with alpha*y)
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (BACKGROUND/AIMS)))(: (:))(NP (NP (DT (The))(NN (success))(NN (sorafenib))(NN (treatment)))(VP (VBD (advanced))(SBAR (S (NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(VP (VBD (focused))(NP (NN (interest))(NN (role))(NN (Ras))(NN (signaling))(NN (malignancy)))))))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 52:E02 69:G02.111.087.800 104:C04.557.470.200.025.255  |ES| 10:1 14:1 19:1 31:1 49:1 104:1 195:1 303:1 304:1 441:1 546:1 691:1 997:1 1775:1 2063:1 2302:1 2309:1 2310:1 2311:1  |EV| 
-0.6303064721895168531773379072547  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(NP (NP (NNP (Magnolol))(, (,))(NN (plant))(NN (lignan)))(NP (VBN (isolated))(NN (bark))(NN (seed))(NN (cone))(NN (Magnolia))(NN (officinalis)))(, (,))(VP (VBN (shown))(NP (JJ (chemopreventive))(NN (effect))(JJ (chemically-induced))(NN (skin))(NN (cancer))(NN (development)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 328:B01.650 619:D02.455.426.559.847.117.159.205 620:B01.650.940.800.575.100.680.500 621:D02.455.426.559.389.140.450 622:A08.675.650.850.625.670.100 623:A08.186.211.730.885.287.500 624:D27.505.696.706.018 625:A06.407.071.140 626:A05.810.453.324 627:A18.024.500.750  |ES| 2:1 18:1 19:1 35:1 75:1 104:1 237:1 1046:1 1098:1 1653:1 1946:1 2233:1 2312:1 2313:1 2314:1 2315:1 2316:1 2317:1 2318:1 2319:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP (It)))(ADVP (RB (also)))(VP (VBD (nominated))(NP (NP (JJ (dichloroacetic))(NN (acid)))(VP (VBN (studied))(NP (NP (JJ (representative))(NN (class))(JJ (haloacetic))(NN (acid)))(NP (VBN (shown))(NN (cause))(NN (liver))(NN (tumor))(NN (rat))(NN (mouse)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1062:D01.029 1219:D02.241.081.018.214.500  |ES| 5:1 7:1 19:1 52:1 237:1 401:1 836:1 849:1 1017:1 1275:1 1327:1 1779:1 2814:1 4273:1 4274:1 4275:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (S (NP (NP (NP (JJ (Caffeic))(NN (acid))(NN (phenethyl))(NN (ester)))(PRN (-LRB- (-LRB-))(NP (NN (CAPE)))(-RRB- (-RRB-))))(, (,))(NP (JJ (natural))(NN (component)))(NP (NN (propolis)))(, (,)))(VP (VBP (show))(S (NP (JJ (anticarcinogenic))(NN (property)))(VP (NP (VBN (modified))(JJ (resistant))(NN (hepatocyte))(NN (model)))(S (NP (VBN (administered))(NN (initiation))(NN (promotion))(NN (hepatocarcinogenesis))(NN (process))))))))(: (;))(RB (however))(, (,))(NP (NP (NN (information))(NN (mechanism)))(VP (VBG (underlying))(S (NP (NN (chemoprotection)))(ADJP (VBN (limited))))))) |ET|  |BS| 262:A11.436.348 632:D05.750.078.840.762  |ES| 2:1 10:1 14:1 19:1 72:1 162:1 217:1 333:1 427:1 429:1 435:1 637:1 638:1 841:1 900:1 1021:1 1275:1 1387:1 1909:1 2131:1 2329:1 2330:1 2331:1 2332:1 2333:1 2334:1 2335:1 2336:1 2337:1 2338:1 2339:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NP (JJ (Epidermal))(NN (growth))(NN (factor))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (EGFR)))(-RRB- (-RRB-))))(NN (tyrosine))(NN (kinase))(NN (inhibitor))(NN (erlotinib)))(VP (VBP (show))(SBAR (S (NP (JJ (potent))(NP (NP (NN (antitumor))(NN (activity))(JJ (non-small-cell))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-))))(NN (cell))(NN (line)))(VP (VBD (approved))(NP (NNP (Food))(NNP (Drug))(NNP (Administration))(JJ (second))(JJ (third))(NN (line))(NN (treatment))(NN (NSCLC)))))))) |ET|  |BS| 52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875  |ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (BACKGROUND/AIMS)))(: (:))(NP (NP (JJ (Several))(NN (study)))(VP (VBD (reported))(NP (NP (NP (NP (NP (NN (efficacy))(NN (combination))(NN (therapy))(NN (interferon)))(PRN (-LRB- (-LRB-))(NP (NN (IFN)))(-RRB- (-RRB-))))(NN (alpha))(NN (5-fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))) |ET|  |BS| 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 617:D12.644.276.374.440 618:E02.186  |ES| 10:1 14:1 19:1 104:1 130:1 131:1 303:1 304:1 441:1 530:1 993:1 1836:1 2302:1 2303:1 2304:1 2305:1 2306:1 2307:1 2308:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (BACKGROUND)))(CC (&))(NP (NNS (AIMS))))(: (:))(S (NP (NP (NN (Androgen))(NN (effect))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(VP (VBP (remain))(SBAR (S (NP (JJ (controversial))(NN (androgen))(NN (ablation))(NN (therapy))(NN (treat))(NNP (HCC)))(ADVP (RB (also)))(VP (VBP (lead))(NP (JJ (inconsistent))(NN (result))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 86:D01.268.556.435 104:C04.557.470.200.025.255 891:D27.505.696.399.472.161 892:D27.505.696.399.472.161  |ES| 5:1 10:1 14:1 19:1 75:1 91:1 101:1 104:1 130:1 254:1 303:1 304:1 441:1 1046:1 1090:1 1777:1 1778:1 1852:1 2181:1 3153:1 3154:1 3155:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NN (BACKGROUND)))(CC (&))(NP (NNS (AIMS))))(: (:))(NP (NP (NP (NN (Chromodomain))(NN (helicase/adenosine))(NN (triphosphatase))(NN (DNA))(NN (binding))(NN (protein)))(NP (ADJP (JJ (1-like))(-LRB- (-LRB-))(NN (CHD1L))(-RRB- (-RRB-))(JJ (SNF2-like)))(NN (transcription))(NN (factor))))(VP (VBN (involved))(S (VP (NN (development))(NP (NP (JJ (human))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))))) |ET|  |BS| 14:F01.525 104:C04.557.470.200.025.255 166:D12.776.930 893:D08.811.277.040.025 894:D08.811.277.040.025  |ES| 4:1 10:1 14:1 19:1 35:1 36:1 104:1 185:1 303:1 304:1 441:1 487:1 666:1 774:1 1046:1 1487:1 1777:1 1778:1 3156:1 3157:1 3158:1 3159:1 3160:1 3161:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (BACKGROUND)))(: (:))(S (NP (PRP (It)))(VP (VBD (suggested))(NP (NP (JJ (altered))(NN (iron))(NN (metabolism))(NN (liver))(NN (tumor)))(, (,))(NP (VBN (characterized))(JJ (iron-deficient))(NN (phenotype)))(, (,))(NP (NN (importance))(NN (tumor))(NN (growth))))))) |ET|  |BS| 8:C04 45:G07.700.320.249 80:G05.695 515:C04.588.274.623 895:D01.490.600 896:D01.268.556.412 897:Z01.252.245.500.375 898:G03.495  |ES| 2:1 7:1 19:1 102:1 104:1 236:1 693:1 836:1 925:1 985:1 1046:1 1327:1 1660:1 3162:1 3163:1 3164:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(S (NP (DT (The))(NP (NN (ErbB2/Her2/Neu))(NN (receptor))(NN (tyrosine))(NN (kinase))))(VP (VBD (amplified))(NP (ADJP (QP (RB (approximately))(CD (30)))(NN (%)))(JJ (human))(NN (breast))(NN (cancer)))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400  |ES| 18:1 19:1 23:1 36:1 104:1 186:1 369:1 470:1 691:1 1046:1 1520:1 1843:1 2208:1 2341:1 3165:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNS (CONCLUSIONS)))(: (:))(S (NP (DT (This))(NN (study)))(VP (VBZ (demonstrates))(NP (JJ (synergistic))(NN (antitumor))(NN (activity))(NN (combination))(NN (dovitinib))(NN (oxaliplatin))(NN (colon))(NN (cancer))(JJ (different))(NN (RAS-RAF))(NN (status)))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550  |ES| 18:1 19:1 104:1 113:1 131:1 239:1 399:1 414:1 416:1 530:1 807:1 2012:1 2244:1 2541:1 2542:1 2543:1 2544:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (NP (PRP$ (Our))(NNS (data)))(VP (VBP (indicate))(SBAR (S (NP (JJ (sustained))(NN (LPS))(NN (accumulation)))(VP (VBZ (represents))(NP (JJ (pathological))(NN (mediator))(NP (NP (JJ (inflammation-associated))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NN (manipulation))(NN (gut))(NN (flora))))))))(VP (VBP (prevent))(SBAR (S (NP (JJ (pathogenic))(JJ (bacterial))(NN (translocation))(NN (endotoxin))(NN (absorption)))(VP (MD (may))(ADVP (RB (favorably)))(VP (VB (influence))(NP (NP (NN (liver))(NN (function))(NN (patient))(NN (cirrhosis))(NN (risk)))(VP (VBG (developing))(NP (NNP (HCC)))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 327:G06.930 357:C06.552.630 417:H02.403.650 662:C23.550.355 954:G06.755.375 955:G06.755.375 956:D09.400.500 957:G06.099.112.105 958:G01.595.014 959:D23.946.123.329 960:D23.469  |ES| 10:1 14:1 19:1 33:1 104:1 120:1 171:1 303:1 304:1 441:1 491:1 590:1 658:1 733:1 793:1 836:1 867:1 1199:1 1426:1 1479:1 1618:1 1698:1 1847:1 1849:1 1882:1 2120:1 2516:1 3350:1 3351:1 3352:1 3353:1 3354:1 3355:1 3356:1 3357:1 3358:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (PP (IN (In))(ADJP (JJ (present))(SBAR (S (NP (NP (NN (paper)))(, (,))(NP (NP (JJ (ethanol-induced))(JJ (acute))(JJ (chronic))(NN (liver))(NN (damage))(NN (rat))(NN (model)))(VP (VBN (used))))(, (,)))(VP (VBP (result))(VP (VBD (showed))(SBAR (S (NP (NN (dioscin)))(ADVP (RB (significantly)))(VP (VBD (alleviated))(SBAR (S (NP (NP (NN (liver))(NN (steatosis)))(, (,))(NP (VBN (reduced))(NN (level))(NN (alanine))(NN (aminotransferase)))(, (,))(NP (NN (aspartate))(NN (aminotransferase)))(, (,))(NP (NP (JJ (total))(NN (triglyceride)))(PRN (-LRB- (-LRB-))(NP (NN (TG)))(-RRB- (-RRB-))))(, (,))(NP (JJ (total))(NN (cholesterol))(NN (malondialdehyde)))(, (,)))(VP (VBD (increased))(NP (NP (NN (level))(JJ (high-density))(NN (lipoprotein)))(, (,))(NP (NN (superoxide))(NN (dismutase)))(, (,))(NP (NN (glutathione))(NN (glutathione))(NN (peroxidase))))))))))))))))) |ET|  |BS| 58:D08.811.682.881 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 655:D04.808.247.222.284 751:D02.033.375 753:C06.552.241 991:D08.811.682.732.500 1207:D08.811.913.477.700.225 1208:D12.644.456.448 1209:D10.532.432 1210:D02.047.700 1211:J01.637.650 1212:D10.351.801  |ES| 2:1 10:1 14:1 19:1 47:1 72:1 90:1 101:1 124:1 132:1 146:1 147:1 244:1 249:1 452:1 476:1 836:1 849:1 1307:1 1790:1 1848:1 2392:1 2393:1 2403:1 2672:1 2674:1 2678:1 2744:1 3132:1 3485:1 4234:1 4235:1 4236:1 4237:1 4238:1 4239:1 4240:1 4241:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Elevated))(NN (expression))(JJ (coactivator-associated))(NN (arginine))(NN (methyltransferase))(CD (1)))(VP (VBN (associated))(NP (JJ (early))(NN (hepatocarcinogenesis))))) |ET| 19:1 98:1 115:1 169:1 900:1 1128:1 1350:1 2655:1 3464:1 3465:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Inhibition))(JJ (hypoxia-inducible))(NN (factor))(NN (limit))(NN (tumor))(NN (progression))(NN (mouse))(NN (model))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 43:F01.145.544 1011:C23.888.852.079 1031:C04.588.274.476.411.307  |ES| 7:1 17:1 18:1 19:1 48:1 52:1 72:1 185:1 2703:1 2797:1 3593:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Magnolol)))(VP (MD (could))(ADVP (RB (potentially)))(NP (JJ (safe))(JJ (potent))(JJ (anticarcinogenic))(NN (agent))(NN (skin))(NN (cancer))))) |ET|  |BS| 778:D27.505.954.444  |ES| 18:1 19:1 22:1 333:1 728:1 773:1 908:1 2312:1 2319:1 2737:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (order))))(VB (clarify))(SBAR (IN (whether))(S (NP (NP (JJ (peroxisomal))(NN (hydrogen))(NN (peroxide)))(PRN (-LRB- (-LRB-))(NP (NN (H2O2)))(-RRB- (-RRB-))))(VP (VBP (play))(NP (JJ (important))(NN (role))(NN (peroxisome))(JJ (proliferator-induced))(NN (hepatocarcinogenesis))))))(, (,))(NP (VBN (examined))(NN (change))(NN (metabolism))(JJ (peroxisomal))(NN (H2O2)))(ADVP (FW (vivo))(FW (vitro)))(VP (VBG (using))(NP (NP (JJ (male))(NN (Fischer-344))(NN (rat))(NN (fed))(NN (clofibrate)))(, (,))(NP (NP (JJ (bezafibrate))(FW (di)))(PRN (-LRB- (-LRB-))(NP (NN (2-ethylhexyl)))(-RRB- (-RRB-))))(NP (NP (NN (phthalate)))(PRN (-LRB- (-LRB-))(NP (NN (DEHP)))(-RRB- (-RRB-)))))(NP (CD (78))(NN (week))))) |ET|  |BS| 12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 479:G08.686.157.500 590:B01.050.050.199.520.760.200 663:C16.320.565.398.500.330.500 898:G03.495 907:D01.248.497.158.685.750.424 908:A11.284.430.214.190.500.585.600 909:D02.065.277.067 910:D02.241.081.114.968.500.500.195 911:D02.241.223.805.250 912:D27.888.569.100.675  |ES| 2:1 10:1 14:1 19:1 31:1 200:1 216:1 221:1 238:1 244:1 324:1 350:1 378:1 783:1 849:1 900:1 902:1 1402:1 1887:1 2426:1 3163:1 3192:1 3193:1 3194:1 3195:1 3196:1 3197:1 3198:1 3199:1 3200:1 3201:1 3202:1 3203:1 3204:1 3205:1 3206:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Herein)))(, (,))(VP (VBD (investigated))(NP (NP (ADJP (FW (vitro))(FW (vivo)))(JJ (anticancer))(NN (effect)))(NP (VBN (associated))(NN (mechanism))(NN (wogonin))(JJ (human))(NN (breast))(NN (cancer)))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400  |ES| 2:1 18:1 19:1 23:1 36:1 75:1 162:1 169:1 216:1 378:1 403:1 428:1 1880:1 2444:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NNP (Gemcitabine)))(, (,))(NP (JJ (current))(JJ (standard-of-care))(NN (chemotherapy))(JJ (pancreatic))(NN (cancer)))(, (,))(NP (JJ (limited))(JJ (clinical))(NN (benefit))))) |ET|  |BS| 151:E02.319  |ES| 2:1 18:1 19:1 84:1 175:1 467:1 495:1 2131:1 2617:1 2618:1 2619:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NP (NN (Expression))(NN (cyclooxygenase)))(PRN (-LRB- (-LRB-))(NP (NN (COX)))(-RRB- (-RRB-))))(CD (-2))(NN (protein))(NN (rat))(NN (hepatocarcinogenesis)))(VP (VBN (associated))(NP (NP (JJ (fatty))(NN (change)))(, (,))(NP (NN (fibrosis)))(, (,)))(NP (NP (NN (cirrhosis))(JJ (oxidative))(NN (DNA))(NN (damage)))(, (,))(VP (VBD (caused))(SBAR (S (NP (ADJP (ADJP (JJ (choline-deficient)))(, (,))(ADJP (ADJP (NN (L-amino))(JJ (acid-defined)))(PRN (-LRB- (-LRB-))(ADJP (JJ (CDAA)))(-RRB- (-RRB-)))))(NN (diet)))(VP (VBD (investigated))(NP (NP (NN (F344))(JJ (male))(NN (rat)))(, (,))(PP (IN (along))(NP (NP (JJ (chemopreventive))(NN (efficacy))(JJ (specific))(NN (COX-2))(NN (inhibitor)))(, (,))(NP (NP (NN (nimesulide)))(PRN (-LRB- (-LRB-))(NP (NN (NIM)))(-RRB- (-RRB-)))))))))))))) |ET|  |BS| 7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 349:D27.505.519.389.310.500 357:C06.552.630 526:G05.355.180 590:B01.050.050.199.520.760.200 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125 662:C23.550.355 691:C23.550.355  |ES| 2:1 4:1 10:1 14:1 19:1 76:1 169:1 200:1 316:1 380:1 403:1 540:1 666:1 849:1 900:1 949:1 1199:1 1402:1 1848:1 1946:1 2070:1 2188:1 2190:1 2191:1 2304:1 2506:1 2583:1 2666:1 3180:1 3181:1 3182:1 3183:1 3184:1 3185:1 3186:1 3187:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(VBP (result)))(VP (VBP (indicate))(SBAR (S (NP (NP (NN (administration))(NN (resveratrol)))(UCP (CC (either))(NP (JJ (early))(JJ (advanced))(NN (stage))(NN (hepatocarcinogenesis)))(ADJP (RB (equally))(JJ (effective)))))(VP (VBZ (involves))(NP (NP (NN (activation)))(NP (JJ (apoptotic))(NN (pathway))(NN (male))(NNP (Wistar))(NN (rat))))))))) |ET|  |BS| 39:G04.299.139.160 723:B01.050.150.900.649.865.635.505.700.900  |ES| 19:1 39:1 101:1 225:1 383:1 658:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1479:1 1639:1 1673:1 1712:1 2223:1 2575:1 2603:1 2854:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (DT (A))(JJ (novel))(NN (inhibitor))(JJ (fatty))(NN (acid))(NN (synthase))(NN (show))(NN (activity))(NN (HER2)))(CC (+))(NP (NN (breast))(NN (cancer))(NN (xenograft))(JJ (active))(JJ (anti-HER2))(JJ (drug-resistant))(NN (cell))(NN (line))))) |ET|  |BS| 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 92:E04.936.764 93:A01.941.875 94:A11.251.210 259:D12.776.395.240.150.500 921:D08.811.682.664.500.772 922:D10.251  |ES| 18:1 19:1 23:1 66:1 69:1 94:1 197:1 264:1 265:1 380:1 399:1 429:1 891:1 1275:1 2070:1 3245:1 3246:1 3247:1  |EV| 
-2.5176273568167744087986648082733  |BT| (NP (NP (NP (JJ (Partial))(JJ (hepatectomized))(NN (rat)))(PRN (-LRB- (-LRB-))(S (NP (NN (n)))(VP (JJ (=))(NP (QP (CD (11))(CD (12))))))(-RRB- (-RRB-))))(VP (VBN (fed))(NP (NN (diet))(VP (VBG (containing))(S (CD (0))(, (,))(NP (CD (0.03))(, (,))(CD (0.06))(, (,))(CD (0.125))(ADJP (CD (0.25))(NN (%)))(NN (BNF)))(NP (NP (CD (6))(NN (week))(JJ (intraperitoneal))(NN (injection))(NN (N-diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(VP (VBP (initiate))(NP (NN (hepatocarcinogenesis))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 595:G07.203.650.240 663:C16.320.565.398.500.330.500 917:E02.319.267.530.490  |ES| 2:1 10:1 14:1 19:1 286:1 369:1 580:1 581:1 783:1 785:1 849:1 900:1 1057:1 1120:1 1875:1 2191:1 2426:1 3230:1 3231:1 3529:1 3595:1 4037:1 4093:1 4163:1 4326:1 4327:1 4328:1 4329:1 4330:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Critical))(NN (function))(NN (ADAM9))(NN (mouse))(NN (prostate))(NN (cancer)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500  |ES| 18:1 19:1 33:1 52:1 77:1 3211:1 3415:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NNS (METHODS))(: (:)))(S (NP (DT (A))(JJ (Solt-Farber))(JJ (two-step))(NN (test))(NN (model))(NN (hepatocarcino))(NN (genesis)))(VP (VBD (established))(S (NP (NP (NP (NP (NP (NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(NN (2-acetylaminofluorene)))(PRN (-LRB- (-LRB-))(NP (NN (AAF)))(-RRB- (-RRB-))))(NN (rat)))(VP (VBP (investigate))(S (VP (VBG (modifying))(NP (NP (NP (NN (effect))(NN (expression))(NN (6-glucosephosphatase)))(PRN (-LRB- (-LRB-))(NP (NN (G-6-Pase)))(-RRB- (-RRB-))))(, (,))(NP (NN (succinodehydrogenase))(-LRB- (-LRB-))(NN (SDH))(-RRB- (-RRB-)))(, (,))(NP (NP (NP (NN (adenosine))(NN (triphosphatase)))(PRN (-LRB- (-LRB-))(NP (NN (ATPase)))(-RRB- (-RRB-))))(JJ (N-nitrosodiethylamine-mediated))(NN (hepatocarcinogenesis))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250  |ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NNP (Ling))(NN (extract)))(, (,))(NP (JJ (high))(NN (furanodiene))(NN (content)))(, (,)))(VP (VBD (showed))(NP (JJ (anti-cancer))(NN (effect))(NN (breast))(NN (cancer))(NN (cell))(NN (vitro))))) |ET|  |BS| 41:A11  |ES| 2:1 18:1 19:1 23:1 75:1 94:1 132:1 178:1 216:1 1112:1 1794:1 2496:1 3610:1 3611:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(S (NP (NN (Alcohol))(NN (consumption)))(VP (VBZ (promotes))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))))) |ET|  |BS| 104:C04.557.470.200.025.255 904:F01.145.317.269  |ES| 10:1 14:1 19:1 104:1 298:1 303:1 304:1 441:1 1046:1 2387:1 3962:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (JJ (current))(NN (study))))(, (,))(NP (NN (serial))(NN (microPET))(NN (imaging)))(VP (VBD (used))(VP (VB (evaluate))(NP (NP (JJ (iodine-124-labeled))(NN (iodo-azomycin-galactoside)))(PRN (-LRB- (-LRB-))(NP (-LRB- (-LRB-))(CD (124))(-RRB- (-RRB-))(NN (I-IAZG)))(-RRB- (-RRB-))))))(PRN (-LRB- (-LRB-))(NP (JJ (4.2-day))(JJ (physical))(NN (half-life)))(-RRB- (-RRB-)))(S (NP (NN (hypoxia))(NN (imaging))(NN (agent)))(NP (CD (17))(NN (MCa))(NN (breast))(NN (tumor))(CD (six))(NN (FSaII))(NNS (fibrosarcomas)))(VP (VBN (implanted))(NP (NN (mouse)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 375:Z01.639.100 967:D01.248.497.158.490 1002:C04.588.180 1011:C23.888.852.079 1017:E01.370.350 1018:C04.557.450.565.590.350 1019:A07.231.114.228.550 1020:G01.910.405 1021:E01.370.600 1022:V02.690  |ES| 2:1 7:1 10:1 14:1 19:1 23:1 52:1 131:1 175:1 244:1 476:1 728:1 890:1 930:1 1781:1 2474:1 3559:1 3560:1 3561:1 3562:1 3563:1 3564:1 3565:1 3566:1 3567:1 3568:1 3569:1 3570:1 3571:1 3572:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (JJ (Chronic))(JJ (excessive))(NN (alcohol))(NN (consumption))(NN (lead))(NN (development)))(NP (NP (JJ (alcoholic))(NN (liver))(NN (disease)))(PRN (-LRB- (-LRB-))(NP (NN (ALD)))(-RRB- (-RRB-))))(S (VP (ADVP (RB (greatly)))(VB (increase))(NP (NN (risk))(NN (liver))(NN (cancer)))))) |ET|  |BS| 61:E05.318.740.600.800 86:D01.268.556.435 650:C06.552 904:F01.145.317.269 1148:M01.066  |ES| 10:1 14:1 18:1 19:1 35:1 40:1 171:1 254:1 836:1 998:1 2387:1 2880:1 3710:1 3967:1 3982:1 3983:1 3984:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (17-Allylamino-17-demethoxygeldanamycin)))(VP (VBZ (overcomes))(NP (NN (TRAIL))(NN (resistance))(NN (colon))(NN (cancer))(NN (cell))(NN (line))))) |ET|  |BS| 94:A11.251.210  |ES| 18:1 19:1 94:1 113:1 264:1 1094:1 1695:1 3238:1 3239:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(VP (VBN (Taken))(ADVP (RB (together)))(, (,))(S (VP (VBG (finding))(VP (VB (identify))(S (NP (NN (mechanism))(NN (ABT-100))(NN (function)))(VP (VBP (show))(NP (NP (NN (efficacy))(NN (ABT-100))(JJ (chemopreventive))(NN (agent)))(NP (JJ (hepatocellular))(NN (carcinoma))))))))))) |ET|  |BS| 104:C04.557.470.200.025.255 375:Z01.639.100  |ES| 2:1 19:1 33:1 104:1 162:1 239:1 303:1 304:1 429:1 728:1 832:1 927:1 1537:1 1538:1 1946:1 2304:1 2538:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Consistent))(NN (finding))(, (,))(JJ (ABCB5-expressing))(NN (tumor))(NN (cell))(NN (population)))(RRC (ADVP (RB (also)))(NP (NN (treatment))(ADJP (JJ (refractory))(S (VP (VBD (exhibited))(NP (NN (resistance))(JJ (5-FU-induced))(NN (apoptosis))(JJ (colorectal))(NN (cancer))(NN (xenograft))(NN (model))(NN (5-FU))(NN (monotherapy)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 52:E02 92:E04.936.764 93:A01.941.875 175:J01.897.280.500.269 275:C23.888 560:D03.383.742.698.875.404 829:M01.686 966:N01.600  |ES| 2:1 5:1 7:1 17:1 18:1 19:1 72:1 89:1 94:1 265:1 546:1 609:1 927:1 1094:1 2023:1 2308:1 3379:1 3395:1 3396:1 3397:1 3398:1  |EV| 
-1.4235997687852659510099329054356  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NP (NP (NN (dioscin))(NN (show))(JJ (excellent))(JJ (protective))(NN (effect)))(JJ (ethanol-induced))(NN (liver))(NN (injury)))(S (VP (VBG (ameliorating))(NP (NP (JJ (ethanol-induced))(JJ (oxidative))(NN (stress)))(, (,))(NP (JJ (mitochondrial))(NN (function)))(, (,)))(NP (NP (JJ (inflammatory))(NP (NN (cytokine)))(NN (production)))(, (,))(NP (NN (apoptosis))(NN (liver))(NN (steatosis)))(, (,))))))(VP (VBD (developed))(NP (JJ (new))(NN (drug))(NN (treatment))(JJ (ethanol-induced))(NN (liver))(NN (injury))(NN (future))))) |ET|  |BS| 39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241  |ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (ADJP (QP (IN (About))(CD (80)))(NN (%)))(JJ (gastric))(NN (cancer)))(VP (VBD (showed))(NP (JJ (high))(NN (level))(NN (expression))(NN (cyclooxygenase))(CD (2)))(, (,))(S (NP (NN (subset))(NN (case)))(VP (VBP (express))(PP (IN (without))(NP (JJ (unknown))(NN (reason)))))))) |ET|  |BS| 24:D08.811.600.720.750  |ES| 2:1 18:1 19:1 86:1 115:1 132:1 148:1 178:1 208:1 249:1 369:1 573:1 934:1 1195:1 1285:1 2182:1 3180:1 3257:1 3258:1  |EV| 
-4.520134953427480617449418787146  |BT| (SINV (NP (NP (JJ (Hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NP (CD (one))(JJ (common))(NN (cancer)))(ADVP (RB (worldwide)))(, (,))(VP (VBD (caused)))(NP (NP (NP (NNP (Hepatitis))(NNP (C))(NN (virus)))(PRN (-LRB- (-LRB-))(NP (NN (HCV)))(-RRB- (-RRB-))))(NN (hepatotoxin)))) |ET|  |BS| 104:C04.557.470.200.025.255 550:B04.450.410  |ES| 2:1 10:1 14:1 18:1 19:1 304:1 441:1 655:1 1010:1 1422:1 1938:1 1954:1 1955:1 2151:1 2506:1 3987:1 3988:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNS (METHODS))(: (:)))(S (NP (DT (A))(JJ (Solt-Farber))(JJ (two-step))(NN (test))(NN (model))(NN (hepatocarcino))(NN (genesis)))(VP (VBD (established))(S (NP (NP (NP (NP (NP (NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(NN (2-acetylaminofluorene)))(PRN (-LRB- (-LRB-))(NP (NN (AAF)))(-RRB- (-RRB-))))(NN (rat)))(VP (VBP (investigate))(S (VP (VBG (modifying))(NP (NP (NP (NN (effect))(NN (expression))(NN (6-glucosephosphatase)))(PRN (-LRB- (-LRB-))(NP (NN (G-6-Pase)))(-RRB- (-RRB-))))(, (,))(NP (NN (succinodehydrogenase))(-LRB- (-LRB-))(NN (SDH))(-RRB- (-RRB-)))(, (,))(NP (NP (NP (NN (adenosine))(NN (triphosphatase)))(PRN (-LRB- (-LRB-))(NP (NN (ATPase)))(-RRB- (-RRB-))))(JJ (N-nitrosodiethylamine-mediated))(NN (hepatocarcinogenesis))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250  |ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1  |EV| 
-0.79289261839562641398515552282333  |BT| (S (NP (NN (5-aza-dC))(NN (treatment)))(ADVP (RB (markedly)))(VP (VBD (decreased))(NP (NP (NN (atherosclerosis))(NN (development))(NN (Ldlr)))(-LRB- (-LRB-))(PRN (: (-))(: (/))(: (-)))(-RRB- (-RRB-))(NN (mouse)))(NP (PP (IN (without))(NP (NN (change))(NN (body))(NN (weight))))(, (,))(NP (NN (plasma))(NN (lipid))(NN (profile)))(, (,))(NP (NN (macrophage))(NN (cholesterol))(NN (level))(NN (plaque))(NN (lipid))(NN (content)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 52:E02 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821 653:C23.888.144 654:D02.145.150 655:D04.808.247.222.284 656:C07.793.208.377 657:A12.207.152.693 658:A11.329.372 659:D10  |ES| 2:1 10:1 14:1 19:1 35:1 45:1 52:1 200:1 202:1 249:1 546:1 1195:1 1711:1 1794:1 1804:1 1981:1 2395:1 2396:1 2397:1 2398:1 2399:1 2400:1 2401:1 2402:1 2403:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNS (Genes)))(VP (VBD (expressed))(NP (NP (NN (PB))(CD (two))(NNS (conazoles)))(RRC (ADVP (RB (also)))(NP (VBN (compared))(NP (NN (gene))(VBN (associated))(JJ (human))(JJ (hepatocellular))(NN (cancer)))))))) |ET|  |BS| 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400  |ES| 5:1 6:1 9:1 18:1 19:1 36:1 50:1 169:1 303:1 933:1 3495:1 3496:1 3497:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Phyllanthus))(NN (urinaria)))(VP (VBZ (ameliorates))(NP (NN (severity))(JJ (nutritional))(FW (steatohepatitis))(FW (vitro))(FW (vivo))))) |ET|  |BS| 508:C06.552.241 813:B01.650.940.800.575.100.350.622  |ES| 19:1 216:1 378:1 1473:1 1791:1 2875:1 2876:1 2877:1 2878:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (PRP$ (Our))(VP (VBP (result))(VP (VBP (demonstrate))(S (VP (NN (resveratrol))(VP (VB (potentiate))(NP (JJ (anti-tumor))(NN (effect))(NN (5-FU))(NN (CRC))(NN (cell))(NN (chemosensitizing)))(, (,))(S (VP (VBG (inhibiting))(NP (NNP (EMT))(NN (phenotype)))(PP (IN (via))(NP (NN (up-regulation))(JJ (intercellular))(NN (junction))(NN (down-regulation))(NN (NF-kappaB))(NN (pathway))))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 41:A11 80:G05.695 85:G02.111.087.225 122:C14.280.383 142:I01.880.604 210:D12.776.260.600 560:D03.383.742.698.875.404 1054:A11.284.149.165.420  |ES| 2:1 19:1 75:1 94:1 101:1 236:1 245:1 257:1 383:1 502:1 596:1 658:1 714:1 880:1 896:1 1712:1 1759:1 2075:1 2308:1 3677:1 3678:1 3679:1 3680:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (JJ (Previous))(NN (study)))(VP (VBN (shown))(S (NP (NN (decorin))(NN (expression)))(VP (ADVP (RB (significantly)))(VBD (reduced))(NP (NP (JJ (colorectal))(NN (cancer))(NN (tissue))(NN (cancer))(NN (cell)))(, (,))(NP (JJ (genetic))(NN (deletion))(NN (decorin))(NN (gene))(JJ (sufficient))(NN (cause))(JJ (intestinal))(NN (tumor))(NN (formation))(NN (mouse)))(, (,))(VP (VBG (resulting))(NP (NN (downregulation))(NN (p21))))(, (,))(NP (NP (NN (p27)))(PRN (-LRB- (-LRB-))(NP (NN (kip1)))(-RRB- (-RRB-))))(FRAG (NP (NN (E-cadherin))(NN (upregulation))(NN (beta-catenin))(NN (signaling)))(-LRB- (-LSB-))(NP (NP (NN (Bi)))(, (,))(NP (NN (X)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 20:G03.495 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 69:G02.111.087.800 85:G02.111.087.225 98:A10 102:C04.588.274.476.411 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 549:G05.355.600.800.320 708:D12.776.395.650.750.625 820:D12.776.395.550.200.200  |ES| 2:1 7:1 9:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 60:1 94:1 109:1 115:1 124:1 131:1 195:1 237:1 242:1 272:1 384:1 452:1 595:1 864:1 929:1 1059:1 1124:1 1126:1 1135:1 1373:1 1779:1 2267:1 2900:1 2901:1 2902:1 2903:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NN (Overexpression))(NN (cyclooxygenase))(CD (2)))(PRN (-LRB- (-LRB-))(NP (NN (COX-2)))(-RRB- (-RRB-))))(ADVP (RB (frequently)))(VP (VBD (found))(NP (JJ (early))(JJ (advanced))(NN (lung))(NN (cancer))))) |ET|  |BS| 24:D08.811.600.720.750  |ES| 10:1 14:1 18:1 19:1 37:1 76:1 148:1 328:1 668:1 698:1 997:1 1128:1 3180:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NNS (Data)))(VP (VBN (obtained))))(VP (VBP (suggest))(S (NP (NN (contribution))(NN (SphK/S1P))(NN (system)))(NP (JJ (related))(NN (signaling))(NN (pathway))(JJ (protective))(NN (effect))(NN (melatonin))(NN (hepatocarcinogenesis)))))) |ET|  |BS| 126:G02.111.087.800 707:D03.438.473.914.481  |ES| 19:1 75:1 195:1 383:1 419:1 493:1 593:1 796:1 900:1 1224:1 1360:1 2554:1 2555:1 2556:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Overall))(NN (finding)))(VP (VBP (substantiate))(SBAR (S (NP (NN (artesunate)))(VP (VBZ (promotes))(SBAR (S (NP (JJ (anti-tumour))(, (,))(JJ (anti-proliferation))(NN (apoptosis))(NN (nitrosodiethylamine)))(VP (VBD (mediated))(NP (JJ (hepatocellular))(NN (carcinoma))))))))))) |ET|  |BS| 8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500  |ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Hepatocarcinogenesis)))(VP (VBD (induced))(NP (NN (diethylnitrosamine))(JJ (hepatic))(NN (deletion))(NN (PTEN))))) |ET|  |BS| 306:G05.355.600.800 554:D02.654.442.200  |ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Inhibition))(NN (licorice))(NN (flavonoid))(NN (oil))(NN (glutathione))(JJ (S-transferase-positive))(NN (focus))(JJ (medium-term))(NN (rat))(NN (hepatocarcinogenesis))(NN (bioassay)))) |ET|  |BS| 43:F01.145.544 106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 534:D03.383.663.283.266.450 780:D08.811.913.225.500 849:G08.686.785.760.769.490.500 914:L01.178 1027:B01.650.940.800.575.100.401.300 1028:B01.650.940.800.575.100.401.300 1029:D10.627.700 1030:D10.627  |ES| 19:1 849:1 900:1 1431:1 1886:1 2614:1 2703:1 2744:1 2931:1 3215:1 3590:1 3591:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (S (VP (TO (To))(VP (VB (clarify))(S (VP (VBG (modifying))(NP (NP (NN (effect))(NN (N-Acetyl-L-Cysteine)))(PRN (-LRB- (-LRB-))(NP (NN (NAC)))(-RRB- (-RRB-)))))))))(, (,))(NP (NP (JJ (antioxidative))(NN (ability)))(, (,))(NP (NN (hepatocarcinogenesis)))(VP (VBD (promoted))(SBAR (S (NP (NP (NP (NP (NN (fenofibrate)))(PRN (-LRB- (-LRB-))(NP (NN (FF)))(-RRB- (-RRB-))))(, (,))(NP (NP (NP (NN (peroxisome))(JJ (proliferator-activated))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (PPAR)))(-RRB- (-RRB-))))(NN (alpha)))(NP (NN (agonist))))(, (,))(NP (NP (JJ (male))(NN (F344/N))(NN (rat)))(VP (VBN (administered))(NP (NP (NP (ADJP (JJ (single))(JJ (intraperitoneal)))(NN (injection))(NN (N-diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(NN (initiator))))))(VP (VBD (followed))(NP (NN (administration))(NN (diet))(VBG (containing))(CD (3,000))(NN (ppm))(NN (FF))(CD (16))(NN (week)))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490  |ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Here)))(, (,))(VP (VBP (provide))(NP (NP (NP (NN (evidence))(NN (periostin))(, (,))(NN (protein))(JJ (structural))(NN (sequence))(NN (homology))(JJ (TGF-beta-inducible))(NN (gene)))(, (,))(NP (NN (beta))(NN (ig-h3)))(, (,)))(VP (VBN (upregulated))(NP (JJ (colorectal))(NN (cancer))(NN (liver))(NN (metastasis)))))(, (,))(VP (MD (may))(VP (VB (play))(NP (NN (role)))(S (VP (VBG (promoting))(NP (NN (growth))(NN (tumor))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 6:G05.360.340.024.340 8:C04 15:F01.829.316.616 45:G07.700.320.249 79:I03.450.642.693 112:D12.776.097.820 113:C04.697.650 242:A03.620 503:D12.644.276.374.687 1005:G02.111.810  |ES| 2:1 4:1 7:1 9:1 17:1 18:1 19:1 31:1 38:1 102:1 125:1 238:1 293:1 400:1 491:1 711:1 806:1 836:1 881:1 1972:1 3512:1 3513:1 3514:1 3515:1 3516:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Administration))(NN (HMGB1))(NN (release))(NN (inhibitor))(NN (ethyl))(NN (pyruvate)))(, (,))(VP (VBP (affect))(NP (NP (JJ (p53-mediated))(JJ (hepatic))(NN (apoptosis)))(, (,))(VP (ADVP (RB (substantially)))(VBD (prevented))(NP (JJ (carcinogen-induced))(NN (cirrhosis))(NN (tumorigenesis))(NN (rat))(NN (liver))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 357:C06.552.630 433:F01.470.047 585:D12.644.276.087.371 589:E02.204.125 662:C23.550.355  |ES| 2:1 19:1 78:1 89:1 380:1 836:1 838:1 849:1 1199:1 1486:1 1944:1 2164:1 2165:1 2346:1 2417:1 2418:1 2419:1 2420:1 2421:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NP (DT (The))(NN (process))(NN (hepatocarcinogenesis))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(JJ (initiation/phenobarbital))(-LRB- (-LRB-))(NN (PB))(-RRB- (-RRB-))(NN (promotion))(NN (mouse))(NN (model)))(VP (VBZ (involves))(NP (NP (JJ (selective))(JJ (clonal))(NN (outgrowth))(NN (cell))(NN (harboring))(NN (oncogene))(NN (mutation))(NN (Ctnnb1)))(, (,))(S (NP (JJ (spontaneous))(JJ (DEN-only-induced))(NN (tumor)))(ADVP (RB (often)))(NP (NP (NN (Ha-ras)))(: (-))(NP (JJ (B-raf-mutated)))))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 8:C04 9:G05.360.340.024.340.375.500 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 41:A11 216:Z01.107.084.900.425 278:D08.811.913.696.620.682.700.559.842.374 301:A11.251.353 554:D02.654.442.200 756:D03.383.742.698.253.650  |ES| 2:1 7:1 10:1 14:1 19:1 24:1 34:1 52:1 72:1 94:1 283:1 632:1 638:1 691:1 900:1 1069:1 1304:1 1673:1 1749:1 1875:1 1952:1 2337:1 3496:1 4030:1 4031:1 4032:1 4033:1 4034:1 4035:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNS (Effects)))(VP (VBP (magnolol))(NP (NP (JJ (UVB-induced))(NN (skin))(NN (cancer))(NN (development))(NN (mouse)))(JJ (possible))(NN (mechanism))(NN (action))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 742:G03.787  |ES| 18:1 19:1 35:1 52:1 162:1 1359:1 2013:1 2319:1 2526:1 2752:1 3461:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NNS (data)))(VP (VBD (indicated))(NP (NP (NN (silymarin))(JJ (therapeutic))(NN (effect)))(NP (JJ (early))(NN (stage))(NN (liver))(NN (damage))))(, (,))(S (VP (VBG (reversing))(NP (NP (JJ (fatty))(NN (change)))(VP (VBG (recovering))(NP (NN (liver))(NN (histopathology))(JJ (dose-dependent))(NN (manner))))))))) |ET|  |BS| 242:A03.620 801:D03.383.663.283.266.450.268.777  |ES| 2:1 19:1 75:1 200:1 541:1 658:1 793:1 836:1 1128:1 1129:1 1541:1 1668:1 1848:1 2070:1 2740:1 2821:1 2822:1 2823:1 2824:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Herein)))(, (,))(VP (VBD (investigated))(NP (NP (NP (NN (effect))(NN (alpha-LA))(NN (development))(NN (rat)))(JJ (pre-neoplastic))(NN (lesion)))(VP (VBD (generated))(NP (NN (model))(NN (hepatocarcinogenesis))(, (,))(NN (similarity))(JJ (histopathological))(NN (sequence))(JJ (human))(JJ (hepatocellular))(NN (carcinoma))(NN (development))(NN (cirrhosis))))))) |ET|  |BS| 8:C04 14:F01.525 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355 1006:D01.268.558.362.500  |ES| 2:1 19:1 35:1 36:1 72:1 73:1 75:1 293:1 303:1 304:1 403:1 428:1 849:1 900:1 1131:1 1199:1 3524:1 3525:1 3526:1 3527:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NNP (Neurotensin))(NN (receptor-1)))(PRN (-LRB- (-LRB-))(NP (NN (NTR-1)))(-RRB- (-RRB-))))(NP (JJ (overexpressed))(NN (colon))(NN (cancer))(NN (colon))(NN (cancer))(NN (cell))(NN (line))))) |ET|  |BS| 94:A11.251.210 1048:D12.776.543.750.100.550  |ES| 10:1 14:1 18:1 19:1 25:1 94:1 113:1 264:1 3656:1 3657:1 3658:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Curcumin)))(VP (VBZ (sensitizes))(NP (NP (JJ (human))(JJ (colorectal))(NN (cancer))(NN (xenograft))(JJ (nude))(NN (mouse))(NN (gamma-radiation)))(VP (VBG (targeting))(NP (JJ (nuclear))(JJ (factor-kappaB-regulated))(NN (gene))(NN (product))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335  |ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (Inhibition))(NP (NN (c-Jun))(JJ (NH2-terminal))(NN (kinase))(NN (switch)))(NN (Smad3))(NN (signaling))(NN (oncogenesis))(NN (tumor)))(: (-))(NP (NN (suppression))(NN (rat))(JJ (hepatocellular))(NN (carcinoma)))) |ET|  |BS| 8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 43:F01.145.544 69:G02.111.087.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 771:D08.811.913.696.620.682.700.567.374  |ES| 19:1 195:1 303:1 304:1 470:1 849:1 1686:1 2453:1 2703:1 2708:1 2709:1 2710:1 2711:1 2712:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (PP (IN (Among))(NP (NNS (others))))(, (,))(NP (NN (bladder))(, (,))(NN (lung))(, (,))(NN (colon))(, (,))(NN (breast))(NN (cancer))(VBN (associated))(NN (4-ABP))))) |ET|  |BS| 46:A03.556.124.526.356 182:A04.411 933:A05.810.890  |ES| 2:1 18:1 19:1 23:1 113:1 169:1 328:1 564:1 1000:1 3281:1 3282:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Bromelain-containing))(NN (food))(CC (and/or))(NN (bromelain)))(VP (MD (may))(VP (VB (represent))(NP (JJ (good))(NN (candidate))(JJ (colorectal))(NN (cancer))(NN (chemoprevention)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 253:E02.319.162 679:D08.811.277.656.262.500.096 680:G07.203.300  |ES| 17:1 18:1 19:1 149:1 491:1 799:1 870:1 1243:1 1318:1 2469:1 2470:1 2471:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (S (NP (JJ (Previous))(NN (work)))(VP (VBD (showed))(NP (NN (loss))(NN (TIP30)))))(, (,))(ADVP (RB (also)))(VP (VBN (called))(S (NP (NN (CC3))))(, (,))(NP (NP (JJ (putative))(NN (tumor))(NN (suppressor)))(, (,))(NP (VBD (increased))(NN (incidence))(JJ (hepatocellular))(NN (carcinoma))(NN (mouse)))(, (,))(NP (JJ (clinical))(NN (sample))(JJ (human))(NN (HCC))(NN (tissue))(JJ (aberrant))(NN (expression))(NN (TIP30)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 98:A10 104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249 434:E05.318.308.985.525.375 445:I03.946  |ES| 2:1 5:1 7:1 19:1 32:1 36:1 47:1 52:1 84:1 115:1 132:1 272:1 303:1 304:1 441:1 700:1 835:1 918:1 1511:1 1546:1 1547:1 1725:1 2900:1 2904:1 2905:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Pamidronate)))(VP (VBD (induced))(NP (JJ (anti-proliferative))(, (,))(NP (JJ (apoptotic))(, (,))(NP (JJ (anti-migratory))(NN (effect))(JJ (hepatocellular))(NN (carcinoma))))))) |ET|  |BS| 39:G04.299.139.160 104:C04.557.470.200.025.255  |ES| 2:1 19:1 75:1 303:1 304:1 412:1 2223:1 3694:1 3695:1 3696:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Erlotinib)))(ADVP (RB (also)))(VP (VBD (decreased))(NP (NN (hepatocyte))(NN (proliferation))(NN (liver))(NN (injury))))) |ET|  |BS| 242:A03.620 262:A11.436.348  |ES| 5:1 19:1 202:1 299:1 836:1 1909:1 2416:1 2596:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Lycopene))(JJ (active))(JJ (chemopreventive))(NN (agent))(NN (offer))(NN (protection))(JJ (DEN-induced))(NN (hepatocarcinogenesis)))(VP (VBG (inhibiting))(NP (NN (NF-kappaB))(NN (mTOR))(NN (pathway))))) |ET|  |BS| 122:C14.280.383 210:D12.776.260.600  |ES| 19:1 197:1 383:1 714:1 728:1 880:1 900:1 1042:1 1946:1 2733:1 2734:1 2735:1 2736:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Dovitinib)))(ADVP (RB (also)))(VP (VP (VBD (caused))(NP (NP (NP (NN (dephosphorylation))(NN (retinoblastoma)))(, (,))(NP (NN (upregulation))(NN (p-histone))(NN (H2A-X))(NN (p27)))(, (,)))(NN (downregulation))(NN (p-cdk-2))(NN (cyclin))(NN (B1))))(, (,))(VP (VBD (resulted))(NP (NN (reduction))(JJ (cellular))(NN (proliferation))(NN (induction))(NN (tumor))(NN (cell))(NN (apoptosis)))))) |ET|  |BS| 8:C04 39:G04.299.139.160 41:A11 85:G02.111.087.225 183:G04.299.233.750 249:G05.355.315.800 339:G02.111.087.880 510:C23.550.444 978:D08.811.913.696.620.682.700.646.500 979:D12.644.360.262.120.100 980:C04.557.465.625.600.725  |ES| 2:1 5:1 7:1 19:1 89:1 94:1 299:1 370:1 594:1 595:1 736:1 743:1 1124:1 1126:1 2506:1 3074:1 3449:1 3450:1 3451:1 3452:1 3453:1 3454:1 3455:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (DT (All))(NN (result)))(VP (VBD (revealed))(NP (NP (NN (pterostilbene))(JJ (effective))(NN (antitumor))(NN (agent)))(NP (RB (well))(NP (JJ (inhibitory))(NN (effect))(NN (down-regulation))(JJ (inflammatory))(NN (iNOS))(NN (COX-2))(NN (gene)))(NN (expression))(NN (up-regulation))(NN (apoptosis))(NN (mouse))(NN (colon))))(, (,))(S (VP (VBG (suggesting))(NP (NP (NP (NN (pterostilbene)))(JJ (novel))(JJ (functional))(NN (agent)))(ADJP (JJ (capable))(S (VP (VBG (preventing))(NP (JJ (inflammation-associated))(NN (colon))(NN (tumorigenesis))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248  |ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Prognostic))(NN (significance))(NN (metallothionein))(JJ (human))(JJ (gastrointestinal))(NN (cancer)))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 777:D12.776.556.670  |ES| 18:1 19:1 36:1 183:1 557:1 2731:1 3716:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (CONCLUSION))(: (:)))(PP (IN (In))(NP (NN (summary))))(, (,))(S (VP (VBG (finding))(VP (VB (provide))(NP (NP (JJ (preclinical))(NN (evidence)))(VP (VBG (supporting))(NP (NN (evaluation))(NN (agent))(NN (DMAPT))(NN (gemcitabine))(NN (prevention))(NN (treatment))(JJ (pancreatic))(NN (cancer))))))))) |ET|  |BS| 52:E02 225:E05.337  |ES| 2:1 18:1 19:1 38:1 104:1 244:1 467:1 490:1 546:1 711:1 728:1 927:1 1472:1 1474:1 1494:1 1882:1 2503:1 2504:1 2505:1  |EV| 
4.520134953427480617449418787146  |BT| (S (VP (ADVP (RB (Here)))(VBP (show))(SBAR (S (NP (NP (JJ (ATP-binding))(NN (cassette))(NN (member))(NN (B5)))(PRN (-LRB- (-LRB-))(NP (NN (ABCB5)))(-RRB- (-RRB-))))(VP (VBZ (identifies))(NP (NP (JJ (therapy-refractory))(NN (tumor))(NN (cell))(JJ (colorectal))(NN (cancer))(NN (patient)))(PP (VBG (following))(NP (NP (NN (fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-)))))))))(: (-))(S (NP (VBN (based))(NN (chemoradiation))(NN (therapy)))(VP (VBP (provide))(NP (NP (NN (evidence)))(JJ (functional))(NN (role))(NN (ABCB5))(JJ (colorectal))(NN (cancer))(NN (5-FU))(NN (resistance))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 50:M01.643 52:E02 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 1004:E02.095.147  |ES| 7:1 10:1 14:1 17:1 18:1 19:1 31:1 38:1 94:1 120:1 130:1 400:1 415:1 429:1 711:1 769:1 1094:1 1610:1 2308:1 2895:1 2919:1 3505:1 3506:1 3507:1 3508:1 3509:1 3510:1 3511:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Acylglycerol))(NN (kinase)))(VP (VBZ (promotes))(NP (NN (cell))(NN (proliferation))(NN (tumorigenicity))(NN (breast))(NN (cancer)))(PP (IN (via))(NP (NN (suppression))(NN (FOXO1))(NN (transcription))(NN (factor)))))) |ET|  |BS| 183:G04.299.233.750 209:G02.111.087.847  |ES| 18:1 19:1 23:1 94:1 185:1 298:1 299:1 300:1 470:1 487:1 596:1 2453:1 3263:1 3264:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (Despite))(NP (JJ (recent))(JJ (therapeutic))(NN (advance))))(, (,))(NP (NP (NN (response))(NN (rate))(NN (chemotherapy))(NN (patient)))(JJ (metastatic))(NN (colon))(NN (cancer)))(VP (VBP (remain))(NP (NP (NP (QP (RB (approximately))(CD (50)))(NN (%)))(NP (NN (fluoropyrimidine))))(, (,))(NP (NN (5-fluorouracil))(-LRB- (-LRB-))(NN (5-FU))(-RRB- (-RRB-))))(, (,))(S (VP (VBG (continuing))(VP (VB (serve))(NP (NN (foundation))(JJ (chemotherapeutic))(NN (agent))(NN (treatment))(NN (disease)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 50:M01.643 52:E02 113:C04.697.650 151:E02.319 288:C23.550.288 560:D03.383.742.698.875.404 660:D27.505.954.248 709:N03.219.483.311  |ES| 2:1 10:1 14:1 18:1 19:1 41:1 113:1 120:1 337:1 368:1 369:1 494:1 495:1 532:1 541:1 546:1 550:1 659:1 728:1 998:1 1762:1 1843:1 2181:1 2307:1 2308:1 2558:1 2559:1 2560:1 2561:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (study))))(, (,))(VP (VBD (determined))(NP (NP (JJ (combined))(NN (effect))(NN (celecoxib)))(, (,))(NP (NN (COX-2))(NN (inhibitor)))(, (,)))(PP (IN (along))(NP (NP (NP (NN (exisulind)))(PRN (-LRB- (-LRB-))(NP (NN (sulindac))(NN (sulfone/Aptosyn)))(-RRB- (-RRB-))))(JJ (low))(NNS (dos))(NN (prostate))(NN (cancer)))))) |ET|  |BS| 349:D27.505.519.389.310.500 684:D02.065.884.247  |ES| 2:1 10:1 14:1 18:1 19:1 75:1 76:1 77:1 131:1 164:1 244:1 380:1 531:1 869:1 1582:1 2653:1 2666:1 2807:1 3575:1 3576:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Immunohistochemical))(NN (analysis))(NN (thymidylate))(NN (synthase)))(, (,))(NP (NN (thymidine))(NN (phosphorylase)))(, (,))(NP (NP (NN (dihydropyrimidine))(NN (dehydrogenase))(JJ (rectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (cUICC))(NN (II/III)))(-RRB- (-RRB-))))(: (:)))(NP (NP (NN (correlation))(JJ (histopathologic))(NN (tumor))(NN (regression)))(NP (JJ (5-fluorouracil-based))(JJ (long-term))(NN (neoadjuvant))(NN (chemoradiotherapy))))) |ET|  |BS| 8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 846:F01.393.784 849:G08.686.785.760.769.490.500 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350 1013:E02.186.450  |ES| 2:1 7:1 10:1 14:1 18:1 19:1 66:1 104:1 661:1 719:1 1986:1 1989:1 2578:1 2648:1 3002:1 3082:1 3083:1 3084:1 3085:1 3542:1 3543:1 3544:1 3545:1 3546:1 3547:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(S (ADVP (RB (Collectively)))(, (,))(VP (VBP (result))(VP (VBP (suggest))(SBAR (S (NP (NN (curcumin)))(VP (VBZ (potentiates))(NP (NP (JJ (antitumor))(NN (effect))(NN (radiation))(NN (therapy)))(JJ (colorectal))(NN (cancer))(VBG (suppressing))(NP (NN (NF-kappaB))(JJ (NF-kappaB-regulated))(NN (gene))(NN (product))))(, (,))(NP (VBG (leading))(NN (inhibition))(NN (proliferation))(NN (angiogenesis)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745  |ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (DT (The))(NN (absence))(JJ (retinoid-containing))(NN (HSC))(NN (lipid))(NN (droplet)))(VP (VBP (promote))(SBAR (S (NP (NN (HSC))(NN (activation)))(VP (VBZ (reduces))(NP (NN (hepatocarcinogenesis))))))))) |ET|  |BS| 711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393  |ES| 19:1 104:1 142:1 225:1 239:1 679:1 691:1 900:1 1534:1 2401:1 3381:1 3382:1 3383:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (PRP$ (Our))(S (VP (VBP (result))(S (VP (VBP (provide))(NP (NP (ADJP (NN (clue))(JJ (molecular)))(NN (event)))(VP (VBN (involved))(NP (NN (mechanism))(NN (action))(JJ (HCB-induced))(NN (hepatocarcinogenesis))))))))))) |ET|  |BS| 742:G03.787 1232:D02.455.426.559.389.261.400  |ES| 19:1 101:1 161:1 162:1 205:1 658:1 711:1 774:1 900:1 1142:1 2013:1 4320:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (line))(NN (observation))))(, (,))(NP (JJR (lower))(NN (serum))(NN (level))(JJ (active))(NN (Caspase-3)))(VP (VBD (found))(SBAR (S (NP (NN (patient))(JJ (metastasised))(NN (CRC)))(VP (VBD (revealed))(NP (NP (JJ (stable))(NN (disease))(NN (tumour))(NN (regression)))(VBN (compared))(NN (disease))(NN (progression)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 50:M01.643 288:C23.550.288 429:N04.761.559.590.900 430:E05.581.249 782:A12.207.152.846 846:F01.393.784 906:D08.811.277.656.262.500.126.350.300  |ES| 2:1 19:1 37:1 48:1 50:1 117:1 120:1 197:1 244:1 245:1 249:1 264:1 275:1 360:1 998:1 1011:1 1477:1 2741:1 3002:1 3190:1 3191:1  |EV| 
-4.3353056468925785793544491752982  |BT| (S (NP (JJ (Branched-chain))(NN (amino))(NN (acid))(-LRB- (-LRB-))(NN (BCAA))(-RRB- (-RRB-)))(, (,))(S (VP (VB (improve))(NP (NN (insulin))(NN (resistance)))))(, (,))(VP (VBD (inhibited))(NP (NP (JJ (obesity-related))(NN (colon))(NN (carcinogenesis))(JJ (rodent))(NN (model)))(, (,))(S (ADVP (RB (also)))(VP (VBD (reduced))(NP (NN (incidence))(JJ (hepatocellular))(NN (carcinoma))(JJ (obese))(NN (patient))(NN (liver))(NN (cirrhosis)))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 50:M01.643 104:C04.557.470.200.025.255 122:C14.280.383 357:C06.552.630 434:E05.318.308.985.525.375 514:B01.050.150.900.649.865 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500  |ES| 2:1 5:1 10:1 14:1 19:1 72:1 113:1 120:1 207:1 303:1 304:1 365:1 452:1 836:1 1094:1 1199:1 1275:1 1511:1 2173:1 2189:1 2360:1 2364:1 2465:1 2466:1 2467:1 2468:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (ADVP (RBR (More))(RB (importantly)))(, (,))(NP (NP (NN (EPLE)))(VBN (hampered))(NN (tumor))(NN (development))(NN (CRC))(NN (xenograft))(NN (model)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 92:E04.936.764 93:A01.941.875  |ES| 2:1 7:1 19:1 35:1 72:1 245:1 265:1 2489:1 2767:1 2768:1 2769:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (view))(JJ (strong))(NN (association))(NN (estrogen))))(, (,))(NP (NP (NN (progesterone)))(, (,))(NP (NN (prolactin)))(, (,))(NP (NN (breast))(NN (cancer)))(, (,))(NP (NN (PhIP))(NN (repertoire)))(NP (JJ (hormone-like))(NN (activity))))(VP (VBZ (provides))(NP (JJ (mechanistic))(NN (support))(JJ (tissue-specific))(NN (carcinogenicity))(NN (chemical))))) |ET|  |BS| 98:A10 161:D06.472 279:D27.888.569.100 386:F02.463.425.069 889:D27.505.696.399.472.277 1010:D04.808.745.745.654.829 1023:D06.472.699.322.576.773  |ES| 2:1 18:1 19:1 23:1 244:1 399:1 815:1 1298:1 1364:1 1626:1 1890:1 2124:1 2641:1 3168:1 3536:1 3578:1 3579:1 3580:1 3581:1 3582:1 3583:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NNP (UNLABELLED)))(: (:))(S (NP (JJ (Epidemiological))(NNS (data)))(VP (VBP (associate))(NP (NP (NN (coffee))(NN (consumption)))(NP (JJR (lower))(NN (prevalence))(JJ (chronic))(NN (liver))(NN (disease))))(VP (VBD (reduced))(NP (NP (NN (risk))(JJ (elevated))(NN (liver))(NN (enzyme))(NN (level)))(PRN (-LRB- (-LRB-))(NP (NN (gamma))(NN (glutamyl))(NN (transpeptidase))(NN (alanine))(NN (aminotransferase)))(-RRB- (-RRB-)))))))(, (,)))(VP (VBD (advanced))(NP (NP (NN (liver))(NN (disease))(NN (complication)))(, (,))(NP (JJ (hepatocellular))(NN (carcinoma)))))) |ET|  |BS| 60:E05.318.308.985.525.750 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 648:D08.811.913.050.200.500 649:E01.370.225.124.200 650:C06.552 651:H02.403.720.500 652:D20.215.784.249  |ES| 2:1 10:1 14:1 19:1 104:1 117:1 171:1 179:1 249:1 303:1 304:1 452:1 756:1 793:1 836:1 997:1 998:1 1790:1 2266:1 2384:1 2385:1 2386:1 2387:1 2388:1 2389:1 2390:1 2391:1 2392:1 2393:1 2394:1  |EV| 
4.520134953427480617449418787146  |BT| (S (S (VP (VBN (Taken))(ADVP (RB (together)))))(, (,))(VP (VBP (result))(VP (VBP (suggest))(SBAR (S (NP (NN (ADAM9)))(VP (VBZ (contributes))(NP (NN (pathogenesis))(NN (prostate))(NN (cancer)))(ADVP (RB (potentially)))(ADVP (RB (also)))(NP (NN (carcinoma)))(, (,))(S (VP (VBG (raising))(SBAR (S (NP (NN (possibility))(NN (ADAM9)))(VP (MD (might))(NP (JJ (good))(NN (target))(NN (antitumor))(NN (drug)))))))))))))) |ET|  |BS| 265:C04.557.470.200 369:E02.319.300  |ES| 2:1 5:1 18:1 19:1 77:1 101:1 160:1 191:1 304:1 343:1 501:1 773:1 796:1 798:1 845:1 1318:1 1537:1 1538:1 2244:1 3211:1 3212:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NNS (data)))(VP (VBD (indicated))(SBAR (S (NP (NN (nifuroxazide)))(VP (MD (may))(ADVP (RB (potentially)))(NP (JJ (therapeutic))(NN (agent))(NN (growth))(NN (metastasis))(NN (breast))(NN (cancer)))))))) |ET|  |BS| 52:E02 113:C04.697.650  |ES| 18:1 19:1 23:1 102:1 491:1 541:1 658:1 728:1 773:1 793:1 806:1 1541:1 2820:1  |EV| 
4.520134953427480617449418787146  |BT| (UCP (ADVP (RB (Here)))(, (,))(NP (NP (NN (report))(NN (identification))(JJ (hepatic))(NNS (microRNAs)))(SBAR (S (NP (VBN (dysregulated))(JJ (early))(NN (stage))(S (VP (VBG (feeding))(NP (NP (NP (NN (C57BL/6))(NN (mouse))(JJ (choline-deficient))(NN (amino))(JJ (acid-defined)))(-LRB- (-LRB-))(JJ (CDAA))(-RRB- (-RRB-))(NN (diet)))(ADJP (VBN (known)))))))(VP (VBP (promote))(FRAG (NP (NP (JJ (nonalcoholic))(NN (steatohepatitis)))(PRN (-LRB- (-LRB-))(NP (NN (NASH)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (hepatocarcinogenesis))(CD (84))(NN (week))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 374:F01.393.446 509:C06.552.241.519 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125  |ES| 2:1 10:1 14:1 19:1 52:1 400:1 409:1 417:1 556:1 679:1 783:1 838:1 900:1 1128:1 1129:1 1259:1 1791:1 1796:1 2188:1 2189:1 2190:1 2191:1 2192:1 2942:1 3065:1 3184:1 3469:1 3517:1 3518:1  |EV| 
-0.87768934717291813285555690526962  |BT| (NP (NP (ADVP (RB (However)))(, (,))(NP (NN (investigation))(JJ (protective))(NN (effect))(NN (betaine))(NN (hepatocarcinogenesis))))) |ET|  |BS| 225:E05.337 743:D02.092.877.883.077  |ES| 2:1 19:1 75:1 433:1 493:1 900:1 1497:1 2636:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (METHODOLOGY/PRINCIPAL))(NNS (FINDINGS)))(: (:))(NP (NP (JJ (Pancreatic))(NN (cancer))(NN (cell))(NN (line)))(VP (VBN (treated))(NP (NN (resveratrol))))))) |ET|  |BS| 52:E02 94:A11.251.210  |ES| 18:1 19:1 94:1 104:1 264:1 1099:1 1213:1 1712:1 2748:1 2749:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (NN (Magnolol))(NNS (pretreatments)))(VP (VBP (prevent))(S (NP (JJ (UVB-induced))(NN (skin))(NN (cancer))(NN (development)))(VP (VBG (enhancing))(NP (NN (apoptosis)))(, (,))(S (VP (VBG (causing))(NP (NN (cell))(NN (cycle))(NN (arrest))(NN (G2/M))(NN (phase)))))))(, (,))(S (VP (VBG (affecting))(NP (JJ (various))(NN (signaling))(NN (pathway)))))))) |ET|  |BS| 39:G04.299.139.160 126:G02.111.087.800 702:G04.299.134.109.750  |ES| 2:1 18:1 19:1 35:1 89:1 94:1 104:1 195:1 239:1 383:1 601:1 602:1 733:1 1096:1 1491:1 2312:1 2319:1 2525:1 2526:1 2527:1 2528:1 2529:1 2530:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNS (METHODS))(: (:)))(S (NP (JJ (Male))(ADJP (ADJP (NN (C57BL/6))(NN (mouse))(NN (fed))(NN (methionine))(JJ (choline-deficient)))(PRN (-LRB- (-LRB-))(NP (NN (MCD)))(-RRB- (-RRB-))))(NN (diet)))(VP (VBP (induce))(NP (NN (steatohepatitis)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 508:C06.552.241 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676  |ES| 10:1 14:1 19:1 52:1 104:1 243:1 565:1 1791:1 2050:1 2188:1 2191:1 2192:1 2426:1 2524:1 3635:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP (It)))(VP (VBD (suggested))(SBAR (S (NP (NN (CYP2E1)))(ADVP (RB (completely)))(VP (VBZ (participates))(NP (JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis)))(, (,))(SBAR (S (NP (JJ (high))(NP (NN (frequency)))(NN (tumor))(JJ (wild-type))(NN (mouse)))(VP (MD (could))(VP (VBN (associated))(NP (VBN (increased))(NN (apoptosis)))))))))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 554:D02.654.442.200 1218:D08.244.453.300  |ES| 2:1 7:1 8:1 19:1 47:1 52:1 89:1 169:1 178:1 900:1 908:1 925:1 1247:1 1327:1 2732:1 4270:1 4271:1 4272:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Antisense))(NP (JJ (E1AF-transfected))(NN (MKN45))(JJ (gastric))(NN (cancer))(NN (cell))))(VP (VBD (expressed))(NP (VBN (reduced))(NN (level))(NN (matrilysin)))(NP (DT (le))(NP (JJ (invasive))(NN (vitro))(JJ (mock-transfected))(NN (MKN45))(NN (cell)))))) |ET|  |BS| 41:A11 937:D08.811.277.656.300.480.525.700.250  |ES| 6:1 18:1 19:1 86:1 94:1 144:1 216:1 249:1 452:1 489:1 2850:1 3287:1 3288:1 3289:1 3290:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Pharmacogenetic))(NN (approach))(NN (capecitabine))(NN (5-fluorouracil))(NN (selection)))(SBAR (S (NP (VBN (combined))(NN (oxaliplatin))(JJ (first-line))(NN (chemotherapy)))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 151:E02.319 375:Z01.639.100 560:D03.383.742.698.875.404 810:D03.383.742.680.245.500.425 811:H01.158.273.343.750 812:G05.355.800  |ES| 17:1 18:1 19:1 164:1 495:1 911:1 997:1 2307:1 2490:1 2543:1 2872:1 2873:1 2874:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (CONCLUSION))(: (:)))(VP (VP (VBN (Taken))(ADVP (RB (together))))(, (,))(SBAR (S (NP (NNS (data))(VBP (show))(NN (Akt))(NN (inhibitor))(NN (AZD5363)))(VP (VBZ (synergizes))(SBAR (S (NP (JJ (lysosomotropic))(NN (inhibitor))(NN (autophagy))(NN (chloroquine)))(VP (VBP (induce))(NP (NN (apoptosis))(NN (delay))(NN (tumor))(NN (progression))(NN (prostate))(NN (cancer))(NN (model))(JJ (resistant))(NN (monotherapy))(NN (AZD5363)))(, (,))(S (VP (VBG (providing))(NP (NP (JJ (new))(JJ (therapeutic))(NN (approach)))(RRC (ADVP (RB (potentially)))(NP (JJ (translatable))(NN (patient))))))))))))))) |ET|  |BS| 8:C04 16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 50:M01.643 52:E02 202:C04.588.945.440.770 390:G04.299.139.399 961:D03.438.810.050.180  |ES| 2:1 7:1 18:1 19:1 48:1 72:1 77:1 89:1 104:1 120:1 136:1 243:1 380:1 427:1 429:1 541:1 712:1 773:1 793:1 911:1 1289:1 1317:1 1537:1 1538:1 1882:1 3025:1 3375:1 3376:1 3377:1 3378:1 3379:1 3380:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (GP73)))(PRN (-LRB- (-LRB-))(PRN (: (-))(: (/))(: (-)))(-RRB- (-RRB-))))(, (,))(NP (NN (GP73))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(: (-)))(-RRB- (-RRB-))(, (,))(NP (NP (NN (GP73))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-)))(NN (mouse)))(VP (VBN (given))(NP (NN (injection))(NN (diethylnitrosamine))))))(S (VP (VBP (induce))(NP (NN (liver))(NN (injury)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 242:A03.620 554:D02.654.442.200  |ES| 2:1 10:1 14:1 19:1 29:1 44:1 45:1 51:1 52:1 243:1 785:1 836:1 1952:1 2416:1 4174:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NNP (UNLABELLED)))(: (:))(NP (NP (DT (The))(NN (Wnt/beta-catenin))(NN (pathway)))(VP (VBN (implicated))(NP (NP (NN (pathogenesis))(JJ (hepatocellular))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))) |ET|  |BS| 23:D12.776.091.249 147:G02.149.115.800.925  |ES| 10:1 14:1 18:1 19:1 104:1 302:1 303:1 383:1 441:1 501:1 691:1 977:1 2266:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Herein)))(, (,))(VP (VBD (found))(SBAR (IN (whereas))(S (VP (VBG (sparing))(NP (NP (JJ (normal))(NP (JJ (human))(NN (colon))(JJ (mucosal))(JJ (epithelial))(NN (cell))))(, (,))(NP (NN (EPLE))))(VP (ADVP (RB (selectively)))(VBD (inhibited))(NP (NN (proliferation))(NN (CRC))(NN (cell))(NN (line)))(ADVP (RB (well)))(NP (JJ (primary))(NN (tumor))(NN (cell))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 41:A11 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 122:C14.280.383 183:G04.299.233.750 302:A10.615.550  |ES| 2:1 7:1 19:1 36:1 37:1 94:1 113:1 118:1 127:1 245:1 264:1 299:1 344:1 365:1 372:1 428:1 787:1 2489:1 3521:1 3522:1 3523:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Garcinol)))(VP (VBZ (suppresses))(NP (JJ (inflammation-associated))(NN (colon))(NN (carcinogenesis))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 53:C06.405.205.265  |ES| 19:1 52:1 113:1 207:1 686:1 1849:1 2612:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (After))(NP (JJ (2-week))(NN (treatment))))(, (,))(NP (NN (animal)))(VP (VBN (subjected))(SBAR (`` (``))(S (NP (NP (JJ (resistant))(NN (hepatocyte))('' (''))(NN (model))(NN (hepatocarcinogenesis)))(PRN (-LRB- (-LRB-))(NP (NP (NN (initiation))(NN (diethylnitrosamine)))(, (,))(NP (NN (selection/promotion))(JJ (2-acetylaminofluorene))(JJ (partial))(NN (hepatectomy))))(-RRB- (-RRB-))))(VP (VBD (euthanized))(NP (ADJP (CD (8))(NN (week)))(NN (treatment)))))))) |ET|  |BS| 19:B01.050 52:E02 262:A11.436.348 554:D02.654.442.200 812:G05.355.800 881:D02.065.064.150 927:E02.760.905.850 928:E04.210.556  |ES| 2:1 10:1 14:1 19:1 46:1 72:1 427:1 546:1 637:1 781:1 783:1 900:1 1909:1 1952:1 3265:1 3266:1 3267:1 3268:1 3269:1 3270:1 3271:1 3272:1 3273:1 3274:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Pravastatin)))(VP (VBZ (reduces))(NP (NN (lung))(NN (metastasis))(NN (rat))(JJ (hepatocellular))(NN (carcinoma)))(PP (IN (via))(NP (VBN (coordinated))(NN (decrease))(NN (MMP))(NN (expression))(NN (activity)))))) |ET|  |BS| 104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 817:D02.455.426.559.847.638.930 818:D08.811.277.656.300.480.525  |ES| 19:1 115:1 142:1 295:1 303:1 304:1 328:1 399:1 596:1 806:1 849:1 2890:1 2891:1 2892:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Constitutive))(NN (activation))(NN (Wnt/beta-catenin))(NN (pathway)))(VP (VBN (implicated))(NP (JJ (primary))(NN (cause))(NN (colon))(NN (cancer))))) |ET|  |BS| 23:D12.776.091.249 147:G02.149.115.800.925  |ES| 18:1 19:1 113:1 225:1 302:1 344:1 383:1 977:1 1779:1 3399:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Latexin)))(VP (VBP (exhibit))(NP (NN (tumor))(NN (suppressor))(JJ (potential))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 104:C04.557.470.200.025.255 175:J01.897.280.500.269 206:G05.360.340.024.340.375.249  |ES| 7:1 19:1 303:1 304:1 587:1 700:1 827:1 2720:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (EX (There)))(NP (JJ (abundant))(JJ (epidemiological))(NN (evidence))(JJ (heavy))(NN (alcohol))(NN (intake)))(VP (VBZ (contributes))(NP (NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NN (development))))) |ET|  |BS| 104:C04.557.470.200.025.255 651:H02.403.720.500 904:F01.145.317.269  |ES| 10:1 14:1 19:1 35:1 38:1 303:1 304:1 441:1 767:1 845:1 1798:1 2563:1 3217:1 3710:1 4039:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Glycine))(NN (soya))(NN (diet)))(ADVP (RB (synergistically)))(VP (VBZ (enhances))(SBAR (S (NP (JJ (suppressive))(NN (effect))(NN (tamoxifen)))(VP (VBZ (inhibits))(NP (NP (JJ (tamoxifen-promoted))(NN (hepatocarcinogenesis)))(JJ (7,12-dimethylbenz))(PRN (-LRB- (-LSB-))(NP (NN (alpha)))(-RRB- (-RSB-)))(JJ (anthracene-induced))(NN (rat))(JJ (mammary))(NN (tumor))(NN (model)))))))) |ET|  |BS| 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 408:C04.588.531 595:G07.203.650.240 596:E02.642.249 640:D02.455.426.559.389.150.700.900 1001:B01.650.940.800.575.100.401.750 1002:C04.588.180 1003:D12.125.481  |ES| 7:1 19:1 72:1 75:1 615:1 849:1 900:1 1356:1 1373:1 1378:1 1836:1 1974:1 2191:1 2248:1 2371:1 3349:1 3499:1 3500:1 3501:1 3502:1 3503:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (DT (The))(JJ (present))(NN (study)))(VP (VBN (undertaken))))(VBP (investigate))(NP (NP (NN (effect))(JJ (dietary))(NN (supplementation))(NN (nimesulide))(NN (eugenol))(NN (N-nitrosodiethylamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(: (-))(VP (VBN (initiated))(NP (JJ (early))(NN (hepatocarcinogenesis))(NN (F344))(JJ (male))(NN (rat))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 554:D02.654.442.200 590:B01.050.050.199.520.760.200 595:G07.203.650.240 1165:D02.241.223.200.054.500  |ES| 10:1 14:1 19:1 75:1 131:1 459:1 691:1 849:1 900:1 1128:1 1307:1 1402:1 1875:1 2567:1 2594:1 2602:1 3185:1 3186:1 4022:1 4023:1 4024:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (However)))(, (,))(NP (JJ (molecular))(NN (mechanism))(NN (progesterone))(NN (action))(NN (breast))(NN (cancer)))(ADVP (RB (still)))(VP (VBP (remain))(ADJP (JJ (elusive))))) |ET|  |BS| 742:G03.787 1010:D04.808.745.745.654.829  |ES| 2:1 18:1 19:1 23:1 161:1 162:1 433:1 776:1 777:1 2013:1 2181:1 3536:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Involvement))(NN (Mouse))(JJ (Constitutive))(NN (Androstane))(NN (Receptor))(JJ (Acifluorfen-Induced))(NN (Liver)))(NP (NNP (Injury))(JJ (Subsequent))(NN (Tumor))(NN (Development))))) |ET|  |BS| 8:C04 242:A03.620  |ES| 19:1 1218:1 2059:1 2127:1 2721:1 3399:1 4264:1 4265:1 4266:1 4267:1 4268:1 4269:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Finally)))(, (,))(NP (NN (Apo-FHL2))(NN (mouse)))(VP (VBD (developed))(SBAR (S (NP (NP (NN (tumor)))(, (,))(NP (NN (FHL2))(NN (transgene))))(VP (VBD (enhanced))(SBAR (S (NP (NN (hepatocarcinogenesis)))(VP (VBD (induced))(NP (JJ (liver-specific))(NN (deletion))(NP (NP (JJ (adenomatous))(NN (polyposis))(NN (coli))(NN (gene))(JJ (aberrant))(NN (Wnt/beta-catenin))(NN (signaling))(NN (Apc)))(PRN (-LRB- (-LRB-))(NP (NN (lox/lox)))(-RRB- (-RRB-))))(NN (animal))))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320  |ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (JJ (Combined))(NN (treatment))(NN (EPLE))(NN (5-fluorouracil)))(, (,))(NP (JJ (first-line))(NN (chemotherapy))(NN (CRC))(NN (patient)))(, (,)))(VP (VBD (achieved))(NP (JJ (synergistic))(NN (effect))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 151:E02.319 560:D03.383.742.698.875.404 618:E02.186  |ES| 2:1 19:1 75:1 120:1 245:1 495:1 546:1 2012:1 2307:1 2488:1 2489:1 2490:1 2491:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Sorafenib))(NN (increase))(NN (survival))(NN (rate))(NN (patient)))(VP (VBD (advanced))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))) |ET|  |BS| 50:M01.643 104:C04.557.470.200.025.255 779:E05.318.308.985.550.900  |ES| 10:1 14:1 19:1 40:1 41:1 120:1 274:1 303:1 304:1 441:1 997:1 3210:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (EXPERIMENTAL))(NN (DESIGN)))(: (:))(S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBD (investigated))(NP (NP (NP (NN (effect))(JJ (novel))(NN (farnesyltransferase))(NN (inhibitor)))(, (,))(NP (NN (ABT-100)))(, (,))(NP (JJ (human))(NN (liver))(NN (cancer))(NN (cell))(NN (line))))(, (,))(NP (NN (HepG2))(NN (Huh7)))(, (,))(NP (NN (animal))(NN (model))(NN (hepatocarcinogenesis))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 204:E05.581.500 205:E05.581.500 259:D12.776.395.240.150.500 285:E05.598 988:D08.811.913.225.431 989:D08.811.913.225.437 990:C22.232  |ES| 2:1 18:1 19:1 36:1 46:1 72:1 75:1 94:1 104:1 131:1 244:1 264:1 380:1 403:1 689:1 690:1 836:1 891:1 900:1 1307:1 2538:1 3480:1 3481:1 3482:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Hepatoprotective))(NN (effect))(NN (tamoxifen))(NN (steatosis))(JJ (non-alcoholic))(NN (steatohepatitis))(NN (mouse))(NN (model)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 509:C06.552.241.519 640:D02.455.426.559.389.150.700.900  |ES| 19:1 52:1 72:1 75:1 1791:1 2069:1 2371:1 2678:1 3504:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (AIM))(: (:)))(S (S (VP (TO (To))(VP (VB (elucidate))(S (NP (JJ (anticancer))(NN (mechanism))(NNP (Huqi))(NNP (San)))(VP (VBG (assessing))(NP (NN (expression))(NN (G-6-Pase))))))))(, (,))(NP (NP (NN (SDH)))(, (,))(NP (NN (ATPase))(NN (AFP))(JJ (N-nitrosodiethylamine-mediated))(NN (hepatocarcinogenesis))(NN (rat)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 893:D08.811.277.040.025 894:D08.811.277.040.025  |ES| 2:1 19:1 104:1 115:1 162:1 828:1 849:1 900:1 959:1 1196:1 1697:1 1880:1 2762:1 2765:1 2766:1 3630:1 3632:1 3634:1 3957:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Epidemiological))(NN (study)))(VP (VBP (indicate))(NP (JJ (adequate))(JJ (dietary))(NN (folate))(JJ (protective))(NN (colon))(NN (cancer)))(, (,))(SBAR (IN (although))(S (NP (NN (mechanism)))(VP (VBP (remain))(ADJP (RB (largely))(JJ (elusive)))))))) |ET|  |BS| 224:D03.438.733.631.400 595:G07.203.650.240 722:E05.318.760.500  |ES| 2:1 18:1 19:1 113:1 131:1 162:1 493:1 777:1 778:1 1479:1 1592:1 2181:1 2384:1 2593:1 2594:1 2595:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (ADVP (RB (However)))(, (,))(NP (NNP (Sorafenib))(NN (treatment)))(ADVP (RB (transiently)))(VP (VBD (inhibited))(SBAR (S (NP (NN (cell))(NN (cycle))(NN (progression)))(VP (VBD (resulted))(SBAR (S (NP (JJ (mitotic))(NN (catastrophe)))(VP (VBD (enhanced))(NP (JJ (non-apoptotic))(NN (liver))(NN (injury))(NN (regeneration))))))))))) |ET|  |BS| 16:C23.550.291.656 39:G04.299.139.160 52:E02 122:C14.280.383 353:G04.299.134 925:G10.261.326.520  |ES| 2:1 19:1 48:1 94:1 365:1 385:1 433:1 546:1 594:1 601:1 720:1 836:1 2416:1 2833:1 3210:1 3260:1 3614:1 4213:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (DT (No))(VBG (Modifying))(NP (NP (NN (Effect))(JJ (Antioxidant))(NN (N-Acetyl-L-Cysteine)))(JJ (Fenofibrate-induced))(NNP (Hepatocarcinogenesis))(NNS (Rats))))) |ET|  |BS| 13:D01.339.387 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 791:D02.886.030.230.259 916:D02.241.081.114.968.500.625 1049:D27.505.519.217  |ES| 19:1 1959:1 3222:1 3638:1 3660:1 3661:1 3662:1 3663:1 3664:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Liver))(NN (tumor)))(VP (VBG (promoting))(NP (NN (effect))(NN (etofenprox))(NN (rat))(JJ (possible))(NN (mechanism))(NN (action))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 742:G03.787  |ES| 7:1 19:1 75:1 162:1 849:1 881:1 1359:1 2013:1 2721:1 4287:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Diet-induced))(NN (obesity))(NN (ethanol)))(VP (VBP (impair))(NP (NN (progression))(JJ (hepatocellular))(NN (carcinoma))(NN (mouse))(JJ (mesenteric))(NN (vein))(NN (injection))(NN (model))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 226:E02.319.267.530 564:C18.654.726.500 595:G07.203.650.240 596:E02.642.249 751:D02.033.375 976:A07.231.908.670.385  |ES| 19:1 48:1 52:1 72:1 303:1 304:1 785:1 2010:1 3439:1 3440:1 3441:1 3442:1 3443:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (For))(NP (FW (vivo))(NN (study))))(, (,))(NP (JJ (1,2-dimethylhydrazine))(NN (dihydrochloride))(-LRB- (-LRB-))(NN (DMH))(-RRB- (-RRB-))(NN (s.c.)))(VP (VBD (injected))(VP (VBP (induce))(NP (NP (NP (NN (colon))(NN (cancer))(NN (PPARgamma)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-))))(NN (PPARgamma))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(: (-)))))(-RRB- (-RRB-))(NP (NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 719:D12.776.826.239.588  |ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 131:1 243:1 378:1 2588:1 2642:1 2643:1 3489:1 3586:1 4165:1 4166:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (VP (TO (To))(VP (VB (clarify))(NP (NP (JJ (possible))(NN (mechanism))(JJ (non-genotoxic))(NN (hepatocarcinogenesis)))(VP (VBD (induced))(NP (NP (NP (NN (piperonyl))(NN (butoxide)))(PRN (-LRB- (-LRB-))(NP (NN (PBO)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (male))(NN (F344))(NN (rat)))(VP (VBN (administered))(S (NP (NN (i.p)))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 590:B01.050.050.199.520.760.200 967:D01.248.497.158.490 1077:D03.383.246.118.600  |ES| 2:1 10:1 14:1 19:1 162:1 412:1 828:1 849:1 900:1 1359:1 1402:1 2336:1 3185:1 3193:1 3777:1 3778:1 4049:1 4050:1 4051:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Cyclooxygenase))(CD (2))(NN (Prostaglandin))(NN (E2)))(VP (VBN (Involved))(NP (JJ (N-Nitrosodiethylamine-Initiated))(JJ (Early))(NN (Rat))(NN (Hepatocarcinogenesis))))) |ET|  |BS| 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1118:D10.251.355.255.550.250.200  |ES| 19:1 148:1 1959:1 3432:1 3909:1 4008:1 4132:1 4133:1 4134:1 4135:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Claudin-1))(NN (overexpression))(JJ (intestinal))(JJ (epithelial))(NN (cell)))(VP (VBZ (enhances))(NP (NN (susceptibility))(JJ (adenamatous))(NN (polyposis))(JJ (coli-mediated))(NN (colon))(NN (tumorigenesis))))) |ET|  |BS| 3:C04.557.470.035.215.100 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 75:A11.436 401:C23.550.291.687 952:D12.776.543.984.200.100  |ES| 19:1 58:1 78:1 94:1 109:1 113:1 127:1 152:1 1353:1 1356:1 3333:1 3334:1 3335:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (NP (NNS (CONCLUSIONS))(: (:)))(NP (NN (Pitavastatin))(JJ (effective))(VBG (inhibiting))(NP (JJ (early))(NN (phase))(JJ (obesity-related))(NN (liver))(NN (tumorigenesis))))(, (,))(ADVP (RB (therefore)))(, (,))(NP (MD (may))(NP (JJ (useful))(NN (chemoprevention))(NN (liver))(NN (cancer))(JJ (obese))(NN (individual))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 122:C14.280.383 242:A03.620 253:E02.319.162 493:M01 564:C18.654.726.500  |ES| 2:1 18:1 19:1 78:1 104:1 218:1 239:1 491:1 836:1 870:1 880:1 1036:1 1128:1 1639:1 2467:1 2468:1 2512:1 2529:1 3387:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Cryptotanshinone)))(VP (VBZ (inhibits))(NP (NP (JJ (constitutive))(NN (signal))(NN (transducer))(NN (activator))(NN (transcription))(CD (3))(NN (function)))(VP (VBG (blocking))(NP (NN (dimerization))(NN (DU145))(NN (prostate))(NN (cancer))(NN (cell))))))) |ET|  |BS| 41:A11 122:C14.280.383 209:G02.111.087.847 250:E07.305.812 970:E06.658.453.560.100 971:G02.149.250  |ES| 18:1 19:1 33:1 77:1 94:1 487:1 604:1 615:1 859:1 860:1 861:1 862:1 3420:1 3421:1 3422:1 3423:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NNP (Farnesyltransferase))(NN (inhibitor)))(, (,))(NP (NN (ABT-100)))(, (,))(NP (JJ (potent))(NN (liver))(NN (cancer))(JJ (chemopreventive))(NN (agent))))) |ET|  |BS| 988:D08.811.913.225.431 989:D08.811.913.225.437  |ES| 2:1 18:1 19:1 22:1 380:1 728:1 836:1 1946:1 2538:1 3487:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (VBN (Increased))(NN (expression))(NN (cyclooxygenase-2))(NN (protein))(NN (rat))(NN (hepatocarcinogenesis)))(VP (VBD (caused))(ADJP (ADJP (JJ (choline-deficient)))(, (,))(NP (NP (NN (L-amino))(JJ (acid-defined))(NN (diet))(JJ (chemopreventive))(NN (efficacy))(JJ (specific))(NN (inhibitor)))(, (,))(NP (NN (nimesulide))))))) |ET|  |BS| 7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125  |ES| 2:1 4:1 19:1 61:1 115:1 380:1 540:1 849:1 900:1 1212:1 1946:1 2188:1 2190:1 2191:1 2304:1 2506:1 3183:1 3186:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(NP (VBD (investigated))(NP (JJ (anticancer))(NN (activity))(JJ (tolfenamic))(NN (acid))(JJ (human))(JJ (colorectal))(NN (cancer))(NN (cell))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 55:B01.050.150.900.649.801.400.112.400.400  |ES| 2:1 17:1 18:1 19:1 36:1 94:1 131:1 244:1 399:1 403:1 1275:1 1307:1 1880:1 2598:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NN (DNA))(NN (microarray))(NN (analysis)))(VP (VBN (used))))(VP (VBP (analyze))(NP (NP (JJ (transcriptional))(NN (profile))(NN (HCT116))(JJ (colorectal))(NN (cancer))(NN (cell)))(VP (VBN (treated))(NP (NP (NP (NN (5-fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NN (oxaliplatin))(VBN (selected))(NN (resistance))(NN (agent))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 198:D13.444.308 209:G02.111.087.847 560:D03.383.742.698.875.404 717:A11.251.210.190.380 718:E05.588.570  |ES| 10:1 14:1 17:1 18:1 19:1 94:1 476:1 559:1 566:1 661:1 666:1 728:1 913:1 1094:1 1099:1 1711:1 2307:1 2308:1 2543:1 2585:1 2586:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Expression))(NN (glutathione))(NN (peroxidase))(CD (2)))(VP (VBN (associated))(NP (JJ (early))(NN (hepatocarcinogenesis)))(ADVP (RB (also)))(NP (JJ (late))(NN (stage))(NN (metastasis))))) |ET|  |BS| 113:C04.697.650 991:D08.811.682.732.500  |ES| 5:1 19:1 148:1 169:1 316:1 806:1 900:1 1128:1 1129:1 2649:1 2744:1 3485:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (ADVP (RB (However)))(, (,))(NP (NP (NN (action))(NN (compound))(JJ (ethanol-induced))(NN (liver))(NN (injury)))(ADJP (RB (still))(JJ (unknown))))) |ET|  |BS| 242:A03.620 751:D02.033.375  |ES| 2:1 19:1 433:1 776:1 836:1 2013:1 2182:1 2416:1 2433:1 2674:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(NP (NNP (Aliskiren)))(VP (VBZ (attenuates))(NP (NN (steatohepatitis))(NN (fibrosis))(NN (mouse))(NN (fed))(NN (MCD))(NN (diet))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 691:C23.550.355  |ES| 19:1 52:1 104:1 239:1 949:1 1791:1 2191:1 2422:1 2423:1 2426:1 2524:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Intake))(NNS (isoflavones)))(SBAR (S (NP (VBN (derived))(NN (soybean))(NN (product)))(VP (MD (may))(VP (VB (impact))(NP (NN (prostate))(NN (cancer))(NN (risk))))))))) |ET|  |BS| 61:E05.318.740.600.800 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400  |ES| 18:1 19:1 77:1 171:1 491:1 675:1 1721:1 3541:1 3597:1 3598:1 3599:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Methylenetetrahydrofolate))(NN (reductase))(NN (gene))(NN (polymorphism))(NN (response))(JJ (fluorouracil-based))(NN (treatment)))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer))(NN (patient))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 50:M01.643 52:E02 307:G05.365.795 333:D01.045 560:D03.383.742.698.875.404 606:D08.811.682.662.290  |ES| 9:1 17:1 18:1 19:1 96:1 120:1 494:1 546:1 997:1 1060:1 3636:1 3637:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Overexpression))(NN (Klotho)))(VP (VBZ (suppresses))(SBAR (S (NP (NN (liver))(NN (cancer))(NN (progression)))(VP (VBZ (induces))(S (NP (NN (cell))(NN (apoptosis)))(ADVP (RB (negatively)))(VP (VBG (regulating))(NP (JJ (wnt/beta-catenin))(NN (signaling))(NN (pathway)))))))))) |ET|  |BS| 16:C23.550.291.656 39:G04.299.139.160 41:A11 105:G02.149.115.800.925  |ES| 18:1 19:1 48:1 89:1 94:1 195:1 214:1 383:1 668:1 686:1 836:1 2867:1 2868:1 2869:1 2870:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Previously)))(, (,))(VP (VBD (showed))(SBAR (S (NP (JJ (habitual))(JJ (heavy))(NN (alcohol))(NN (ingestion)))(VP (VBD (amplified))(S (NP (NP (JJ (age-related))(NN (hepatocarcinogenesis))(NN (P))(NN (rat)))(, (,))(NP (NP (CD (80))(NN (%)))(NP (JJ (alcohol-consuming))(NP (NN (P))(NN (rat))(VBG (developing))(NNS (HCCs)))(NP (CD (18))(NN (month))(NN (alcohol))(NN (exposure)))))(, (,)))(VP (VBN (compared))(NP (ADJP (CD (5))(NN (%)))(NN (water-drinking))(NN (control)))))))))) |ET|  |BS| 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 751:D02.033.375 822:D02.033 904:F01.145.317.269 1060:D01.045.250.875.300  |ES| 2:1 19:1 50:1 132:1 289:1 311:1 369:1 573:1 578:1 590:1 767:1 849:1 900:1 1132:1 1953:1 2208:1 2723:1 3708:1 3709:1 3710:1 3711:1 3712:1 3713:1 3714:1 3715:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Dovitinib)))(VP (VBZ (demonstrates))(NP (JJ (antitumor))(JJ (antimetastatic))(NN (activity))(NN (xenograft))(NN (model))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255  |ES| 19:1 72:1 265:1 303:1 304:1 399:1 2244:1 2245:1 2541:1 3449:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (VP (NP (NNP (Digital)))(VBG (karyotyping))(VP (VBZ (identifies))(NP (NN (thymidylate))(NN (synthase))(NN (amplification))(NN (mechanism))(NN (resistance))(NN (5-fluorouracil))(JJ (metastatic))(JJ (colorectal))(NN (cancer))(NN (patient)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430  |ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Decrease))(JJ (hepatic))(JJ (stellate))(NN (cell))(NN (rat)))(VP (VBD (enhanced))(NP (NN (sensitivity))(JJ (clofibrate-induced))(NN (hepatocarcinogenesis))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 677:A11.561 910:D02.241.081.114.968.500.500.195  |ES| 19:1 94:1 385:1 607:1 838:1 849:1 900:1 2461:1 3433:1 3434:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (S (VP (TO (To))(VP (VB (investigate))(NP (NP (NP (JJ (protective))(NN (effect))(NN (bilberry))(NN (extract)))(PRN (-LRB- (-LRB-))(NP (NN (BBE)))(-RRB- (-RRB-))))(NP (NP (NP (ADJP (RB (enzymatically))(VBN (modified)))(NN (isoquercitrin)))(PRN (-LRB- (-LRB-))(NP (NN (EMIQ)))(-RRB- (-RRB-))))(NP (NP (JJ (hepatocarcinogenic))(NN (process)))(VP (VBG (involving))(NP (NP (JJ (oxidative))(NN (stress))(NN (response)))(, (,))(VP (VBN (used))(S (NP (NP (JJ (two-stage))(NN (hepatocarcinogenesis))(NN (model))(JJ (N-diethylnitrosamine-initiated))(NN (piperonyl))(NN (butoxide)))(PRN (-LRB- (-LRB-))(NP (NN (PBO)))(-RRB- (-RRB-))))))))))))))(: (-))(VP (VBD (promoted))(NP (NN (rat))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 1077:D03.383.246.118.600  |ES| 2:1 10:1 14:1 19:1 72:1 75:1 459:1 476:1 493:1 494:1 638:1 828:1 849:1 900:1 2335:1 2372:1 2496:1 2522:1 2583:1 2971:1 3773:1 3774:1 3777:1 3778:1 4029:1 4050:1 4052:1 4053:1 4054:1 4055:1 4056:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (ADVP (RB (Collectively)))(, (,))(NP (NP (NNS (data)))(SBAR (IN (along))(S (NP (JJ (negative))(NN (genotoxicity)))(VP (VBP (demonstrate))(SBAR (S (NP (NP (NN (oxyfluorfen)))(PRN (-LRB- (-LRB-))(NP (ADJP (QP (JJR (>))(CD (98)))(NN (%)))(NN (purity)))(-RRB- (-RRB-))))(ADJP (JJ (potential)))(VP (VBP (induce))(S (NP (NN (mouse))(NN (liver))(NN (tumor)))(ADJP (JJ (nongenotoxic)))))))(, (,))(NP (NP (JJ (mitogenic))(NNP (MOA))(JJ (clear))(NN (threshold)))(VP (VBD (predicted))(NP (JJ (carcinogenic))(JJ (human))(JJ (relevant))(NN (exposure))(NN (level)))))))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 515:C04.588.274.623 575:V02.050 953:D27.505.519.593.624  |ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 243:1 249:1 369:1 449:1 502:1 793:1 827:1 836:1 865:1 1466:1 1872:1 1953:1 2666:1 3336:1 3337:1 3338:1 3339:1 3340:1 3341:1 3342:1 3343:1 3344:1 3345:1 3346:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (BACKGROUND)))(: (:))(NP (NP (JJ (Prolonged))(JJ (high))(NN (intake))(JJ (dietary))(NN (selenium)))(VP (VBN (shown))(VP (VBP (induce))(NP (JJ (gestational))(NN (diabetes))(NN (rat))(NN (hyperinsulinemia))(NN (pig)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 935:D01.268.185.850 1053:C18.452.394.968 1142:B01.050.150.900.649.077.880.399 1143:B01.050.150.900.649.077.880 1144:C13.703.170  |ES| 19:1 104:1 178:1 237:1 243:1 849:1 1046:1 2009:1 2563:1 2594:1 3284:1 3670:1 3975:1 3976:1 3977:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Beta-ionone)))(VP (VP (VBZ (inhibits))(NP (JJ (colonic))(JJ (aberrant))(NN (crypt))(NN (focus))(NN (formation))(NN (rat))))(, (,))(VP (VBZ (suppresses))(NP (NN (cell))(NN (growth))))(, (,))(VP (VBZ (induces))(NP (NN (retinoid))(NN (X))(NN (receptor-alpha))(JJ (human))(NN (colon))(NN (cancer))(NN (cell)))))) |ET|  |BS| 20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 824:C04.834.020 941:D12.776.826.701.500.500  |ES| 2:1 18:1 19:1 36:1 43:1 94:1 102:1 113:1 214:1 615:1 677:1 686:1 849:1 929:1 1431:1 1725:1 1889:1 2454:1 2573:1 2913:1  |EV| 
-2.919285113907562845270149409771  |BT| (S (NP (NP (JJ (Dietary))(NN (intake))(NN (pterostilbene)))(, (,))(NP (NN (constituent))(NN (blueberry)))(, (,)))(VP (VBZ (inhibits))(NP (NN (beta-catenin/p65))(JJ (downstream))(NN (signaling))(NN (pathway))(NN (colon))(NN (carcinogenesis))(NN (rat))))) |ET|  |BS| 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249  |ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NNP (UNLABELLED)))(: (:))(NP (NP (NP (JJ (Antidiabetic))(NNS (thiazolidinediones)))(PRN (-LRB- (-LRB-))(NP (NN (TZD)))(-RRB- (-RRB-))))(PP (FW (vitro))(NP (NP (JJ (antiproliferative))(NN (effect))(JJ (epithelial))(NN (cancer)))(, (,))(PP (VBG (including))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))))) |ET|  |BS| 104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422  |ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Overall))(NN (finding)))(VP (VBP (substantiate))(SBAR (S (NP (NN (artesunate)))(VP (VBZ (promotes))(SBAR (S (NP (JJ (anti-tumour))(, (,))(JJ (anti-proliferation))(NN (apoptosis))(NN (nitrosodiethylamine)))(VP (VBD (mediated))(NP (JJ (hepatocellular))(NN (carcinoma))))))))))) |ET|  |BS| 8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500  |ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Peroxisome))(JJ (proliferator-activated))(NN (receptor-gamma)))(VP (VBZ (contributes))(NP (JJ (inhibitory))(NN (effect))(NN (Embelin))(NN (colon))(NN (carcinogenesis))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 719:D12.776.826.239.588  |ES| 19:1 75:1 113:1 207:1 845:1 1800:1 1801:1 2429:1 2587:1 2871:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Monensin)))(VP (VBZ (inhibits))(SBAR (S (NP (JJ (canonical))(NP (NN (Wnt))(NN (signaling))(JJ (human))(JJ (colorectal))(NN (cancer))(NN (cell))))(VP (VBZ (suppresses))(NP (NN (tumor))(NN (growth))(JJ (multiple))(JJ (intestinal))(NN (neoplasia))(NN (mouse)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 102:C04.588.274.476.411 122:C14.280.383 1043:D03.383.312.600  |ES| 7:1 17:1 18:1 19:1 36:1 52:1 94:1 102:1 109:1 195:1 615:1 640:1 649:1 686:1 877:1 3236:1 3648:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (GT-094))(JJ (first))(NN (nitrate)))(VP (VBD (reported))(VP (VB (reduce))(NP (NP (NP (JJ (aberrant))(NN (crypt))(NN (focus)))(PRN (-LRB- (-LRB-))(NP (CD (45))(NN (%)))(-RRB- (-RRB-))))(NP (VBN (administered))(NN (carcinogen))(NN (standard))(NN (azoxymethane))(NN (rat))(NN (model))(JJ (colorectal))(NN (cancer))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 824:C04.834.020 1195:D01.248.497.158.606  |ES| 10:1 14:1 17:1 18:1 19:1 72:1 369:1 816:1 849:1 993:1 1431:1 1725:1 1993:1 2125:1 2336:1 2361:1 2913:1 4175:1 4176:1 4177:1 4178:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (JJ (Arsenic))(VP (VBN (induced))(NP (NP (NP (JJ (dose-related))(NN (increase))(NN (lung))(NN (adenocarcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (sex)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (sex)))(-RRB- (-RRB-))))(, (,))(NP (NP (NN (gallbladder))(NN (tumor)))(PRN (-LRB- (-LRB-))(NP (NN (male)))(-RRB- (-RRB-))))(, (,))(NP (JJ (uterine))(NN (carcinoma)))))) |ET|  |BS| 104:C04.557.470.200.025.255 265:C04.557.470.200 1158:D01.268.513.249 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1182:C04.588.274.120.401 1183:A05.360.319.679  |ES| 2:1 7:1 10:1 14:1 19:1 40:1 255:1 303:1 304:1 328:1 412:1 1402:1 4086:1 4087:1 4088:1 4089:1 4090:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (NP (NP (NN (ErbB2))(NN (ErbB3))(NN (receptor))(NN (tyrosine))(NN (kinase)))(NP (VBN (associated))(NN (development))(JJ (human))(NN (colon))(NN (cancer)))(, (,))(NP (NN (expression))(NN (receptor))(JJ (high))(NN (HT-29))(NN (cell))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 792:A11.251.210.190.475 987:D08.811.913.696.620.682.725.400  |ES| 2:1 18:1 19:1 35:1 36:1 94:1 113:1 115:1 169:1 178:1 186:1 470:1 1705:1 2341:1 2782:1 3475:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (INTERPRETATION)))(: (:))(S (S (NP (NN (Stimulation))(NN (survivin))(NN (expression))(NN (TCF/beta))(NN (catenin)))(VP (MD (might))(VP (VB (impose))(NP (NN (stem))(JJ (cell-like))(NN (phenotype)))(SBAR (S (NP (JJ (colonic))(NN (crypt))(NN (epithelium))(NN (coupling)))(VP (VBD (enhanced))(NP (NN (cell))(NN (proliferation))(NN (resistance))(NN (apoptosis)))))))))(, (,))(VP (VBP (contribute))(NP (JJ (molecular))(NN (pathogenesis))(JJ (colorectal))(NN (cancer)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 39:G04.299.139.160 46:A03.556.124.526.356 62:A10.272 80:G05.695 183:G04.299.233.750 308:A11.872  |ES| 2:1 17:1 18:1 19:1 89:1 94:1 104:1 115:1 161:1 173:1 236:1 299:1 385:1 450:1 501:1 677:1 798:1 1094:1 1106:1 2229:1 2913:1 3601:1 3602:1 3603:1 3604:1 3605:1 3606:1 3607:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (PRP$ (Our))(NNS (data)))(VP (VBP (suggest))(S (NP (VBN (truncated))(NN (PPARalpha))(NN (splice))(JJ (variant))(NN (function)))(NP (NP (JJ (endogenous))(NN (inhibitor))(JJ (proliferative))(JJ (pro-inflammatory))(NN (gene)))(SBAR (S (NP (JJ (human))(NN (cell))(NN (absence))(NN (mouse)))(VP (MD (may))(VP (VB (explain))(NP (JJ (species-specific))(NN (difference))(JJ (fibrate-induced))(NN (hepatocarcinogenesis)))))))))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 55:B01.050.150.900.649.801.400.112.400.400 536:D12.776.826.239.500 1185:D12.125.072.401.623 1186:G16.824  |ES| 9:1 19:1 33:1 36:1 52:1 94:1 104:1 239:1 380:1 491:1 658:1 793:1 796:1 900:1 990:1 1534:1 1674:1 3870:1 4114:1 4115:1 4116:1 4117:1 4118:1 4119:1 4120:1 4121:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Coffee)))(VP (VBZ (reduces))(NP (NP (NN (liver))(NN (damage))(NN (rat))(NN (model))(NN (steatohepatitis)))(: (:))(NP (VBG (underlying))(NN (mechanism))(NN (role))(NNS (polyphenols))(NNS (melanoidins)))))) |ET|  |BS| 15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249  |ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (ADVP (RB (Importantly)))(, (,))(NP (NN (cotreatment))(JJ (low))(NNS (dos))(NP (NP (NNS (oligoamines))(NN (DNA))(NN (methyltransferase))(NN (inhibitor)))(ADVP (RB (highly)))))(VP (VBZ (induces))(SBAR (S (NP (NN (reexpression)))(ADVP (RB (aberrantly)))(VP (VBD (silenced))(SBAR (S (NP (NN (SFRP2))(NN (gene)))(VP (VBP (result))(NP (NP (JJ (significant))(NN (inhibition))(NN (growth)))(VBN (established))(NN (tumor))(JJ (human))(NN (colon))(NN (tumor))(NN (model)))(FW (vivo)))))))))) |ET|  |BS| 6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240  |ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (K-Ras))(NN (mutation))(NN (treatment))(NN (outcome))(JJ (colorectal))(NN (cancer))(NN (patient)))(VP (VBG (receiving))(NP (JJ (exclusive))(NN (fluoropyrimidine))(NN (therapy))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800  |ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (PRP$ (Our))(NN (result)))(VP (VBP (suggest))(SBAR (S (NP (NN (Raloxifene))(JJ (potent))(NN (IL-6))(: (/))(NN (GP130))(NN (inhibitor)))(VP (MD (may))(VP (VB (chemoprevention))(NP (NP (NN (agent))(NN (liver))(NN (cancer)))(VP (VBG (targeting))(NP (JJ (persistent))(NN (STAT3))(NN (signaling)))))))))))) |ET|  |BS| 69:G02.111.087.800 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 253:E02.319.162 964:D02.455.426.559.389.150.700.900.775  |ES| 18:1 19:1 22:1 101:1 104:1 195:1 239:1 251:1 380:1 491:1 616:1 658:1 728:1 796:1 836:1 870:1 3384:1 3385:1 3386:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNP (Promotion))(NN (hepatocarcinogenesis))(NN (perfluoroalkyl))(NN (acid))(NN (rainbow))(NNS (trout)))) |ET|  |BS| 38:Z01.058.290.120.180 40:Z01.542.248.700 1061:B01.050.150.900.493.817.750.825.580.600 1062:D01.029  |ES| 19:1 900:1 1275:1 3717:1 3718:1 3719:1 3720:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NN (finding)))(VP (VBP (suggest))(NP (NN (rimonabant))(ADJP (JJ (able))(S (VP (VBP (inhibit))(NP (NP (JJ (colorectal))(NN (cancer))(NN (cell))(NN (growth))(JJ (different))(NN (stage))(NN (colon))(NN (cancer))(NN (pathogenesis)))(VP (VBG (inducing))(NP (JJ (mitotic))(NN (catastrophe))(NN (vitro))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 122:C14.280.383 385:F02.784.629.131  |ES| 17:1 18:1 19:1 94:1 102:1 113:1 216:1 414:1 501:1 658:1 720:1 796:1 927:1 1129:1 1370:1 1864:1 2831:1 2832:1 2833:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Nitidine))(NN (chloride)))(VP (VBZ (inhibits))(NP (NP (JJ (hepatocellular))(NN (carcinoma))(NN (cell)))(NN (growth)))(NP (FW (vivo))(NN (suppression))(NN (JAK1/STAT3))(NN (signaling))(NN (pathway))))) |ET|  |BS| 41:A11 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 122:C14.280.383 126:G02.111.087.800 794:D08.811.913.696.620.682.725.124.100  |ES| 19:1 94:1 102:1 195:1 303:1 304:1 378:1 383:1 615:1 2453:1 2787:1 2788:1 2789:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(JJ (present))(NN (study)))(VP (VBP (identify))(S (NP (NP (JJ (chemopreventive))(JJ (potential))(NN (pterostilbene))(JJ (colonic))(NN (tumor))(NN (formation)))(NN (end))(NN (point)))(VP (VB (evaluate))(NP (JJ (mechanistic))(NN (action))(NN (pterostilbene))(NN (colon))(NN (carcinogenesis))))))) |ET|  |BS| 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 225:E05.337 742:G03.787  |ES| 7:1 19:1 43:1 113:1 131:1 207:1 658:1 677:1 827:1 832:1 890:1 1307:1 1890:1 1946:1 2013:1 2121:1 2428:1 2834:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (JJ (Dimethylarsinic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (DMA)))(-RRB- (-RRB-))))(JJ (major))(NN (metabolite))(JJ (inorganic))(JJ (arsenical)))(, (,))(NP (ADJP (RB (epidemiologically))(JJ (significant)))(NN (chemical))(NN (relation))(NN (liver))(NN (cancer))(NN (mammal)))) |ET|  |BS| 901:B01.050.150.900.649 902:D02.691.088.100 903:D01.075  |ES| 2:1 10:1 14:1 18:1 19:1 135:1 462:1 836:1 1275:1 1678:1 2124:1 3171:1 3172:1 3173:1 3174:1 3175:1 3176:1 3177:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (SBAR (IN (Although))(S (VP (ADVP (RB (spontaneously)))(VB (develop))(NP (NP (NN (liver))(NN (tumor)))(, (,))(NP (NN (IL-22TG))(NN (mouse))(JJ (susceptible))(JJ (diethylnitrosamine-induced))(NN (liver))(NN (cancer)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 554:D02.654.442.200 897:Z01.252.245.500.375 931:Z01.107.567.875.350.350 932:D12.644.276.374.465  |ES| 2:1 7:1 18:1 19:1 52:1 107:1 648:1 836:1 899:1 1506:1 2732:1 3279:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (EX (There)))(VP (VBG (increasing))(NP (NN (interest))(NP (NP (NNS (phytoestrogens))(JJ (potential))(JJ (alternative))(JJ (synthetic))(JJ (selective))(NN (estrogen))(NN (receptor))(NNS (modulators)))(PRN (-LRB- (-LRB-))(NP (NNS (SERMs)))(-RRB- (-RRB-))))(NN (prevention))(NN (therapy))(NN (breast))(NN (cancer))))) |ET|  |BS| 52:E02 375:Z01.639.100 831:D27.505.696.399.472.277.540.500 915:D06.347.360.827  |ES| 10:1 14:1 18:1 19:1 23:1 130:1 186:1 715:1 827:1 1474:1 1749:1 2311:1 2671:1 2955:1 3168:1 3217:1 3218:1 3219:1 3220:1  |EV| 
-1.0934493017928161862073466181755  |BT| (NP (NP (NN (indica)))(NP (NP (-RRB- (-RRB-))(NN (extract))(-LRB- (-LRB-))(NN (FIE))(-RRB- (-RRB-))(NN (N-nitrosodiethylamine))(NN (CCl)))(FRAG (-LRB- (-LRB-))(NP (NP (CD (4))(-RRB- (-RRB-))(: (-)))(VBN (induced))(NN (hepatocarcinogenesis))(NNP (Wistar))(NN (rat)))))) |ET|  |BS| 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1217:A02.513.514.100  |ES| 10:1 14:1 19:1 319:1 409:1 849:1 900:1 2496:1 2601:1 2602:1 2603:1 4260:1 4261:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Loss))(NN (metallothionein)))(VP (VBZ (predisposes))(NP (NN (mouse))(JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(VBG (activating))(NN (NF-kappaB))(NN (target))(NN (gene))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670  |ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1  |EV| 
-4.520134953427480617449418787146  |BT| (SINV (ADVP (RB (Here)))(VP (VBN (aimed)))(VP (VBP (determine))(NP (NP (NN (mechanism))(NN (action))(NN (DHEA)))(, (,))(NP (NP (NN (comparison))(NN (vitamin))(NN (E)))(, (,))(NP (JJ (chemically-induced))(JJ (hepatocellular))(NN (carcinoma))(NN (model))(NN (rat))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 740:D04.808.054.079.429.625 741:D03.383.663.283.909 742:G03.787  |ES| 2:1 19:1 72:1 74:1 162:1 303:1 304:1 400:1 844:1 849:1 2013:1 2085:1 2233:1 2591:1 2633:1 2634:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (HepG2))(NN (cell))))(, (,))(S (S (NP (NN (transfection))(NN (RARgamma)))(VP (VBD (enhanced))))(, (,))(IN (whereas))(S (NP (NN (downregulation))(NN (RARgamma))(NN (expression))(NN (siRNA))(NN (approach)))(VP (VBD (impaired)))))(, (,))(NP (NN (effect))(NN (RA))(VBG (inducing))(NN (expression))(NN (alpha-fetoprotein))(, (,))(NN (protein))(NN (marker))(NN (hepatocarcinogenesis)))) |ET|  |BS| 85:G02.111.087.225 112:D12.776.097.820 117:D13.150.650.700 158:D23.101 217:E05.393.350.810 748:D12.776.124.790.106.092 1015:A11.251.860.180.432  |ES| 2:1 4:1 19:1 75:1 94:1 115:1 244:1 351:1 372:1 385:1 534:1 595:1 746:1 900:1 911:1 1864:1 2003:1 2665:1 3481:1 3556:1 3557:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(S (NP (PRP$ (Our))(NN (result)))(VP (VBP (suggest))(SBAR (S (NP (NN (garcinol)))(VP (MD (may))(VP (VB (merit))(S (NP (JJ (clinical))(NN (investigation))(NN (chemoprophylactic))(NN (food))(NN (help)))(VP (VB (prevent))(NP (JJ (colitis-associated))(NN (colon))(NN (cancer)))))))))))) |ET|  |BS| 53:C06.405.205.265 225:E05.337 680:G07.203.300  |ES| 18:1 19:1 84:1 101:1 104:1 113:1 410:1 491:1 658:1 733:1 796:1 1497:1 1882:1 2470:1 3371:1 3372:1 3373:1 3374:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Here)))(, (,))(NP (NN (report))(NNP (MPA)))(ADVP (RB (also)))(VP (VBZ (induces))(NP (NP (NN (differentiation))(JJ (androgen-independent))(NN (prostate))(NN (cancer)))(NP (VBN (derived))(NN (cell))(NN (line))(NN (DU145)))))) |ET|  |BS| 74:G04.299.151 94:A11.251.210 852:C04.588.945.440.770.500  |ES| 2:1 5:1 18:1 19:1 77:1 94:1 214:1 215:1 264:1 400:1 417:1 1721:1 3423:1 3519:1 3520:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NP (NN (5-Fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (common))(JJ (chemotherapeutic))(NN (agent)))(VP (VBN (used))(NP (NP (NP (NN (treatment))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(, (,))(NP (JJ (inadequate))(NN (response))(NN (rate)))(: (;))(VP (VBG (highlighting))(NP (NN (need))(NN (novel))))))))(VP (VBD (improved))(NP (NN (treatment))(NNS (regimen))(NN (patient))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 259:D12.776.395.240.150.500 284:N03.349.380.420 532:E02.183 560:D03.383.742.698.875.404 660:D27.505.954.248  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 41:1 120:1 217:1 245:1 476:1 494:1 546:1 655:1 728:1 891:1 1762:1 1881:1 2308:1 2404:1 2407:1 2408:1 2409:1 2410:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Liver))(NN (tumor)))(VP (VBD (induced))(NP (NP (JJ (male))(NNP (Fischer))(NN (F344))(NN (rat))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-)))))) |ET|  |BS| 515:C04.588.274.623 554:D02.654.442.200 590:B01.050.050.199.520.760.200  |ES| 7:1 10:1 14:1 19:1 412:1 849:1 1402:1 1875:1 1952:1 2721:1 3185:1 4288:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (VBN (Combined))(NN (lapatinib))(NN (panobinostat))(NN (treatment)))(VP (VBD (interacted))(ADVP (RB (synergistically)))(VP (VB (inhibit))(NP (NP (NN (proliferation))(NN (colony))(NN (formation))(NN (CRC))(NN (cell))(NN (line)))(VP (VBN (tested))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 94:A11.251.210 109:I01.696.116 122:C14.280.383  |ES| 19:1 43:1 94:1 245:1 264:1 299:1 314:1 546:1 741:1 1370:1 2488:1 2988:1 3347:1 3348:1 3349:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (Amelioration))(JJ (free))(NN (fatty))(JJ (acid-induced))(NN (fatty))(NN (liver))(NN (quercetin-3-O-beta-D-glucuronide))(NN (modulation))(NN (peroxisome))(JJ (proliferator-activated))(JJ (receptor-alpha/sterol))(JJ (regulatory))(JJ (element-binding))(JJ (protein-1c))(NN (signaling)))) |ET|  |BS| 69:G02.111.087.800 242:A03.620 533:D03.383.663.283.266.450.284.777 536:D12.776.826.239.500 576:D12.776.260.103.500.750.500 1133:D10.251.310  |ES| 19:1 195:1 836:1 1801:1 1817:1 1887:1 1945:1 2070:1 2599:1 3958:1 3960:1 4082:1 4083:1 4084:1 4085:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBN (investigated))(S (NP (NP (NN (role))(NN (IDO))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(: (-))(VP (VBN (induced))(NP (NN (hepatocarcinogenesis)))(S (VP (VBG (using))(NP (NP (NP (NN (IDO-knockout)))(PRN (-LRB- (-LRB-))(NP (NN (KO)))(-RRB- (-RRB-))))(NN (mouse))))))))) |ET|  |BS| 15:F01.829.316.616 29:B01.050.050.136.500.500 554:D02.654.442.200  |ES| 2:1 10:1 14:1 19:1 31:1 52:1 131:1 244:1 350:1 403:1 409:1 900:1 1307:1 1875:1 1952:1 2849:1 4243:1 4244:1  |EV| 
4.520134953427480617449418787146  |BT| (S (VP (VBG (Modifying))(NP (NP (NN (effect))(NN (chitin))(, (,))(NN (chitosan))(JJ (related))(NN (compound))(JJ (2-amino-3,8-dimethylimidazo)))(PRN (-LRB- (-LSB-))(NP (NP (NP (NP (JJ (4,5-f))(-RRB- (-RSB-))(NN (quinoxaline)))(PRN (-LRB- (-LRB-))(NP (NN (MeIQx)))(-RRB- (-RRB-))))(NN (rat))(JJ (medium-term))(NN (hepatocarcinogenesis))(NN (model)))(, (,))(NP (JJ (post-initiation))(NN (effect))(JJ (female))(NN (rat))(JJ (2-stage))(JJ (multi-organ))(NN (carcinogenesis))(NN (model)))))))) |ET|  |BS| 33:C04.697.098 118:D01.248.497.158.380 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 642:M01.975 849:G08.686.785.760.769.490.500 854:D05.750.078.139.500 855:D05.750.078.139 914:L01.178  |ES| 2:1 10:1 14:1 19:1 72:1 75:1 207:1 419:1 849:1 900:1 1373:1 1378:1 1404:1 2433:1 3051:1 3052:1 3215:1 3638:1 3639:1 3640:1 3641:1 3642:1 3643:1 3644:1 3645:1  |EV| 
-4.520134953427480617449418787146  |BT| (SINV (S (NP (JJ (Overall))(NN (analysis)))(VP (VBD (indicated))(SBAR (S (NP (NN (pterostilbene)))(VP (VBD (reduced))(NP (NN (colon))(NN (tumor))(NN (multiplicity))(JJ (non-invasive))(NN (adenocarcinoma))))))))(, (,))(VP (VBD (lowered))(S (VP (VBG (proliferating))(NP (NN (cell))(JJ (nuclear))(NN (antigen))))))(VP (VBD (downregulated))(NP (NN (expression))(NN (beta-catenin))(NN (cyclin))(NN (D1))))) |ET|  |BS| 23:D12.776.091.249 51:C04.588.274.476.411.307.180 84:C04.557.470.200.025 215:D12.644.360.262.150.100 696:V02.270.500 768:D12.776.660.740  |ES| 2:1 7:1 19:1 60:1 94:1 113:1 115:1 255:1 426:1 452:1 661:1 743:1 744:1 1030:1 1256:1 1361:1 1541:1 2428:1 2858:1 2863:1 2864:1 2865:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NN (Hepatocyte))(NP (NP (CD (I))(NN (kappaB))(NN (kinase))(NN (beta)))(PRN (-LRB- (-LRB-))(NP (NN (IKK))(NN (beta)))(-RRB- (-RRB-))))(VBZ (inhibits))(NP (NP (NN (hepatocarcinogenesis)))(VP (VBG (suppressing))(NP (NP (NP (NN (accumulation))(JJ (reactive))(NN (oxygen))(NN (specie)))(PRN (-LRB- (-LRB-))(NP (NN (ROS)))(-RRB- (-RRB-))))(NN (liver))(NN (damage)))))(, (,))(SBAR (IN (whereas))(S (NP (NN (JNK1))(NN (activation)))(VP (VBZ (promotes))(NP (NP (NN (ROS))(NN (accumulation)))(, (,))(NP (NN (liver))(NN (damage)))(, (,))(NP (NN (carcinogenesis)))))))) |ET|  |BS| 33:C04.697.098 122:C14.280.383 242:A03.620 262:A11.436.348 635:D08.811.913.696.620.682.700.494 636:D01.339.431  |ES| 2:1 10:1 14:1 19:1 207:1 225:1 298:1 372:1 470:1 615:1 836:1 900:1 1848:1 1972:1 2120:1 2250:1 2349:1 2350:1 2351:1 2352:1 2353:1 2354:1 2355:1 2356:1 2357:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (ESE-1))(: (/))(NN (EGR-1))(NN (pathway)))(VP (VBP (play))(NP (NN (role)))(NP (ADJP (JJ (tolfenamic))(JJ (acid-induced)))(NP (NN (apoptosis))(JJ (colorectal))(NN (cancer))(NN (cell)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 39:G04.299.139.160 41:A11 79:I03.450.642.693  |ES| 17:1 18:1 19:1 31:1 89:1 94:1 238:1 383:1 2597:1 2598:1 2599:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NN (Downregulation))(JJ (tumor-suppressor))(NN (miR-16)))(PP (IN (via))(NP (JJ (progestin-mediated))(JJ (oncogenic))(NN (signaling)))))(VP (VBZ (contributes))(NP (NN (breast))(NN (cancer))(NN (development))))) |ET|  |BS| 69:G02.111.087.800 85:G02.111.087.225 206:G05.360.340.024.340.375.249 279:D27.888.569.100 981:D27.505.696.399.472.858  |ES| 18:1 19:1 23:1 35:1 195:1 296:1 596:1 845:1 953:1 1156:1 3456:1 3457:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Desmoplakin))(NN (act))(NN (tumor))(NN (suppressor))(NN (inhibition))(NN (Wnt/beta-catenin))(NN (signaling))(NN (pathway))(JJ (human))(NN (lung))(NN (cancer)))) |ET|  |BS| 38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249 975:D12.776.220.790.500  |ES| 7:1 18:1 19:1 36:1 103:1 195:1 246:1 302:1 328:1 383:1 700:1 3438:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Melatonin)))(VP (VBD (improved))(SBAR (S (NP (NN (survival))(NN (rate)))(VP (ADVP (RB (successfully)))(VBD (attenuated))(NP (NN (liver))(NN (injury))))))(, (,))(VP (VBN (shown))(NP (NN (histopathology))))(, (,))(VP (VBD (decreased))(NP (NP (NN (level))(NN (serum))(NN (transaminase)))(NP (VBN (reduced))(NN (expression))(JJ (placental))(NN (glutathione))(NN (S-transferase))))))) |ET|  |BS| 242:A03.620 707:D03.438.473.914.481 779:E05.318.308.985.550.900 780:D08.811.913.225.500 781:D08.811.913.477.700 782:A12.207.152.846 783:A16.710  |ES| 2:1 19:1 41:1 115:1 202:1 237:1 249:1 274:1 452:1 808:1 836:1 2410:1 2416:1 2738:1 2739:1 2740:1 2741:1 2742:1 2743:1 2744:1 2745:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Bortezomib)))(ADVP (RB (also)))(VP (VBD (prevented))(SBAR (S (NP (NN (activation))(JJ (hepatic))(JJ (stellate))(NN (cell)))(VP (VBD (inhibited))(NP (NN (liver))(NN (fibrosis))(NN (DEN/CDAA))(NN (model)))))))) |ET|  |BS| 122:C14.280.383 675:D01.029.260.110.500 676:C06.552.630 677:A11.561  |ES| 5:1 19:1 72:1 94:1 225:1 365:1 836:1 838:1 949:1 1944:1 2460:1 2461:1 2462:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Hyperactive))(NN (EGFR))(NN (signaling))(NN (Stat3))(NN (Jak-Stat3))(NN (activity)))(ADVP (RB (together)))(VP (VBP (promote))(SBAR (S (NP (NP (JJ (ovarian))(NN (cancer))(NN (progression))(NN (cisplatin))(NN (resistance)))(ADVP (RB (therefore))))(VP (VBP (represent))(NP (NP (NN (target)))(VP (VBG (preventing))(NP (NN (development))(NN (cisplatin))(NN (resistance))(JJ (recurrent))(NN (disease))(NN (cisplatin))(NN (therapy))(JJ (ovarian))(NN (cancer)))))))))) |ET|  |BS| 16:C23.550.291.656 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 288:C23.550.288 496:C23.550.291.937 498:D01.210.375 745:C10.597.350.350  |ES| 18:1 19:1 35:1 48:1 130:1 160:1 187:1 195:1 218:1 399:1 679:1 799:1 998:1 1094:1 1538:1 1753:1 1761:1 1763:1 1937:1 2645:1 2646:1 2647:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (NP (NNP (Boswellia))(NNP (serrata))(NN (resin))(NN (extract)))(VBZ (alleviates))(NP (NP (NN (azoxymethane)))(PRN (-LRB- (-LRB-))(NP (NN (AOM)))(-RRB- (-RRB-))))(: (/))(NP (NP (NN (dextran))(NN (sodium))(NN (sulfate)))(PRN (-LRB- (-LRB-))(NP (NN (DSS)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (colon))(NN (tumorigenesis)))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 942:D05.750.078.840.490  |ES| 10:1 14:1 19:1 78:1 113:1 406:1 407:1 409:1 1993:1 1994:1 2496:1 3301:1 3302:1 3303:1 3304:1 3305:1 3306:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNS (Polymorphisms))(NP (JJ (estrogen-metabolizing))(NN (gene))(NN (risk))(JJ (hepatocellular))(NN (carcinoma)))(NNP (Taiwan))(NN (female)))) |ET|  |BS| 6:G05.360.340.024.340 61:E05.318.740.600.800 104:C04.557.470.200.025.255 307:G05.365.795 889:D27.505.696.399.472.277 1058:Z01.252.474.872  |ES| 9:1 19:1 171:1 303:1 304:1 1404:1 3700:1 3701:1 3702:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (NP (NN (Deficiency))(NN (folate)))(, (,))(NP (S (VP (VBP (play))(NP (NN (role))(NN (synthesis))(NNP (SAM))(NN (lead)))))(NP (VBD (increased))(NN (risk))(NN (colon))(NN (cancer))))) |ET|  |BS| 15:F01.829.316.616 20:G03.495 61:E05.318.740.600.800 79:I03.450.642.693 86:D01.268.556.435 232:D02.886.030.676.180 974:C18.654.521.500.133.699.308  |ES| 2:1 18:1 19:1 31:1 47:1 113:1 171:1 238:1 254:1 778:1 3435:1 3436:1 3437:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(NP (DT (These))(VBP (result))(NP (VBN (suggested))(NN (TFA))(VBD (protected))(ADJP (NN (mouse))(JJ (CCl4-induced))(ADJP (NN (liver))(NN (injury))(JJ (antioxidant)))(NN (stress))(JJ (antiinflammatory)))(NN (effect))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217  |ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Disruption))(NN (Ptk6))(NN (decrease))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080  |ES| 19:1 52:1 78:1 113:1 295:1 2533:1 3444:1 3445:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Past))(NN (study)))(VP (VBN (shown))(VP (VBD (amplified))(NP (NP (NP (JJ (insulin-like))(NN (growth))(NN (factor))(CD (1)))(PRN (-LRB- (-LRB-))(NP (NN (IGF1)))(-RRB- (-RRB-))))(: (/))(NP (NP (NP (NP (NN (IGF1))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (IGF1-R)))(-RRB- (-RRB-))))(NN (signalling))(JJ (important))(NN (role)))(NP (NP (NP (JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(NP (NN (development)))))(, (,))(NP (NN (progression))(NN (resistance))(NN (treatment))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 16:C23.550.291.656 52:E02 518:D08.811.913.696.620.682.725.400.185 598:D12.644.276.937.400 599:M01.526.799.500  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 31:1 35:1 48:1 98:1 102:1 131:1 185:1 186:1 237:1 245:1 546:1 902:1 1094:1 2093:1 2198:1 2208:1 2437:1 3697:1 3698:1 3699:1  |EV| 
-4.520134953427480617449418787146  |BT| (SINV (PP (IN (As))(NP (NN (wogonin))(ADJP (JJ (effective))(ADVP (FW (vitro))(FW (vivo))))))(, (,))(NP (JJ (novel))(S (VP (VBG (finding))(S (NP (JJ (open))(NN (possibility))(NN (wogonin))(JJ (effective))(ADJP (ADJP (JJ (therapeutic)))(CC (and/or))(ADJP (JJ (chemopreventive))))(NN (agent)))(ADJP (JJ (ER-positive))))(: (-))(NP (NP (JJ (negative))(NN (breast))(NN (cancer)))(, (,))(NP (RB (particularly))(JJ (aggressive))(JJ (hormonal))(JJ (therapy-resistant))(JJ (ER-negative))(NN (type)))))))) |ET|  |BS| 52:E02 162:F01.145.126.125 259:D12.776.395.240.150.500  |ES| 2:1 18:1 19:1 23:1 149:1 168:1 216:1 343:1 378:1 538:1 541:1 543:1 728:1 891:1 927:1 1045:1 1639:1 1654:1 1946:1 2380:1 2444:1 2445:1 2446:1 2447:1 2448:1  |EV| 
4.520134953427480617449418787146  |BT| (S (VP (NP (NNP (Digital)))(VBG (karyotyping))(VP (VBZ (identifies))(NP (NN (thymidylate))(NN (synthase))(NN (amplification))(NN (mechanism))(NN (resistance))(NN (5-fluorouracil))(JJ (metastatic))(JJ (colorectal))(NN (cancer))(NN (patient)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430  |ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1  |EV| 
4.520134953427480617449418787146  |BT| (S (S (NP (DT (A))(JJ (potential))(VBG (underlying))(NN (mechanism))(NN (role))(NN (ADAM9))(NN (prostate))(NN (cancer)))(VP (VBD (emerged))(NP (JJ (cell-based))(NN (assay)))))(: (:))(S (NP (NN (ADAM9)))(VP (VBP (cleave))(NP (NP (NN (release))(JJ (epidermal))(NN (growth))(NN (factor))(NN (FGFR2iiib))(NN (cell)))(, (,))(NP (JJ (pivotal))(NN (function))(NN (pathogenesis))(NN (disease))))))) |ET|  |BS| 15:F01.829.316.616 41:A11 106:E05.091 288:C23.550.288 333:D01.045 589:E02.204.125 923:D06.472.317.350  |ES| 2:1 18:1 19:1 31:1 33:1 69:1 77:1 94:1 102:1 104:1 162:1 184:1 185:1 310:1 435:1 501:1 827:1 998:1 1113:1 2165:1 3211:1 3248:1 3249:1 3250:1 3251:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Nuclear))(NN (Maspin))(NN (expression)))(NP (ADJP (RB (highly))(JJ (predictive)))(NN (5-FU))(NN (chemotherapy))(NN (response))(NN (patient)))(VP (VBD (advanced))(NP (NN (stage))(NN (colon))(NN (cancer))))) |ET|  |BS| 50:M01.643 151:E02.319 560:D03.383.742.698.875.404  |ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1  |EV| 
4.520134953427480617449418787146  |BT| (SINV (NP (NP (NNP (Geraniol)))(, (,))(NP (NN (component))(NN (plant))(JJ (essential))(NN (oil)))(, (,)))(VP (VBZ (modulates))(NP (NN (DNA))(NN (synthesis))))(VP (VBZ (potentiates))(NP (NN (5-fluorouracil))(NN (efficacy))(JJ (human))(NN (colon))(NN (tumor))(NN (xenograft))))) |ET|  |BS| 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 78:G02.111.087.222 92:E04.936.764 93:A01.941.875 560:D03.383.742.698.875.404 999:D10.627.675 1000:A18  |ES| 2:1 7:1 19:1 36:1 113:1 265:1 606:1 666:1 1021:1 1098:1 1776:1 2304:1 2307:1 2499:1 2614:1 3436:1 3498:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (NP (DT (The))(JJ (present))(NN (work)))(VP (VBZ (provides))(NP (NP (JJ (novel))(NNS (data)))(PP (VBG (concerning))(NP (JJ (preventive))(NN (action))(NN (glycerol))(NN (development))(NN (liver))(NN (cancer)))))))(VP (VBZ (represents))(NP (ADJP (RB (economically))(JJ (feasible)))(NN (intervention))(NN (treat))(JJ (high-risk))(NN (individual)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 61:E05.318.740.600.800 259:D12.776.395.240.150.500 445:I03.946 493:M01 697:D02.033.800.421 698:I01.261  |ES| 18:1 19:1 35:1 104:1 106:1 691:1 793:1 815:1 836:1 891:1 1090:1 1307:1 1546:1 1645:1 1882:1 1883:1 2013:1 2512:1 2514:1 2515:1 2516:1 2517:1 2518:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(PP (IN (Since))(NP (NN (lymph))(NN (node))(NN (involvement))(JJ (important))(JJ (prognostic))(NN (factor))(NN (breast))(NN (cancer))(NN (patient))))(, (,))(NP (JJ (antimetastatic))(NN (activity))(NN (alpha-mangostin)))(VP (VBD (detected))(NP (NP (JJ (mammary))(NN (cancer)))(VP (VBG (carrying))(NP (NN (p53))(NN (mutation))(JJ (present))(NN (study)))))(VP (MD (may))(NP (JJ (specific))(JJ (clinical))(NN (application)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 18:G05.365.590 50:M01.643 247:G01.374.676.530 703:A10.549.400  |ES| 2:1 12:1 18:1 19:1 23:1 34:1 84:1 104:1 120:1 131:1 165:1 185:1 239:1 399:1 491:1 540:1 636:1 850:1 884:1 902:1 1007:1 1307:1 2245:1 2246:1 2248:1 2535:1 2536:1 2537:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Progastrin))(VBG (targeting))(NN (strategy)))(VP (VBP (provide))(NP (JJ (exciting))(NN (prospect))(NN (differentiation))(NN (therapy))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 52:E02 74:G04.299.151 821:E05.318.760.500.750.500  |ES| 17:1 18:1 19:1 130:1 215:1 616:1 711:1 1114:1 2906:1 2907:1 2908:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Inhibition))(NN (autophagy)))(VP (VBZ (potentiates))(NP (JJ (antitumor))(NN (effect))(NN (multikinase))(NN (inhibitor))(NN (sorafenib))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 43:F01.145.544 104:C04.557.470.200.025.255 390:G04.299.139.399  |ES| 19:1 75:1 303:1 304:1 380:1 1317:1 2063:1 2244:1 2499:1 2703:1 3592:1  |EV| 
-1.8963774987640817926148883998394  |BT| (S (NP (NN (Combination))(NN (aspirin))(NN (sorafenib)))(VP (MD (may))(NP (JJ (effective))(NN (regimen))(NN (treat))(NN (HCC))(NN (colon))(NN (cancer))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 532:E02.183 670:D02.455.426.559.389.657.410.595.176  |ES| 18:1 19:1 113:1 441:1 491:1 1090:1 1639:1 1881:1 2063:1 2486:1 2487:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Melatonin)))(VP (VBZ (prevents))(NP (NN (deregulation))(NN (sphingosine))(NN (kinase/sphingosine))(NN (1-phosphate))(NN (signaling))(NN (pathway))(NN (mouse))(NN (model))(JJ (diethylnitrosamine-induced))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 469:D08.811.913.696 554:D02.654.442.200 707:D03.438.473.914.481 1227:D01.029.260.700.675.374 1228:D02.705.400  |ES| 19:1 52:1 72:1 195:1 303:1 304:1 383:1 402:1 2718:1 2732:1 2738:1 4306:1 4307:1 4308:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (5-Lipoxygenase)))(VP (VBZ (contributes))(NP (NN (progression))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 16:C23.550.291.656 104:C04.557.470.200.025.255 918:D08.811.682.690.416.583.500.055  |ES| 19:1 48:1 303:1 304:1 845:1 3240:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NP (NN (Balb/c))(NN (mouse))(VBN (treated))(NN (azoxymethane)))(PRN (-LRB- (-LRB-))(NP (NN (AOM)))(-RRB- (-RRB-))))(NN (dextran))(NN (sulfate))(NN (sodium)))(VP (VBP (induce))(NP (NN (colon))(NN (cancer))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 131:D09.698.365.272.300 132:D02.172.080 940:B01.050.050.199.520.520.338  |ES| 10:1 14:1 18:1 19:1 52:1 113:1 243:1 406:1 407:1 1099:1 1993:1 1994:1 3299:1 3300:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Nuclear))(NN (Maspin))(NN (expression)))(NP (ADJP (RB (highly))(JJ (predictive)))(NN (5-FU))(NN (chemotherapy))(NN (response))(NN (patient)))(VP (VBD (advanced))(NP (NN (stage))(NN (colon))(NN (cancer))))) |ET|  |BS| 50:M01.643 151:E02.319 560:D03.383.742.698.875.404  |ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (JJ (High-saturate-fat))(NN (diet))(NN (delay))(NN (initiation))(JJ (diethylnitrosamine-induced))(JJ (hepatocellular))(NN (carcinoma)))) |ET|  |BS| 104:C04.557.470.200.025.255 554:D02.654.442.200 694:G07.203.650.240.267  |ES| 19:1 136:1 303:1 304:1 637:1 2191:1 2732:1 4211:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NNP (Brucine)))(, (,))(NP (NN (alkaloid))(NN (seed))))(VP (VBZ (Strychnos))(NP (JJ (nux-vomica))(NNP (Linn))))) |ET|  |BS| 12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 631:D03.132 681:G04.299.283 682:D12.776.260.103.625  |ES| 2:1 19:1 31:1 63:1 94:1 98:1 104:1 185:1 303:1 304:1 383:1 514:1 806:1 2315:1 2320:1 2321:1 2322:1 2323:1 2472:1 2473:1 2474:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Cellular))(JJ (FLICE-inhibitory))(NN (protein))(NN (down-regulation)))(VP (VBZ (contributes))(NP (JJ (celecoxib-induced))(NN (apoptosis))(JJ (human))(NN (lung))(NN (cancer))(NN (cell))))) |ET|  |BS| 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 684:D02.065.884.247 948:D12.644.360.024.296.024  |ES| 4:1 18:1 19:1 36:1 89:1 94:1 257:1 328:1 845:1 3319:1 3320:1 3321:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Nestin))(NN (silencing)))(VP (ADVP (RB (also)))(VP (VBD (upregulated))(NP (NP (NN (Axin))(, (,))(NP (NP (NN (glycogen))(NN (synthase))(NN (kinase-3))(NN (beta)))(PRN (-LRB- (-LRB-))(NP (NN (GSK-3beta)))(-RRB- (-RRB-))))(, (,))(NP (JJ (adenomatous))(NN (polyposis))(NN (coli))(PRN (-LRB- (-LRB-))(NP (NN (APC)))(-RRB- (-RRB-))))(, (,)))(NP (NP (NN (peroxisome))(JJ (proliferator-activated))(NN (receptor))(NN (alpha)))(PRN (-LRB- (-LRB-))(NP (NN (PPARa)))(-RRB- (-RRB-))))))(, (,))(VP (VBD (downregulated))(NP (NP (NN (beta-catenin)))(, (,))(NP (NN (c-Myc)))(, (,))(NP (NP (NN (cyclin))(NN (D)))(NN (MMP-7))(NN (expression))(NNP (CSC))))))) |ET|  |BS| 3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540  |ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Nifuroxazide)))(VP (VBZ (induces))(SBAR (S (NP (NN (apoptosis)))(VP (VBZ (impairs))(NP (JJ (pulmonary))(NN (metastasis))(NN (breast))(NN (cancer))(NN (model)))))))) |ET|  |BS| 10:A01.236 39:G04.299.139.160 113:C04.697.650 182:A04.411  |ES| 18:1 19:1 23:1 72:1 89:1 214:1 806:1 948:1 2729:1 3659:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Cytochrome))(NN (P450))(NN (1A2)))(VP (VBZ (Metabolizes))(S (NP (NN (17beta-Estradiol)))(VP (VB (Suppress))(NP (JJ (Hepatocellular))(NN (Carcinoma))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 705:D08.244.453.040.443 706:D04.808.365.415.248  |ES| 19:1 1241:1 2151:1 2548:1 2549:1 2550:1 2551:1 2552:1 2553:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Cross-talk))(NN (aryl))(NN (hydrocarbon))(NN (receptor))(JJ (mitogen-activated))(NN (protein))(NN (kinase))(NN (signaling))(NN (pathway))(NN (liver))(NN (cancer))(NN (c-raf))(JJ (transcriptional))(NN (regulation)))) |ET|  |BS| 69:G02.111.087.800 126:G02.111.087.800 142:I01.880.604 148:G12.425.143.281 209:G02.111.087.847 478:D08.811.913.696.620.682.700.567 969:D12.776.260.643.715  |ES| 4:1 18:1 19:1 186:1 195:1 383:1 438:1 470:1 559:1 836:1 3295:1 3416:1 3417:1 3418:1 3419:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (PRP$ (Our))(VP (VBP (result))(VP (VBP (demonstrate)))(, (,))(NP (ADVP (JJ (first))(NN (time)))(, (,))(NP (NP (NP (ADJP (NN (elaiophylin))(JJ (novel)))(NN (autophagy))(NN (inhibitor)))(, (,))(NP (NP (JJ (significant))(NN (antitumor))(NN (efficacy)))(JJ (single))(NP (NN (agent))(NN (combination))(JJ (human))(JJ (ovarian))(NN (cancer))(NN (cell)))))(, (,))(VP (VBG (establishing))(NP (JJ (potential))(NN (treatment))(JJ (ovarian))(NN (cancer))(NN (compound))))))))) |ET|  |BS| 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 259:D12.776.395.240.150.500 322:G01.910 390:G04.299.139.399 660:D27.505.954.248 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725  |ES| 2:1 18:1 19:1 36:1 94:1 101:1 135:1 380:1 502:1 530:1 546:1 658:1 728:1 816:1 827:1 891:1 1081:1 1317:1 1763:1 2244:1 2304:1 2433:1 2845:1 2846:1 2847:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(VP (VBP (result))(VP (VBP (indicate))(SBAR (S (NP (JJ (insulin-independent))(NN (liver))(NN (tumor))(NN (promotion)))(VP (VBD (occurred))(NP (JJ (diabetic))(NN (mouse))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 637:D06.472.699.587.200.500.625  |ES| 2:1 7:1 19:1 52:1 101:1 244:1 553:1 836:1 1284:1 1479:1 2337:1 2964:1 3551:1  |EV| 
4.520134953427480617449418787146  |BT| (S (S (NP (JJ (Low))(NN (level))(NN (Caspase-3)))(VP (VBP (predict))(SBAR (S (NP (JJ (favourable))(NN (response))(JJ (5FU-based))(NN (chemotherapy)))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer))))))))(: (:))(S (NP (NN (Caspase-3))(NN (inhibition))(JJ (therapeutic))(NN (approach))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404 906:D08.811.277.656.262.500.126.350.300  |ES| 17:1 18:1 19:1 103:1 104:1 249:1 494:1 495:1 541:1 911:1 997:1 1302:1 2232:1 3190:1 3615:1 3616:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NN (simvastatin)))(VP (VBD (inhibited))(NP (NP (NN (colon))(NN (cancer))(NN (development))(NN (induction)))(NN (apoptosis))(NN (suppression))(NN (angiogenesis))))) |ET|  |BS| 39:G04.299.139.160 122:C14.280.383 754:D02.455.426.559.847.638.400.900  |ES| 2:1 18:1 19:1 35:1 89:1 113:1 244:1 365:1 736:1 1284:1 2453:1 2502:1 2679:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Epidemiological))(NN (evidence)))(VP (VBZ (suggests))(S (NP (NN (vitamin))(NN (D)))(VP (MD (may))(VP (VB (play))(NP (NP (NN (role)))(VP (VBG (inhibiting))(NP (NN (development))(NN (colon))(NN (prostate))(NN (cancer)))))))))) |ET|  |BS| 15:F01.829.316.616 46:A03.556.124.526.356 79:I03.450.642.693 122:C14.280.383 651:H02.403.720.500 720:D04.808.247.222.474 721:D04.808.812.768  |ES| 18:1 19:1 31:1 35:1 38:1 77:1 113:1 238:1 331:1 491:1 880:1 2384:1 2591:1 2592:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNP (Prevention))(JJ (upper))(JJ (aerodigestive))(NN (tract))(NN (cancer))(JJ (zinc-deficient))(JJ (rodent)))(: (:))(NP (NN (inefficacy))(JJ (genetic))(JJ (pharmacological))(NN (disruption))(NN (COX-2)))) |ET|  |BS| 514:B01.050.150.900.649.865 874:D01.268.556.940 1059:H01.158.703  |ES| 18:1 19:1 76:1 104:1 864:1 1602:1 2173:1 2898:1 3101:1 3703:1 3704:1 3705:1 3706:1 3707:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (UCP (NP (JJ (Insulin-independent))(NN (promotion)))(ADVP (RB (chemically)))(NP (VBN (induced))(JJ (hepatocellular))(NN (tumor))(NN (development)))(NP (ADJP (RB (genetically))(JJ (diabetic)))(NN (mouse))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 637:D06.472.699.587.200.500.625  |ES| 7:1 19:1 35:1 52:1 303:1 412:1 898:1 2337:1 2581:1 2964:1 3596:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Aberrant))(NN (beta-catenin))(JJ (intracellular))(NN (distribution)))(VP (VBD (found))(NP (NP (JJ (gastric))(NP (NN (cancer)))(, (,))(NP (NN (pattern))(NN (Wnt))(NN (expression))(JJ (stepwise))(NN (gastrocarcinogenesis))(JJ (potential))(NN (influence))(NN (beta-catenin))(NN (distribution)))(ADJP (RB (still))(JJR (lesser))))(VP (VBN (known)))))) |ET|  |BS| 23:D12.776.091.249 826:F01.752.609 924:A11.284.430.214  |ES| 2:1 18:1 19:1 37:1 60:1 80:1 86:1 115:1 260:1 556:1 776:1 827:1 867:1 877:1 2805:1 3252:1 3253:1 3254:1 3255:1  |EV| 
-1.1828696325457008775572376180207  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(NP (NN (Silibinin))(NN (target))(NN (beta-catenin))(NN (IGF-1Rbeta))(NN (pathway))(JJ (chemopreventive))(NN (efficacy))(JJ (azoxymethane-induced))(NN (colon))(NN (carcinogenesis))(NN (A/J))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937  |ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Aspirin))(NN (use))(NN (survival))(NN (diagnosis))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 96:I03.784 263:E01 670:D02.455.426.559.389.657.410.595.176  |ES| 17:1 18:1 19:1 274:1 1037:1 1659:1 2449:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (PRP$ (Our))(NNS (data)))(VP (VBP (demonstrate))(SBAR (S (NP (NN (coffee))(NN (consumption)))(VP (VBZ (protects))(SBAR (S (NP (NN (liver))(NN (damage)))(VP (VBD (caused))(NP (JJ (high-fat))(NN (diet)))))))))))) |ET|  |BS| 242:A03.620 652:D20.215.784.249 694:G07.203.650.240.267  |ES| 19:1 104:1 502:1 658:1 793:1 836:1 1848:1 1863:1 1882:1 2191:1 2386:1 2387:1 2506:1 2507:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Nitric))(JJ (oxide-releasing))(NN (aspirin))(NN (indomethacin))(JJ (potent))(NN (inhibitor))(NN (colon))(NN (cancer))(JJ (azoxymethane-treated))(NN (rat)))(: (:))(NP (NN (effect))(JJ (molecular))(NN (target))))) |ET|  |BS| 52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420  |ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (ADVP (RB (Herein)))(VP (VBP (show))(SBAR (S (NP (JJ (global))(NN (loss))(NN (ERRalpha)))(VP (VBZ (accelerates))(NP (NP (NN (development))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-)))))))(: (-))(S (VP (VBN (induced))(NP (JJ (hepatocellular))(NN (carcinoma))))))) |ET|  |BS| 104:C04.557.470.200.025.255 197:A01.456.505.420 554:D02.654.442.200  |ES| 10:1 14:1 19:1 32:1 35:1 303:1 304:1 409:1 428:1 429:1 529:1 660:1 1875:1 1952:1 4209:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (DT (The))(NN (purpose))(NN (investigation)))(VP (VB (evaluate))(NP (NP (JJ (possible))(NN (influence))(NN (mixture))(NN (pesticide))(JJ (medium-term))(NN (carcinogenesis)))(VP (VBG (using))(NP (VBN (improved))(NN (hepatocarcinogenesis))(NN (protocol))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 225:E05.337 826:F01.752.609 849:G08.686.785.760.769.490.500 913:D27.720.031.700 914:L01.178  |ES| 19:1 207:1 350:1 691:1 867:1 890:1 900:1 1359:1 1497:1 2410:1 3011:1 3213:1 3214:1 3215:1 3216:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NN (Breast))(NN (cancer)))(VP (VBG (expressing))(NP (VBN (activated))(NN (HER2/neu))(JJ (sensitive))(FW (gefitinib))(FW (vitro))(FW (vivo)))))(VP (VBZ (acquires))(NP (NN (resistance))(JJ (novel))(NN (point))(NN (mutation))(NN (HER2/neu))))) |ET|  |BS| 63:G05.360.340.024.340.375.500.791.295.305 259:D12.776.395.240.150.500 438:G05.365.590.675  |ES| 18:1 19:1 34:1 163:1 216:1 378:1 810:1 891:1 901:1 1094:1 2121:1 3308:1 3309:1 3310:1 3311:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (Modulation))(NN (energy))(JJ (metabolic))(NN (enzyme))(NN (expression))(JJ (N-nitrosodiethylamine-mediated))(NN (hepatocarcinogenesis))(JJ (Chinese))(NN (herb)))(, (,))(NP (NNP (Huqi))(NNP (San)))) |ET|  |BS| 554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500  |ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NN (Dehydroepiandrosterone)))(PRN (-LRB- (-LRB-))(NP (NN (DHEA)))(-RRB- (-RRB-))))(, (,))(NP (JJ (major))(NN (precursor))(NN (androgen))(NN (estrogen)))(, (,)))(NP (NP (JJ (several))(JJ (beneficial))(NN (effect))(JJ (immune))(NN (system)))(, (,))(NP (NN (memory))(NN (function)))(, (,))(S (VP (VBG (modulating))(NP (NP (NN (effect))(NN (diabetes)))(, (,))(NP (NN (obesity)))(, (,))(NP (NN (chemical))(NN (carcinogenesis)))))))) |ET|  |BS| 33:C04.697.098 564:C18.654.726.500 726:C18.452.394.750 740:D04.808.054.079.429.625 889:D27.505.696.399.472.277 892:D27.505.696.399.472.161 899:F02.463.425.540 900:A15.382  |ES| 2:1 10:1 14:1 19:1 33:1 75:1 207:1 262:1 462:1 593:1 984:1 2009:1 2010:1 2124:1 2435:1 2633:1 3154:1 3166:1 3167:1 3168:1 3169:1 3170:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (DT (This))(NN (study)))(VP (VBZ (validates))(NP (NP (NP (NN (utility))(NN (Gum))(JJ (Arabic-conjugated))(NN (gold))(NNS (nanoparticles)))(PRN (-LRB- (-LRB-))(NP (NNS (GA-AuNPs)))(-RRB- (-RRB-))))(SBAR (S (NP (NN (laser)))(VP (VBP (induce))(NP (JJ (photothermal))(NN (inhibition))(NN (hepatocarcinogenesis)))))))(, (,))(PP (IN (via))(S (VP (VBG (employing))(NP (NP (NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-)))))))(FRAG (: (-))(NP (VBN (mediated))(JJ (hepatocellular))(NN (carcinoma))(NN (model)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 104:C04.557.470.200.025.255 554:D02.654.442.200 1166:Z01.058.290.190.300 1167:D05.750.078.739.500 1168:J01.637.512.600 1169:D01.268.556.322 1170:E07.632.490  |ES| 2:1 10:1 14:1 19:1 72:1 103:1 131:1 243:1 303:1 304:1 596:1 807:1 900:1 1875:1 1952:1 2194:1 4011:1 4040:1 4041:1 4042:1 4043:1 4044:1 4045:1 4046:1 4047:1 4048:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Loss))(NN (Dicer)))(ADVP (RB (primarily)))(VP (VBZ (impairs))(SBAR (S (NP (NN (hepatocyte))(NN (survival)))(VP (VBP (promote))(NP (NN (hepatocarcinogenesis))(NN (cooperation))(JJ (additional))(JJ (oncogenic))(NN (stimulus)))))))) |ET|  |BS| 96:I03.784 262:A11.436.348 279:D27.888.569.100  |ES| 19:1 274:1 679:1 900:1 953:1 980:1 1788:1 1909:1 1960:1 1970:1 2728:1 2729:1 2730:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (DT (A))(JJ (novel))(JJ (CYR61-triggered))(`` (`))(NN (CYR61-alphavbeta3))(NN (integrin))(NN (loop)))('' ('))(VP (VBZ (regulates))(NP (NN (breast))(NN (cancer))(NN (cell))(NN (survival))(NN (chemosensitivity))(NN (activation))(NN (ERK1/ERK2))(NN (MAPK))(NN (signaling))(NN (pathway))))) |ET|  |BS| 69:G02.111.087.800 108:G04.299.316 116:D08.811.913.696.620.682.700.567.249.750 126:G02.111.087.800 259:D12.776.395.240.150.500 573:N05.715.350.200.650 919:D08.811.913.696.620.682.700.567.249.500 920:D12.776.543.750.705.408  |ES| 18:1 19:1 23:1 69:1 94:1 195:1 225:1 248:1 274:1 383:1 386:1 603:1 809:1 891:1 1489:1 3241:1 3242:1 3243:1 3244:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Compound))(NN (Astragalus)))(NP (FW (Salvia))(FW (miltiorrhiza))(NN (extract)))(VP (VBZ (suppresses))(NP (NP (JJ (hepatocellular))(NN (carcinoma))(NN (progression)))(VP (VBG (inhibiting))(NP (NN (fibrosis))(NN (PAI-1))(NN (mRNA))(NN (transcription))))))) |ET|  |BS| 16:C23.550.291.656 104:C04.557.470.200.025.255 111:D13.444.735.544 122:C14.280.383 209:G02.111.087.847 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 690:D12.644.861.695.500 691:C23.550.355  |ES| 19:1 48:1 303:1 304:1 325:1 487:1 686:1 880:1 949:1 2492:1 2493:1 2494:1 2495:1 2496:1 2497:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNP (Lupeol))(NN (target))(NN (liver))(JJ (tumor-initiating))(NN (cell))(NN (phosphatase))(NN (tensin))(NN (homolog))(NN (modulation)))) |ET|  |BS| 242:A03.620 1035:D08.811.277.352.650 1036:A11.872.650  |ES| 19:1 94:1 160:1 836:1 1945:1 3617:1 3618:1 3619:1 3620:1 3621:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (FW (In))(FW (vivo)))(, (,))(NP (NP (NP (NN (nimbolide)))(PRN (-LRB- (-LRB-))(NP (CD (5))(CD (20))(NN (mg/kg))(NN (body))(NN (weight)))(-RRB- (-RRB-))))(, (,))(VP (VBN (injected))(ADVP (RB (intraperitoneally)))(NP (NN (tumor))(NN (inoculation))))(, (,)))(ADVP (RB (significantly)))(VP (VBD (decreased))(NP (NN (volume))(JJ (colorectal))(NN (cancer))(NN (xenograft))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 92:E04.936.764 93:A01.941.875 653:C23.888.144 1024:D20.215.894.200 1025:Z01.252.100.450 1026:Z01.252.474.651  |ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 124:1 202:1 244:1 265:1 378:1 578:1 1870:1 2398:1 2399:1 3584:1 3585:1 3586:1 3587:1 3588:1 3589:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (Modulation))(NN (energy))(JJ (metabolic))(NN (enzyme))(NN (expression))(JJ (N-nitrosodiethylamine-mediated))(NN (hepatocarcinogenesis))(JJ (Chinese))(NN (herb)))(, (,))(NP (NNP (Huqi))(NNP (San)))) |ET|  |BS| 554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500  |ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (VBN (Enhanced))(NN (liver))(NN (tumor))(NN (promotion))(NN (liver))(NN (initiation))(NN (activity)))(NP (NN (rat))(VBN (subjected))(JJ (combined))(NN (administration))(NN (omeprazole))(NN (beta-naphthoflavone))))) |ET|  |BS| 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 983:D03.383.663.283.266.450.175.100 984:D02.886.640.074.500  |ES| 7:1 19:1 164:1 399:1 637:1 836:1 849:1 2337:1 2575:1 3267:1 3466:1 3467:1 3468:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(PP (IN (In))(NP (NNS (hepatocytes))))(, (,))(NP (NN (JNK1))(NN (JNK2)))(VP (VP (VBP (appear))(NP (NP (JJ (combined))(NN (effect)))(VP (VBG (protecting))(NP (NN (mouse))(NN (CCl4))))))(: (-))(NP (JJ (acetaminophen-induced))(NN (liver))(NN (injury))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 262:A11.436.348 661:D02.065.199.092.040  |ES| 2:1 19:1 52:1 75:1 104:1 164:1 239:1 244:1 836:1 894:1 2251:1 2357:1 2416:1 4110:1 4111:1 4112:1 4113:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Interferon-gamma-mediated))(NN (hepatocarcinogenesis))(NN (mouse)))(VP (VBN (treated))(NP (NN (diethylnitrosamine)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 52:E02 554:D02.654.442.200 1033:D12.644.276.374.440.893  |ES| 19:1 52:1 900:1 1099:1 1952:1 3600:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Liver))(NN (fibrosis)))(VP (VBD (induced))(NP (NP (NN (carbon))(NN (tetrachloride)))(, (,))(NP (NN (bile))(NN (duct))(NN (ligation)))(, (,))(NP (NP (NN (disruption))(JJ (multidrug-resistance))(NN (transporter))(CD (2))(NN (gene)))(PRN (-LRB- (-LRB-))(NP (NN (Mdr2)))(-RRB- (-RRB-))))))) |ET|  |BS| 227:D12.776.157.530 676:C06.552.630 1220:D02.455.526.439.150 1221:G05.360.340.024.340.361 1222:A03.159.183 1223:E04.426  |ES| 2:1 9:1 10:1 14:1 19:1 148:1 412:1 779:1 949:1 1602:1 1621:1 1622:1 2721:1 4278:1 4279:1 4282:1 4283:1 4284:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (NP (NP (JJ (Anti-tumor))(NN (effect)))(VBN (pegylated))(NN (interferon))(NN (rat))(NN (hepatocarcinogenesis))(NN (model)))) |ET|  |BS| 8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 617:D12.644.276.374.440  |ES| 19:1 72:1 75:1 849:1 900:1 2305:1 2442:1 2443:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NN (Folbp1))(NN (RFC1)))(ADVP (RB (genetically)))(VP (NP (VBN (modified))(NN (mouse))(NN (exhibit))(JJ (distinct))(NN (change))(NN (colonocyte))(NN (phenotype)))(ADVP (RB (therefore)))(SBAR (S (NP (NN (utility))(NN (model)))(VP (VBP (examine))(NP (NP (NN (role)))(JJ (folate))(NN (homeostasis))(NN (colon))(NN (cancer))(NN (development)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 80:G05.695 152:G07.700.345 175:J01.897.280.500.269 224:D03.438.733.631.400  |ES| 2:1 18:1 19:1 31:1 35:1 52:1 72:1 113:1 200:1 218:1 236:1 244:1 500:1 587:1 778:1 898:1 960:1 1284:1 2026:1 2194:1 2335:1 3548:1 3549:1 3550:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (CD (One))(JJ (reasonable))(NN (possibility))(JJ (attributable))(NN (hyperinsulinemia))(JJ (compensatory))(JJ (obesity-related))(NN (insulin))(NN (resistance)))) |ET|  |BS| 564:C18.654.726.500 678:C18.452.394.968.500 1053:C18.452.394.968  |ES| 19:1 343:1 654:1 1094:1 2364:1 2467:1 3668:1 3669:1 3670:1 3671:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (JJ (Kruppel-like))(NN (factor))(CD (9)))(PRN (-LRB- (-LRB-))(NP (NN (KLF9)))(-RRB- (-RRB-))))(VP (VBZ (prevents))(NP (JJ (colorectal))(NN (cancer))(NN (inhibition))(JJ (interferon-related))(NN (signaling))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 69:G02.111.087.800 617:D12.644.276.374.440 774:D12.776.124.125.375  |ES| 10:1 14:1 17:1 18:1 19:1 103:1 185:1 195:1 318:1 703:1 2717:1 2718:1 2719:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NNP (Diosmin)))(VP (VBZ (abrogates))(VP (ADVP (RB (chemically)))(VBN (induced))(NN (hepatocarcinogenesis))(PP (IN (via))(NP (NP (NN (alleviation))(JJ (oxidative))(NN (stress)))(, (,))(NP (JJ (hyperproliferative))(JJ (inflammatory))(NN (marker))(JJ (murine))(NN (model)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 158:D23.101 715:D03.383.663.283.266.450.260.222 716:G03.495.710  |ES| 2:1 19:1 72:1 412:1 534:1 596:1 627:1 900:1 2430:1 2522:1 2579:1 2580:1 2581:1 2582:1 2583:1 2584:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Mycophenolic))(JJ (acid-induced))(NN (replication))(NN (arrest)))(, (,))(NP (NN (differentiation))(NN (marker))(NN (cell))(NN (death))(JJ (androgen-independent))(NN (prostate))(NN (cancer))(NN (cell))(NN (DU145)))) |ET|  |BS| 41:A11 78:G02.111.087.222 134:G04.299.139 852:C04.588.945.440.770.500 1044:D02.241.081.193.678 1045:D23.050.301.264  |ES| 2:1 18:1 19:1 77:1 94:1 215:1 231:1 411:1 534:1 602:1 2599:1 3423:1 3520:1 3649:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(JJ (prior))(NN (work)))(VP (VBD (showed))(NP (NP (NP (JJ (brief))(NN (exposure))(JJ (pregnant))(NN (C3H))(NN (mouse))(JJ (inorganic))(JJ (arsenic-induced))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NP (NN (formation))(JJ (adult))(JJ (male))(NN (offspring)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 445:I03.946 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1156:F01.829.263.065 1157:E05.916.039 1158:D01.268.513.249  |ES| 10:1 14:1 19:1 43:1 52:1 132:1 303:1 304:1 355:1 441:1 658:1 1402:1 1546:1 1953:1 3174:1 3998:1 3999:1 4000:1 4001:1 4002:1 4003:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNS (Effects))(JJ (S-adenosylmethionine))(NN (methylthioadenosine))(JJ (inflammation-induced))(NN (colon))(NN (cancer))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 232:D02.886.030.676.180 525:C23.550.470  |ES| 18:1 19:1 52:1 113:1 1793:1 3461:1 3462:1 3463:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (DT (A))(NP (JJ (pivotal))(NN (signaling))(NN (network))(JJ (colorectal))(NN (cancer))(NN (cell))))(VP (VBZ (involves))(NP (NP (NP (NN (glycogen))(NN (synthase))(NN (kinase-3beta)))(PRN (-LRB- (-LRB-))(NP (NN (GSK3beta)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (multifunctional))(NN (kinase)))(SBAR (WHNP (WP$ (whose))(NN (role))(NN (tumor))(NN (cell))(NN (survival)))(S (VP (VBN (defined))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 69:G02.111.087.800 108:G04.299.316 469:D08.811.913.696 588:I01.880.853.500.600  |ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 66:1 69:1 92:1 93:1 94:1 195:1 274:1 470:1 680:1 919:1 1673:1 1878:1 1894:1 2154:1 3248:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (ADVP (RB (Overall)))(, (,))(VP (VBP (result))(NP (NN (support))(JJ (translational))(JJ (potential))(NN (silibinin))(JJ (colorectal))(NN (cancer))(NN (chemoprevention))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 145:G02.111.087.675.871 253:E02.319.162 696:V02.270.500 809:L01.178.682.920  |ES| 2:1 17:1 18:1 19:1 101:1 827:1 870:1 1364:1 2635:1 2858:1 2866:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (PP (IN (In))(NP (NP (NP (NN (azoxymethane)))(PRN (-LRB- (-LRB-))(NP (NN (AOM)))(-RRB- (-RRB-))))(NN (model))(NN (colon))(NN (cancer))))(, (,))(NP (NP (NN (addition))(NN (K-ras))(NN (mutation)))(, (,))(VP (VBN (shown))(S (NP (ADJP (ADJP (JJ (wild-type)))(PRN (-LRB- (-LRB-))(ADJP (JJ (WT)))(-RRB- (-RRB-))))(NN (Ras)))(VP (VBD (activated))(NP (NP (JJ (upstream))(NN (pathway)))(, (,))(S (VBG (including))(, (,))(PP (FW (e.g.)))(, (,))(VP (VBG (signaling))(NP (NN (ErbB))(NN (receptor))))))))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009  |ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(NP (NP (NNP (Drug))(NN (combination))(NN (therapy)))(VP (VBG (using))(NP (NP (NN (cisplatin))(JJ (natural))(NN (product)))(JJ (common))(NN (practice))(NN (treatment))(JJ (human))(NN (lung))(NN (cancer)))))) |ET|  |BS| 52:E02 55:B01.050.150.900.649.801.400.112.400.400 498:D01.210.375 793:D20.215 939:E02.319.310  |ES| 18:1 19:1 36:1 104:1 130:1 328:1 350:1 530:1 546:1 655:1 675:1 1046:1 1761:1 2333:1 2345:1 3296:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Decorin-mediated))(NN (inhibition))(JJ (colorectal))(NN (cancer))(NN (growth))(NN (migration)))(NP (VBN (associated))(NN (E-cadherin))(NN (vitro))(NN (mouse))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625  |ES| 17:1 18:1 19:1 52:1 102:1 103:1 169:1 216:1 514:1 2267:1 2557:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(NP (NP (NNP (Metformin)))(, (,))(VP (ADVP (RB (generally)))(VBN (considered))(S (ADJP (JJ (nontoxic))(SBAR (S (ADJP (RB (remarkably))(JJ (inexpensive)))(, (,))(VP (MD (might))(NP (VBN (used))(NN (combination))(NNS (TKIs))(NN (patient))(JJ (non-small))(NN (cell))(NN (lung))(NN (cancer)))(, (,))(S (VP (VBG (harboring))(S (NP (NN (EGFR))(NN (mutation)))(VP (VBP (overcome))(S (NP (NN (TKI))(NN (resistance)))(VP (VB (prolong))(NP (NN (survival))))))))))))))))) |ET|  |BS| 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 96:I03.784 110:C04.588.894.797.520.109.220.249 784:D02.078.370.141.450  |ES| 2:1 18:1 19:1 34:1 94:1 104:1 120:1 187:1 274:1 328:1 476:1 530:1 694:1 798:1 1061:1 1094:1 1304:1 1882:1 2746:1 2998:1 3364:1 3365:1 3366:1 3367:1 3368:1 3369:1 3370:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (AIM))(: (:)))(S (VP (TO (To))(VP (VB (investigate))(NP (NP (NP (JJ (therapeutic))(NN (effect))(JJ (potential))(NN (mechanism))(JJ (natural))(NN (flavonoid))(NN (quercetin-3-O-beta-D-glucuronide)))(PRN (-LRB- (-LRB-))(NP (NN (Q3GA)))(-RRB- (-RRB-))))(VP (NN (lipid))(NP (NP (NN (metabolism))(NN (disorder))(JJ (free))(JJ (fatty))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (FFA)))(-RRB- (-RRB-)))))))))(: (-))(VP (VBN (induced))(NP (NN (fatty))(NN (liver)))(ADVP (FW (vivo))(FW (vitro))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 1132:C18.452.584 1133:D10.251.310  |ES| 10:1 14:1 19:1 75:1 104:1 162:1 216:1 378:1 409:1 459:1 541:1 827:1 828:1 836:1 959:1 1275:1 1886:1 2007:1 2070:1 2333:1 2401:1 3163:1 3958:1 3959:1 3960:1 3961:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Loss))(NN (metallothionein)))(VP (VBZ (predisposes))(NP (NN (mouse))(JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(VBG (activating))(NN (NF-kappaB))(NN (target))(NN (gene))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670  |ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (DT (The))(JJ (key))(NN (event))(JJ (responsible))(NN (mouse))(NN (liver))(NN (tumor)))(VP (VBD (induced))(NP (NP (NN (pesticide)))(PRN (-LRB- (-LRB-))(NP (NP (NN (viz.)))(, (,))(NP (NN (pronamide))))(-RRB- (-RRB-))))))(VP (VBD (investigated))(NP (S (NP (NN (series))(NN (study)))(VP (VBG (employing))(ADJP (ADJP (JJ (molecular)))(, (,))(ADJP (JJ (biochemical)))(, (,))(ADJP (JJ (cellular))))))(, (,))(NP (JJ (apical))(NN (endpoint)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 41:A11 515:C04.588.274.623 913:D27.720.031.700  |ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 159:1 161:1 205:1 403:1 412:1 691:1 836:1 1689:1 1807:1 2132:1 3074:1 3214:1 3323:1 4010:1 4011:1 4012:1 4013:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Branched-chain))(NN (amino))(NN (acid))(-LRB- (-LRB-))(NN (BCAA))(-RRB- (-RRB-)))(, (,))(VP (VB (improve))(NP (NP (NN (protein))(NN (malnutrition))(NN (patient))(NN (liver))(NN (cirrhosis)))(, (,))(S (VP (VB (reduce))(NP (NN (risk))(JJ (hepatocellular))(NN (carcinoma))(NN (patient))(NN (obesity)))))))) |ET|  |BS| 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 564:C18.654.726.500 639:D12.125.070 943:C18.654.521.719.500  |ES| 2:1 4:1 10:1 14:1 19:1 120:1 171:1 303:1 304:1 836:1 1199:1 1275:1 2010:1 2189:1 2360:1 2361:1 2465:1 2466:1 3307:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(NP (JJ (Chronic))(NP (NP (NN (ethanol))(NN (consumption))(NN (increase))(NN (risk))(JJ (hepatic))(NN (cirrhosis))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))) |ET|  |BS| 61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 904:F01.145.317.269  |ES| 10:1 14:1 19:1 40:1 104:1 171:1 303:1 304:1 441:1 838:1 1046:1 1199:1 2387:1 3440:1 3967:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NN (observation)))(VP (VBP (suggest))(NP (NP (JJ (chemoprotective))(NN (effect))(NN (isorhamnetin))(NN (colon))(NN (cancer)))(VP (VBN (linked))(NP (NP (JJ (anti-inflammatory))(NN (activity))(NN (inhibition))(JJ (oncogenic))(NN (Src))(NN (activity))(JJ (consequential))(NN (loss)))(VP (JJ (nuclear))(NP (NP (NN (beta-catenin)))(, (,))(NP (NN (activity)))(NP (JJ (dependent))(NN (CSK))(NN (expression)))))))))) |ET|  |BS| 23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158  |ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBP (demonstrate))(NP (NP (JJ (altered))(NN (gene))(NN (expression))(JJ (various))(NNS (proteins/enzymes)))(VP (VBN (involved))(NP (NP (NN (DNA))(NN (repair)))(, (,))(NP (NP (NN (cell))(NN (growth))(NN (cell))(NN (cycle))(NN (process)))(JJ (tamoxifen-induced))(NN (hepatocarcinogenesis)))))))) |ET|  |BS| 41:A11 45:G07.700.320.249 353:G04.299.134 640:D02.455.426.559.389.150.700.900 730:D08.811 1134:G02.111.087.219 1213:D12.776  |ES| 2:1 9:1 19:1 94:1 102:1 115:1 131:1 244:1 502:1 513:1 601:1 638:1 666:1 693:1 774:1 900:1 1096:1 1307:1 3965:1 3966:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Exenatide)))(PRN (-LRB- (-LRB-))(NP (NN (Ex-4)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (potent))(NN (diabetes))(NN (drug)))(VP (VBG (targeting))(NP (NP (JJ (glucagon-like))(NN (peptide-1))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (GLP-1R)))(-RRB- (-RRB-))))))(, (,))(NP (NP (JJ (protective))(JJ (non-alcoholic))(NN (fatty))(NN (liver))(NN (disease)))(PRN (-LRB- (-LRB-))(NP (NN (NAFLD)))(-RRB- (-RRB-))))) |ET|  |BS| 369:E02.319.300 577:C06.552.241.519 725:D12.776.543.750.100.021.500 726:C18.452.394.750  |ES| 2:1 10:1 14:1 19:1 22:1 186:1 191:1 493:1 616:1 836:1 998:1 2009:1 2069:1 2070:1 2604:1 2605:1 2606:1 2607:1 2608:1 2609:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Cryptotanshinone)))(ADVP (RB (rapidly)))(VP (VBD (inhibited))(NP (NN (STAT3))(NN (Tyr705))(NN (phosphorylation))(NN (DU145))(NN (prostate))(NN (cancer))(NN (cell))(NN (growth))(NN (cell)))(NP (CD (96))(NN (hour))(NN (treatment))))) |ET|  |BS| 41:A11 45:G07.700.320.249 52:E02 82:D12.644.360.024.342.300 122:C14.280.383 972:G02.111.087.677  |ES| 18:1 19:1 77:1 94:1 102:1 251:1 365:1 546:1 3420:1 3423:1 3424:1 3425:1 3426:1 3427:1 3428:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Natural))(NN (product))(NN (pectolinarigenin)))(VP (VBZ (inhibits))(NP (NN (osteosarcoma))(NN (growth))(NN (metastasis)))(PP (IN (via))(NP (JJ (SHP-1-mediated))(NN (STAT3))(NN (signaling))(NN (inhibition)))))) |ET|  |BS| 43:F01.145.544 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383 447:C04.557.450.565.575.650 793:D20.215  |ES| 19:1 102:1 103:1 195:1 251:1 596:1 615:1 675:1 806:1 1562:1 2780:1 2785:1 2786:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (JJ (2-Amino-1-methyl-6-phenylimidazo))(PRN (-LRB- (-LSB-))(ADJP (JJ (4,5-b)))(-RRB- (-RSB-)))(NN (pyridine))(NN (increase))(NN (number))(NN (tumor)))(, (,))(NP (JJ (cystic))(NN (crypt))(JJ (aberrant))(NN (crypt))(NN (focus))(JJ (multiple))(JJ (intestinal))(NN (neoplasia))(NN (mouse)))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 555:C04.182 744:D03.383.725 824:C04.834.020  |ES| 2:1 7:1 19:1 40:1 52:1 109:1 640:1 646:1 649:1 1373:1 1378:1 1431:1 1725:1 2639:1 2640:1 2913:1 4060:1 4061:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (JJ (Hypoxia-inducible))(NN (factor)))(PRN (-LRB- (-LRB-))(NP (NNS (HIFs)))(-RRB- (-RRB-))))(VP (VBP (accumulate))(NP (NP (JJ (neoplastic))(JJ (inflammatory))(NN (cell)))(PP (IN (within))(NP (NN (tumor))(NN (microenvironment))(NN (impact))(NN (progression))(NN (variety))(NN (disease))))(, (,))(PP (VBG (including))(NP (JJ (colorectal))(NN (cancer))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 41:A11 1011:C23.888.852.079 1012:G04.366.500  |ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 48:1 94:1 185:1 561:1 893:1 952:1 998:1 2122:1 2430:1 3537:1 3538:1 3539:1 3540:1 3541:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (PP (IN (On))(NP (NN (basis))(NN (finding))(, (,))(NN (development))(NN (2-aryl))(NN (benzimidazole))(NN (derivative))))(, (,))(NP (NP (JJ (new))(NN (class))(JJ (multitarget))(JJ (anticancer))(NN (agent)))(, (,))(VP (VBD (warranted))(VP (VBZ (represents))(NP (NP (JJ (novel))(NN (strategy)))(VP (VBG (improving))(NP (NN (breast))(NN (cancer))(NN (treatment))))))))) |ET|  |BS| 52:E02 259:D12.776.395.240.150.500 660:D27.505.954.248 798:D03.438.103  |ES| 2:1 18:1 19:1 23:1 35:1 546:1 712:1 728:1 891:1 927:1 1114:1 1140:1 1880:1 2363:1 2516:1 2810:1 2811:1 2812:1 2813:1 2814:1 2815:1 2816:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (JJ (wild-type))(NN (mouse))))(, (,))(NP (CD (200))(NN (ppm))(NN (cyproconazole)))(VP (VBD (caused))(NP (NP (NP (NP (NN (liver))(NN (hypertrophy)))(, (,))(NP (VBD (increased))(NN (liver))(NN (weight))(NN (cell))(NN (proliferation)))(, (,)))(JJ (single-cell))(NN (necrosis))(JJ (fat))(NN (vacuolation)))(, (,))(NP (NP (NP (NN (effect)))(ADJP (RB (generally))(JJ (similar))))(VP (VBN (caused))(NP (CD (850))(NN (ppm))(NN (phenobarbital)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 183:G04.299.233.750 242:A03.620 756:D03.383.742.698.253.650 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1151:C06.552.416 1215:C23.888.144.243.926 1216:C23.550.717  |ES| 2:1 8:1 19:1 47:1 52:1 75:1 94:1 244:1 299:1 332:1 836:1 2399:1 2425:1 2506:1 2685:1 3233:1 3364:1 3992:1 4254:1 4255:1 4256:1 4257:1 4258:1 4259:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Characterization))(JJ (nuclear))(JJ (receptor-mediated))(JJ (murine))(NN (hepatocarcinogenesis))(NN (herbicide))(NN (pronamide))(JJ (human))(NN (relevance)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 949:D27.720.031.700.366 950:D12.776.826  |ES| 19:1 36:1 627:1 900:1 1064:1 1256:1 3123:1 3322:1 3323:1 3324:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Colitis)))(VP (VBD (induced))(NP (NP (NN (knockout)))(, (,))(NP (NP (NP (JJ (transgenic))(, (,))(NN (control)))(PRN (-LRB- (-LRB-))(NP (NN (C57BL/B6)))(-RRB- (-RRB-))))(NP (NP (NN (mouse))(NN (administration))(NN (dextran))(NN (sulfate))(NN (sodium)))(PRN (-LRB- (-LRB-))(NP (NN (DSS)))(-RRB- (-RRB-)))))(, (,))(NP (NP (NN (mouse)))(VP (VBN (given))(NP (NN (azoxymethane))))))(VP (VBP (induce))(NP (JJ (colorectal))(NN (carcinogenesis)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 131:D09.698.365.272.300 132:D02.172.080 352:B01.050.050.136 593:B01.050.050.199.520.520.420  |ES| 2:1 10:1 14:1 17:1 19:1 29:1 52:1 71:1 207:1 243:1 285:1 289:1 406:1 407:1 412:1 1993:1 2575:1 3300:1 3306:1 4108:1 4109:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Constitutive))(NN (activation))(NN (phosphoinositide))(NN (3-kinase)))(PRN (-LRB- (-LRB-))(NP (NN (PI3K)))(-RRB- (-RRB-))))(: (-))(S (NP (NN (Akt))(NN (pathway)))(VP (VBZ (transmits))(NP (NP (JJ (growth-regulatory))(NN (signal))(NN (play))(JJ (central))(NN (role)))(S (VP (VBG (promoting))(NP (NP (NN (survival)))(, (,))(NP (NN (proliferation)))(, (,))(NP (NN (angiogenesis))(JJ (human))(NN (prostate))(NN (cancer))(NN (cell)))))))))) |ET|  |BS| 15:F01.829.316.616 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 96:I03.784 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550  |ES| 2:1 10:1 14:1 18:1 19:1 31:1 36:1 77:1 94:1 225:1 238:1 274:1 299:1 383:1 859:1 881:1 2080:1 2502:1 3235:1 3394:1 3399:1 3400:1 3401:1 3402:1 3403:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (DT (All))(NN (result)))(VP (VBP (suggest))(SBAR (S (NP (JJ (low))(NN (concentration))(NN (acrylamide)))(VP (MD (may))(VP (VB (contribute))(NP (NP (NN (progression))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))))) |ET|  |BS| 16:C23.550.291.656 104:C04.557.470.200.025.255 905:F02.830.104.214 930:D02.065.122.015  |ES| 10:1 14:1 19:1 48:1 101:1 303:1 304:1 441:1 450:1 491:1 531:1 796:1 965:1 3189:1 3278:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (S (NP (JJ (Chronic))(JJ (inorganic))(JJ (arsenic))(NN (exposure)))(VP (VBZ (induces))(NP (JJ (hepatic))(JJ (global))(JJ (individual))(NN (gene))(NN (hypomethylation)))))(: (:))(NP (NN (implication))(JJ (arsenic))(NN (hepatocarcinogenesis)))) |ET|  |BS| 6:G05.360.340.024.340 197:A01.456.505.420 493:M01 1158:D01.268.513.249  |ES| 9:1 19:1 85:1 104:1 214:1 660:1 838:1 900:1 1953:1 2512:1 3174:1 3967:1 4106:1 4107:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Cooperativity))(NN (E-cadherin))(NN (Smad4))(NN (loss)))(VP (VBP (promote))(NP (JJ (diffuse-type))(JJ (gastric))(NN (adenocarcinoma))(NN (metastasis))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 70:A03.556.875.875 84:C04.557.470.200.025 113:C04.697.650 613:D12.776.395.550.200.200 968:F01.145.813.115  |ES| 19:1 32:1 86:1 255:1 521:1 679:1 806:1 2267:1 3411:1 3412:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (VBG (Following))(NP (NP (JJ (initial))(CD (14))(NN (day)))(JJ (dietary))(NN (dose))(NN (range-finding))(NN (study))(JJ (male))(NN (mouse))))(, (,))(ADJP (NP (NP (JJ (mechanistic))(NN (study)))(PRN (-LRB- (-LRB-))(NP (NP (CD (0))(, (,))(CD (3))(, (,))(CD (32))(, (,))(CD (320))(NN (ppm))(NN (toxaphene))(NN (diet))(CD (7)))(, (,))(NP (CD (14)))(, (,))(NP (ADJP (CD (28))(NN (day)))(NN (treatment))))(-RRB- (-RRB-))))(VBN (performed)))(VP (VBP (examine))(SBAR (S (NP (JJ (potential))(NN (mechanism))(NN (toxaphene)))(VP (VBD (induced))(NP (NN (mouse))(NN (liver))(NN (tumor)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 275:C23.888 515:C04.588.274.623 595:G07.203.650.240 596:E02.642.249 1149:D02.455.526.439.913  |ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 162:1 412:1 458:1 546:1 827:1 836:1 862:1 960:1 988:1 1401:1 1402:1 1440:1 1890:1 2191:1 2301:1 2546:1 2594:1 3233:1 3985:1 4078:1 4160:1 4161:1 4162:1 4163:1 4164:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(VP (VBN (Taken))(ADVP (RB (together))))(, (,))(S (NP (NNS (data)))(VP (VBP (provide))(NP (NP (JJ (first))(ADJP (FW (vitro))(FW (vivo)))(NN (evidence))(JJ (integral))(NN (role)))(NP (NN (LKB1-AMPK))(NN (axis))(JJ (honokiol-mediated))(NN (inhibition))(NN (invasion))(NN (migration))(NN (breast))(NN (cancer))(NN (cell))))))) |ET|  |BS| 15:F01.829.316.616 43:F01.145.544 579:A02.835.232.834.151.383 681:G04.299.283  |ES| 2:1 18:1 19:1 23:1 31:1 38:1 94:1 103:1 104:1 216:1 239:1 378:1 514:1 620:1 711:1 793:1 816:1 1537:1 1538:1 2089:1 2269:1 3388:1 3389:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (AIRmax)))(ADVP (RB (also)))(NP (JJ (susceptible))(NN (AIRmin))(NN (colon))(NN (cancer)))(VP (VP (VBD (induced))(NP (NP (QP (CD (2))(CD (7)))(JJ (weekly))(NNS (dos)))(ADJP (ADJP (JJ (1,2-dimethylhydrazine)))(PRN (-LRB- (-LRB-))(NP (NN (DMH)))(-RRB- (-RRB-)))))(, (,))(S (VP (VBG (showing))(NP (NP (ADJP (RB (significantly))(JJR (higher)))(NN (number))(JJ (colonic))(JJ (aberrant))(NN (crypt))(NN (focus)))(PRN (-LRB- (-LRB-))(NP (NN (ACF)))(-RRB- (-RRB-))))(NP (CD (150))(NN (day))(NN (DMH))(NN (treatment))))))(PRN (-LRB- (-LRB-))(S (NP (NN (P)))(VP (JJ (=))(NP (CD (0.01)))))(-RRB- (-RRB-))))(NP (ADJP (RB (significantly))(JJR (higher)))(NN (number))(NN (tumor))(VBG (affecting))(NP (NP (JJR (larger))(JJ (intestinal))(NN (area)))(CD (300-475))(NN (day))))) |ET|  |BS| 8:C04 46:A03.556.124.526.356 52:E02 292:Z01 433:F01.470.047 824:C04.834.020 1177:A03.556.124.526  |ES| 2:1 5:1 7:1 10:1 14:1 18:1 19:1 109:1 113:1 124:1 148:1 170:1 311:1 315:1 412:1 546:1 581:1 646:1 677:1 899:1 988:1 1431:1 1725:1 2201:1 2530:1 2642:1 2643:1 2653:1 2913:1 2914:1 4074:1 4075:1 4076:1 4077:1 4078:1 4079:1 4080:1 4081:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (contrast))))(, (,))(NP (NP (JJ (high))(NN (level))(NN (sPLA2))(NN (expression)))(JJ (likely))(VBG (contributing))(JJ (elevated))(NN (level))(JJ (arachidonic))(NN (acid)))(VP (VBD (found))(SBAR (S (NP (NP (JJ (colorectal))(NN (cancer)))(, (,))(NP (NN (conjunction))(JJ (elevated))(NN (expression))(NN (cyclooxygenase-2)))(, (,)))(VP (MD (could))(NP (DT (another))(NN (factor))(NN (tumor))(NN (formation)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 20:G03.495 24:D08.811.600.720.750 491:D27.505.259.500 1014:D10.251.355.255.100.100  |ES| 2:1 7:1 17:1 18:1 19:1 37:1 43:1 61:1 115:1 178:1 185:1 244:1 249:1 756:1 908:1 1275:1 1295:1 1328:1 1392:1 3552:1 3553:1 3554:1 3555:1  |EV| 
4.520134953427480617449418787146  |BT| (S (VP (VBG (Modifying))(NP (NP (NN (effect))(NN (liver))(NN (tumor))(NN (promotion))(NN (rat)))(VBN (subjected))(NN (co-administration))(NN (indole-3-carbinol))(NN (phenobarbital))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1042:Z01.107.757.284  |ES| 7:1 19:1 75:1 836:1 849:1 2337:1 2685:1 3267:1 3638:1 3646:1 3647:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (JJ (Hepatocarcinogenic))(NN (susceptibility))(NN (fenofibrate))(JJ (possible))(NN (mechanism))(NN (carcinogenicity))(JJ (two-stage))(NN (hepatocarcinogenesis))(NN (model))(NN (rasH2))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 401:C23.550.291.687 916:D02.241.081.114.968.500.625  |ES| 19:1 52:1 72:1 162:1 900:1 1353:1 1359:1 2971:1 3225:1 3583:1 4186:1 4187:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Polyenephosphatidylcholine)))(VP (VBZ (prevents))(NP (NP (JJ (alcoholic))(NN (liver))(NN (disease))(NN (PPARalpha-null))(NN (mouse))(NN (attenuation))(NN (increase)))(JJ (oxidative))(NN (stress))))) |ET|  |BS| 29:B01.050.050.136.500.500 536:D12.776.826.239.500 716:G03.495.710 814:C06.552.645  |ES| 19:1 40:1 52:1 836:1 998:1 2522:1 2583:1 2718:1 2879:1 2880:1 2881:1 2882:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (JJ (Functional))(NN (interaction))(NN (FOXO3a))(NN (ER)))(VP (VBP (play))(NP (JJ (critical))(NN (role)))(S (VP (VBG (suppressing))(ADVP (NP (JJ (estrogen-dependent))(NN (breast))(NN (cancer))(NN (cell))(NN (growth))(NN (tumorigenesis)))(FW (vivo)))))))) |ET|  |BS| 15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 41:A11 45:G07.700.320.249 79:I03.450.642.693 889:D27.505.696.399.472.277  |ES| 18:1 19:1 23:1 31:1 78:1 94:1 102:1 104:1 238:1 378:1 618:1 825:1 1882:1 2250:1 3360:1 3361:1 3362:1 3363:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Methyl))(NN (antcinate))(NN (A))(NN (Antrodia))(NN (camphorata)))(VP (VBZ (induces))(NP (NP (NN (apoptosis))(JJ (human))(NN (liver))(NN (cancer))(NN (cell))(JJ (oxidant-mediated))(NN (cofilin)))(: (-))(NP (JJ (Bax-triggered))(JJ (mitochondrial))(NN (pathway)))))) |ET|  |BS| 39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 573:N05.715.350.200.650 786:B01.300.179.120.174.070 787:D27.720.642  |ES| 18:1 19:1 36:1 69:1 89:1 94:1 214:1 383:1 836:1 2004:1 2753:1 2754:1 2755:1 2756:1 2757:1 2758:1 2759:1  |EV| 
-4.520134953427480617449418787146  |BT| (SINV (ADVP (RB (Furthermore)))(, (,))(NP (NN (exposure))(JJ (colorectal))(NN (cancer))(NN (cell))(JJ (anti-periostin))(NN (antibody)))(VP (VBZ (activates))(NP (NN (apoptosis))))(VP (VBZ (potentiates))(NP (NN (effect))(NN (5-fluorouracil))(NN (chemotherapy))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 151:E02.319 560:D03.383.742.698.875.404 727:D12.776.124.486.485.114.071  |ES| 2:1 17:1 18:1 19:1 75:1 89:1 94:1 301:1 334:1 495:1 1953:1 2307:1 2499:1 2610:1 2611:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NN (injection))(NN (N-diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(VP (VBP (initiate))(NP (NN (hepatocarcinogenesis))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 554:D02.654.442.200  |ES| 10:1 14:1 19:1 785:1 900:1 1875:1 3231:1 3595:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (VBN (injected))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(VP (VBP (induce))(NP (JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 554:D02.654.442.200  |ES| 10:1 14:1 19:1 243:1 303:1 304:1 1875:1 1952:1 3586:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Epigenetic))(NN (identification))(NN (ubiquitin))(JJ (carboxyl-terminal))(NN (hydrolase))(NN (L1))(JJ (functional))(NN (tumor))(NN (suppressor))(NN (biomarker))(JJ (hepatocellular))(NN (carcinoma))(JJ (digestive))(NN (tumor)))) |ET|  |BS| 104:C04.557.470.200.025.255 158:D23.101 206:G05.360.340.024.340.375.249 244:C04.588.274.476 374:F01.393.446 985:D08.811.277.352.897.850 986:C04.588.274  |ES| 7:1 19:1 303:1 304:1 415:1 700:1 885:1 1201:1 3469:1 3470:1 3471:1 3472:1 3473:1 3474:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (VBN (Accelerated))(NN (liver))(NN (regeneration))(NN (hepatocarcinogenesis))(NN (mouse)))(VP (VBG (overexpressing))(NP (NN (serine-45))(JJ (mutant))(NN (beta-catenin))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 925:G10.261.326.520 926:D12.125.154.800  |ES| 19:1 52:1 60:1 811:1 836:1 900:1 3259:1 3260:1 3261:1 3262:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NN (Aspirin)))(PRN (-LRB- (-LSB-))(NP (NP (JJ (acetylsalicylic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (ASA)))(-RRB- (-RRB-))))(-RRB- (-RSB-))))(VP (VBN (shown))(VP (VBP (prevent))(NP (NN (CRC))))))(: (;))(S (ADVP (RB (however)))(, (,))(NP (JJ (epigenetic))(NN (mechanism))(NN (action)))(VP (VBP (remain))(ADJP (JJ (unknown)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203  |ES| 2:1 10:1 14:1 19:1 162:1 217:1 237:1 245:1 733:1 1275:1 1373:1 1378:1 1387:1 1603:1 2013:1 2181:1 2182:1 2449:1 2450:1 2451:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NNP (Gefitinib)))(, (,))(NP (NN (EGFR))(NN (inhibitor)))(, (,)))(VP (VBZ (prevents))(NP (JJ (hepatocellular))(NN (carcinoma))(NN (development))(NN (rat))(NN (liver))(NN (cirrhosis))))) |ET|  |BS| 104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355  |ES| 2:1 19:1 35:1 187:1 303:1 304:1 380:1 836:1 849:1 1199:1 2718:1 3024:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (S (NP (JJ (Liver-specific))(NN (deletion))(NN (prohibitin))(CD (1)))(VP (VBP (result))(NP (JJ (spontaneous))(NN (liver))(NN (injury)))))(, (,))(NP (NP (NN (fibrosis)))(, (,))(NP (JJ (hepatocellular))(NN (carcinoma))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 242:A03.620 306:G05.355.600.800 691:C23.550.355  |ES| 2:1 19:1 52:1 98:1 101:1 283:1 303:1 304:1 836:1 949:1 1059:1 2416:1 2726:1 2727:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (OBJECTIVE))(: (:)))(NP (NP (NN (Vitamin))(NN (D)))(PRN (-LRB- (-LRB-))(NP (CD (3)))(-RRB- (-RRB-))))(VP (VBN (upregulated))(NP (NP (NN (protein))(CD (1))(PRN (-LRB- (-LRB-))(NP (NN (VDUP1)))(-RRB- (-RRB-))))(NP (NP (JJ (potent))(NN (tumour))(NN (suppressor)))(SBAR (WHNP (WP$ (whose))(NN (expression)))(S (ADVP (RB (dramatically)))(VP (VBD (reduced))(NP (NP (JJ (various))(NN (type))(JJ (human))(NN (cancer)))(, (,))(PP (VBG (including))(NP (JJ (gastric))(NN (cancer)))))))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 415:F01.658.500 1050:D12.776.157.125.050.060 1051:D04.808.247.222.159 1052:D12.776.641.750  |ES| 2:1 4:1 10:1 14:1 18:1 19:1 22:1 36:1 86:1 98:1 104:1 115:1 125:1 452:1 543:1 561:1 645:1 700:1 862:1 919:1 1011:1 1096:1 1417:1 2592:1 3665:1 3666:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NN (finding)))(ADVP (RB (also)))(VP (VBD (showed))(SBAR (S (NP (NP (JJ (myrtenal))(NNS (restrains))(NN (liver))(NN (cancer)))(VP (VBG (preventing))(NP (NN (DEN-PB)))))(VP (VBD (induced))(NP (NN (up-regulation))(NN (TNF-alpha))(NN (protein))(NN (expression))(NN (immunoblot)))))))) |ET|  |BS| 7:D12.776 122:C14.280.383 142:I01.880.604 789:D12.644.276.374.500.800 790:D12.644.276.374.750 802:E05.478.566.320  |ES| 4:1 5:1 18:1 19:1 115:1 132:1 412:1 658:1 836:1 896:1 927:1 1937:1 2682:1 2775:1 2828:1 2829:1 2830:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNP (Folate))(NN (transport))(NN (gene))(NN (inactivation))(NN (mouse))(NN (increase))(NN (sensitivity))(NN (colon))(NN (carcinogenesis)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 42:G05.355.315.203.374 46:A03.556.124.526.356 224:D03.438.733.631.400 947:G03.495.166  |ES| 9:1 19:1 40:1 52:1 113:1 207:1 607:1 1314:1 3318:1 3488:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Liver))(NN (tumor))(NN (formation))(JJ (female))(NN (rat)))(VP (VBD (induced))(NP (NN (fluopyram))(JJ (mediated))(NN (CAR/PXR))(JJ (nuclear))(NN (receptor))(NN (activation))))) |ET|  |BS| 20:G03.495 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 642:M01.975  |ES| 7:1 19:1 43:1 186:1 225:1 412:1 437:1 849:1 1256:1 1404:1 2721:1 4285:1 4286:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NNS (METHODS))(: (:)))(NP (NP (JJ (UVB-induced))(NN (skin))(NN (carcinogenesis))(NN (model))(NN (SKH-1))(NN (mouse)))(VP (VBN (used))(S (VP (VBG (determining))(NP (JJ (preventive))(NN (effect))(NN (magnolol))(NN (skin))(NN (cancer))(NN (development)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 168:E05.581 785:A17.815  |ES| 18:1 19:1 35:1 52:1 72:1 75:1 104:1 207:1 476:1 565:1 1883:1 2319:1 2526:1 2750:1 2751:1 2752:1  |EV| 
4.520134953427480617449418787146  |BT| (S (S (NP (NNP (Lycopene)))(VP (VBZ (modulates))(SBAR (S (NP (NN (initiation))(NN (N-nitrosodiethylamine)))(VP (VBD (induced))(NP (NN (hepatocarcinogenesis))))))))(: (:))(S (NP (NP (NN (study))(JJ (chromosomal))(NN (abnormality)))(, (,))(NP (NN (membrane))(NN (fluidity))(JJ (antioxidant))(NN (defense))(NN (system)))))) |ET|  |BS| 554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260  |ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1  |EV| 
4.520134953427480617449418787146  |BT| (S (ADVP (RB (Conversely)))(, (,))(NP (NP (JJ (partial))(NN (loss))(NN (A20)))(, (,))(NP (NN (A20))(NN (heterozygote))(NN (mouse)))(, (,)))(ADVP (RB (significantly)))(VP (VBZ (impairs))(NP (NP (NN (liver))(NN (regeneration))(NN (damage)))(, (,))(NP (VP (VBZ (confers))(NP (JJ (high))(NN (lethality)))(S (VP (ADVP (RB (otherwise)))(NP (JJ (safe))(NN (procedure))))))(NP (FW (i.e.))(, (,))(CD (2/3))(JJ (partial))(NN (hepatectomy))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 375:Z01.639.100 925:G10.261.326.520 928:E04.210.556 967:D01.248.497.158.490  |ES| 2:1 19:1 32:1 52:1 124:1 178:1 836:1 1508:1 1826:1 1848:1 2729:1 2737:1 3260:1 3272:1 3273:1 3404:1 3405:1 3406:1 3407:1 3408:1 3409:1 3410:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (NP (NN (CONCLUSION)))(: (:))(S (NP (DT (This))(NN (study)))(VP (VBZ (provides))(SBAR (S (NP (NN (evidence))(NN (saffron)))(VP (VBZ (exerts))(NP (JJ (significant))(JJ (chemopreventive))(NN (effect))(NN (liver))(NN (cancer))(NN (inhibition))(NN (cell))(NN (proliferation))(NN (induction))(NN (apoptosis))))))))) |ET|  |BS| 39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 624:D27.505.696.706.018 701:B01.650.940.800.575.100.549.500  |ES| 18:1 19:1 38:1 75:1 89:1 94:1 103:1 104:1 131:1 135:1 299:1 736:1 807:1 815:1 836:1 1882:1 1946:1 1977:1 2523:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NP (NP (NN (PPARgamma)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(: (-))))(-RRB- (-RRB-))(NN (mouse))(JJ (susceptible))(JJ (DMH-induced))(NN (colon))(NN (carcinogenesis))(NN (PPARgamma)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-))))(NP (NN (mouse))))(, (,))(S (NP (NN (embelin)))(ADVP (RB (significantly)))(VP (VBD (reduced))(NP (NP (NP (NN (incidence))(NN (colon))(NN (cancer))(NN (PPARgamma)))(PRN (-LRB- (-LRB-))(NP (NP (CC (+))(: (/))(CC (+))(-RRB- (-RRB-))(NN (mouse))(NN (PPARgamma)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(: (-))))(-RRB- (-RRB-))))(NN (mouse)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 434:E05.318.308.985.525.375 719:D12.776.826.239.588  |ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 124:1 207:1 452:1 899:1 1511:1 2588:1 2888:1 2889:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (HTHQ)))(ADVP (RB (also)))(VP (VBD (inhibited))(NP (NP (NP (JJ (2-amino-1-methyl-6-phenylimidazo))(-LRB- (-LSB-))(JJ (4,5-b))(-RRB- (-RSB-))(NN (pyridine)))(PRN (-LRB- (-LRB-))(NP (NN (PhIP)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (colon))(NN (carcinogenesis))(CD (two))(NN (stage))(NN (colon))(NN (carcinogenesis))(NN (model)))(S (VP (VBG (using))(NP (NP (NP (NN (1,2-dimethylhydrazine)))(PRN (-LRB- (-LRB-))(NP (NN (DMH)))(-RRB- (-RRB-))))(NN (initiator)))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725  |ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Overexpression))(NN (glutamine))(NN (synthetase)))(VP (VBN (associated))(NP (NNS (beta-catenin-mutations))(NN (mouse))(NN (liver))(NN (tumor))(NN (promotion))(NN (hepatocarcinogenesis))(NN (phenobarbital))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 515:C04.588.274.623 756:D03.383.742.698.253.650 1057:D08.811.464.259.200.600  |ES| 7:1 19:1 52:1 169:1 668:1 836:1 900:1 2337:1 2685:1 3691:1 3692:1 3693:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NNP (Hepatitis))(NN (B))(NN (virus))(-LRB- (-LRB-))(NN (HBV))(-RRB- (-RRB-))(: (-)))(NP (VBN (induced))(NN (hepatitis))(NP (NP (JJ (carcinogen-induced))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NP (JJ (associated))(NN (serum))(NN (androgen))(NN (concentration))))) |ET|  |BS| 104:C04.557.470.200.025.255 279:D27.888.569.100 782:A12.207.152.846 863:B04.280.375.650.425 892:D27.505.696.399.472.161 905:F02.830.104.214  |ES| 10:1 14:1 19:1 169:1 303:1 304:1 409:1 441:1 763:1 1422:1 1954:1 2048:1 2421:1 2741:1 3154:1 3188:1 3189:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Anticancer))(NN (effect))(NN (wogonin))(NN (estrogen))(JJ (receptor-positive)))(: (-))(NP (JJ (negative))(JJ (human))(NN (breast))(NN (cancer))(NN (cell))(NN (line))(NN (vitro))(JJ (nude))(NN (mouse))(NN (xenograft))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 936:D12.776.826.750.350  |ES| 18:1 19:1 23:1 36:1 52:1 75:1 94:1 216:1 264:1 265:1 266:1 2444:1 2446:1 3168:1 3285:1 3286:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Apoptosis))(JJ (signal-regulating))(NN (kinase))(CD (1)))(VP (VBZ (inhibits))(NP (NP (NN (hepatocarcinogenesis)))(VP (VBG (controlling))(NP (JJ (tumor-suppressing))(NN (function))(JJ (stress-activated))(JJ (mitogen-activated))(NN (protein))(NN (kinase))))))) |ET|  |BS| 8:C04 122:C14.280.383 478:D08.811.913.696.620.682.700.567 938:D08.811.913.696.620.682.700.559.500  |ES| 4:1 19:1 33:1 98:1 470:1 615:1 900:1 2220:1 3291:1 3292:1 3293:1 3294:1 3295:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Essential))(NN (contribution))(NN (chemokine)))(, (,))(NP (NN (CCL3)))(, (,))(NP (NN (receptor)))(, (,))(NP (NN (CCR1)))(, (,))(NP (JJ (hepatocellular))(NN (carcinoma))(NN (progression)))) |ET|  |BS| 16:C23.550.291.656 104:C04.557.470.200.025.255 313:D12.644.276.374.200  |ES| 2:1 19:1 48:1 186:1 303:1 304:1 1360:1 3476:1 3477:1 3478:1 3479:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (JJ (human))(JJ (colorectal))(NN (cancer))))(, (,))(NP (JJ (arachidonic))(NN (acid))(NN (eicosanoid))(NN (level)))(VP (VBD (elevated)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 1014:D10.251.355.255.100.100 1016:D10.251.355.255  |ES| 2:1 17:1 18:1 19:1 36:1 244:1 249:1 756:1 1275:1 3553:1 3558:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (PP (IN (In))(NP (NN (contrast))))(, (,))(NP (NP (CD (three))(CD (18))(NN (vinyl))(JJ (carbamate-induced))(NN (liver))(NN (tumor)))(, (,))(NP (CD (one))(CD (18))(JJ (TCDD-induced))(NN (liver))(NN (tumor)))(, (,))(NP (CD (two))(CD (22))(JJ (spontaneous))(NN (liver))(NN (neoplasm))(NN (mutation))(NN (beta-catenin))))) |ET|  |BS| 18:G05.365.590 23:D12.776.091.249 491:D27.505.259.500 515:C04.588.274.623 1096:D03.383.231.900  |ES| 2:1 7:1 19:1 34:1 60:1 244:1 283:1 482:1 836:1 933:1 1010:1 1193:1 1392:1 1523:1 3714:1 4221:1 4222:1 4223:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Inhibition))(NN (STAT3))(NN (signaling))(NN (pathway))(NN (nitidine))(NN (chloride)))(VP (VBD (suppressed))(NP (NN (angiogenesis))(NN (growth))(JJ (human))(JJ (gastric))(NN (cancer))))) |ET|  |BS| 43:F01.145.544 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 82:D12.644.360.024.342.300 126:G02.111.087.800  |ES| 18:1 19:1 36:1 86:1 102:1 195:1 251:1 307:1 383:1 2502:1 2703:1 2788:1 3594:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Inflexinol)))(VP (VBZ (inhibits))(NP (NN (colon))(NN (cancer))(NN (cell))(NN (growth))(NN (inhibition))(JJ (nuclear))(NN (factor-kappaB))(NN (activity)))(PP (IN (via))(NP (JJ (direct))(NN (interaction))(NN (p50)))))) |ET|  |BS| 41:A11 43:F01.145.544 45:G07.700.320.249 122:C14.280.383 210:D12.776.260.600  |ES| 18:1 19:1 94:1 102:1 103:1 113:1 399:1 596:1 615:1 618:1 1256:1 1891:1 2377:1 2701:1 2702:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Chlorophyllin)))(VP (VP (VBN (shown))(ADVP (RB (significantly)))(VP (VB (reduce))(S (NP (JJ (genotoxic))(NN (AFB))(NNS (biomarkers)))(ADJP (JJ (human))))))(, (,))(ADVP (RB (therefore)))(VP (VBP (hold))(NP (NP (NN (promise))(JJ (practical))(NN (mean)))(VP (VBG (reducing))(NP (NN (incidence))(JJ (AFB-induced))(NN (liver))(NN (cancer)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 158:D23.101 434:E05.318.308.985.525.375  |ES| 2:1 18:1 19:1 36:1 124:1 218:1 237:1 836:1 1269:1 1511:1 2215:1 2361:1 2825:1 2827:1 3039:1 3328:1 3329:1 3330:1 3331:1 3332:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Garlic))(NN (oil)))(VP (VBD (attenuated))(NP (NP (JJ (nitrosodiethylamine-induced))(NN (hepatocarcinogenesis)))(VP (VBG (modulating))(NP (JJ (metabolic))(NN (activation))(NN (detoxification))(NN (enzyme))))))) |ET|  |BS| 554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811  |ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Ethanol))(NN (consumption))(NN (cause))(JJ (serious))(NN (liver))(NN (injury)))(PP (VBG (including))(NP (NN (cirrhosis))(JJ (hepatocellular))(NN (carcinoma)))))) |ET|  |BS| 73:N05.715.350.200 104:C04.557.470.200.025.255 242:A03.620 357:C06.552.630 662:C23.550.355 904:F01.145.317.269  |ES| 19:1 303:1 304:1 561:1 836:1 1199:1 1779:1 2387:1 2416:1 3178:1 3179:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (PRP$ (Our))(VP (VBP (result))(NP (NN (show))(NN (enzastaurin))(JJ (effective))(JJ (chemopreventive))(NN (agent))(NN (mouse))(NN (model))(JJ (sporadic))(NN (colon))(NN (cancer)))(SBAR (S (ADVP (RB (significantly)))(VP (VBZ (reduces))(NP (NP (NN (tumor))(NN (initiation))(NN (progression)))(VP (VBG (inhibiting))(NP (NN (expression))(JJ (proproliferative))(NN (gene))))))))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 16:C23.550.291.656 122:C14.280.383 155:G05.355.310  |ES| 7:1 9:1 18:1 19:1 48:1 52:1 72:1 101:1 113:1 115:1 124:1 142:1 429:1 637:1 658:1 725:1 728:1 880:1 1639:1 1946:1 2855:1 2856:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NN (Overexpression))(NN (cyclooxygenase))(CD (2)))(PRN (-LRB- (-LRB-))(NP (NN (COX2)))(-RRB- (-RRB-))))(NP (NP (JJ (uncontrolled))(JJ (wingless))(NN (Int))(-LRB- (-LRB-))(NN (Wnt))(-RRB- (-RRB-))(: (-)))(NN (signaling))(NN (pathway)))(ADVP (RB (long)))(VP (VBD (suggested))(NP (NP (NN (play))(JJ (crucial))(NN (role)))(NP (JJ (colorectal))(NN (cancer)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 24:D08.811.600.720.750 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 147:G02.149.115.800.925  |ES| 10:1 14:1 17:1 18:1 19:1 31:1 148:1 238:1 383:1 668:1 877:1 925:1 2325:1 3180:1 3685:1 3686:1 3687:1 3688:1 3689:1 3690:1  |EV| 
-4.520134953427480617449418787146  |BT| (FRAG (NP (NNS (CONCLUSIONS))(: (:)))(PP (DT (These))(S (VP (VBG (finding))(S (VP (VBP (suggest))(NP (NP (NN (MPT0E028))(NN (combination))(NN (sorafenib))(JJ (significant))(JJ (anti-hepatocellular))(NN (carcinoma))(NN (activity))(JJ (preclinical))(NN (model)))(, (,))(S (ADVP (RB (potentially)))(VP (VBG (suggesting))(SBAR (S (NP (JJ (novel))(JJ (therapeutic))(NN (strategy))(NN (patient)))(VP (VBD (advanced))(NP (JJ (hepatocellular))(NN (carcinoma))))))))))))))) |ET|  |BS| 50:M01.643 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500  |ES| 2:1 19:1 72:1 104:1 120:1 135:1 239:1 303:1 304:1 399:1 530:1 541:1 773:1 792:1 796:1 891:1 927:1 997:1 1009:1 1114:1 1494:1 2063:1 2539:1 2540:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NN (Protein))(NN (kinase))(NN (CbetaII)))(PRN (-LRB- (-LRB-))(NP (NN (PKCbetaII)))(-RRB- (-RRB-))))(VP (VP (VBP (play))(NP (JJ (requisite))(NN (role))(NN (initiation))(NN (colon)))(NP (NP (NN (carcinogenesis))(JJ (preclinical))(NN (mouse))(NN (model)))(VP (VBG (promoting))(NP (NN (proliferation))))))(VP (VBD (increased))(NP (NN (beta-catenin))(NN (accumulation)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 866:D08.811.913.696.620.682.700.725.049 1063:D08.811.913.696.620.682  |ES| 10:1 14:1 19:1 31:1 47:1 52:1 60:1 72:1 113:1 207:1 238:1 299:1 470:1 637:1 881:1 1494:1 2120:1 2911:1 3077:1 3722:1 3723:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NN (Dextran))(NN (sodium))(NN (sulfate)))(PRN (-LRB- (-LRB-))(NP (NN (DSS)))(-RRB- (-RRB-))))(VP (VBN (given))(S (VP (VBP (induce))(NP (NP (NP (NN (colitis))(NN (C57/BL6)))(PRN (-LRB- (-LRB-))(NP (NN (control)))(-RRB- (-RRB-))))(NN (mouse)))))(, (,))(NP (ADVP (RB (well)))(NP (NP (NN (mouse))(NN (disruption))(NN (hydroxyprostaglandin))(NN (dehydrogenase))(CD (15))(NN (gene)))(PRN (-LRB- (-LRB-))(NP (JJ (15-PGDH-knockout))(NN (mouse)))(-RRB- (-RRB-))))(, (,))(NP (NP (NN (Yap1))(NN (gene)))(PRN (-LRB- (-LRB-))(NP (JJ (YAP-knockout))(NN (mouse)))(-RRB- (-RRB-))))(, (,))(NP (JJ (double-knockout))(NN (mouse)))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 53:C06.405.205.265 131:D09.698.365.272.300  |ES| 2:1 9:1 10:1 14:1 19:1 29:1 52:1 143:1 243:1 289:1 406:1 407:1 787:1 1602:1 3085:1 3306:1 4143:1 4144:1 4145:1 4146:1 4147:1 4148:1 4149:1 4150:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (HTHQ)))(ADVP (RB (also)))(VP (VBD (inhibited))(NP (NP (NP (JJ (2-amino-1-methyl-6-phenylimidazo))(-LRB- (-LSB-))(JJ (4,5-b))(-RRB- (-RSB-))(NN (pyridine)))(PRN (-LRB- (-LRB-))(NP (NN (PhIP)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (colon))(NN (carcinogenesis))(CD (two))(NN (stage))(NN (colon))(NN (carcinogenesis))(NN (model)))(S (VP (VBG (using))(NP (NP (NP (NN (1,2-dimethylhydrazine)))(PRN (-LRB- (-LRB-))(NP (NN (DMH)))(-RRB- (-RRB-))))(NN (initiator)))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725  |ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1  |EV| 
4.520134953427480617449418787146  |BT| (FRAG (ADVP (RB (Overall)))(, (,))(NP (NP (JJ (2-SeCD))(NNS (sensitises))(JJ (resistant))(NN (breast))(NN (cancer))(NN (cell))(JJ (TRAIL-based))(NN (apoptosis)))(ADVP (FW (vitro))(FW (vivo))))) |ET|  |BS| 39:G04.299.139.160 41:A11 333:D01.045 696:V02.270.500  |ES| 2:1 18:1 19:1 23:1 89:1 94:1 216:1 378:1 427:1 2858:1 3681:1 3682:1 3683:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Garlic))(NN (oil)))(VP (VBD (attenuated))(NP (NP (JJ (nitrosodiethylamine-induced))(NN (hepatocarcinogenesis)))(VP (VBG (modulating))(NP (JJ (metabolic))(NN (activation))(NN (detoxification))(NN (enzyme))))))) |ET|  |BS| 554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811  |ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Oncogenic))(NN (tumor))(JJ (suppressive))(NN (role)))(NP (JJ (polo-like))(NN (kinase))(JJ (human))(JJ (hepatocellular))(NN (carcinoma)))) |ET|  |BS| 8:C04 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 279:D27.888.569.100  |ES| 7:1 19:1 31:1 36:1 303:1 304:1 470:1 1974:1 2143:1 3667:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (BTG3))(NN (tumor))(NN (suppressor))(NN (gene))(NN (promoter))(NN (demethylation)))(, (,))(NP (NN (histone))(NN (modification))(NN (cell))(NN (cycle))(NN (arrest)))(NP (NN (genistein))(JJ (renal))(NN (cancer))))) |ET|  |BS| 206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375  |ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (VP (VBG (Combining))(NP (NN (kallistatin))(NN (gene))(NN (therapy))(NN (meloxicam))(NN (treat))(JJ (hepatocellular))(NN (carcinoma))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255  |ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (ADVP (RB (Moreover)))(, (,))(NP (NN (mechanism))(NNS (fibrates)))(VP (VBP (induce))(NP (NN (hepatocyte))(NN (proliferation))(NN (cholestasis)))(ADVP (RB (still)))(VP (ADVP (RB (fully)))(VBN (understood))))) |ET|  |BS| 239:F02.463.188.357 262:A11.436.348 879:C06.130.120.135 1188:D02.241.081.114.968.500  |ES| 2:1 19:1 162:1 243:1 299:1 622:1 776:1 889:1 979:1 1909:1 4130:1 4131:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNS (CONCLUSIONS)))(: (:))(NP (DT (This))(NN (study)))(VP (VBD (showed))(SBAR (S (NP (NN (5-LOX)))(VP (VBD (up-regulated))(NP (NP (JJ (adenomatous))(NN (colon))(NN (polyp))(NN (cancer)))(NP (VBN (compared))(JJ (normal))(JJ (colonic))(NN (mucosa))))))))) |ET|  |BS| 46:A03.556.124.526.356 142:I01.880.604 150:Z01.542.248.960 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215  |ES| 18:1 19:1 50:1 57:1 104:1 113:1 118:1 131:1 132:1 239:1 579:1 647:1 677:1 807:1 1301:1 3390:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NN (study)))(VP (VBZ (demonstrates))(NP (NP (NN (inhibition))(NN (cell))(NN (proliferation))(NN (regulation)))(SBAR (S (NP (JJ (inflammatory))(NN (marker)))(VP (MD (may))(, (,))(ADVP (JJS (least))(NN (part)))(, (,))(S (VP (VBG (underlying))(NP (NN (mechanism))(JJ (related))(NN (liver))(NN (tumor))(NN (inhibition))(NN (diosmin))))))))))) |ET|  |BS| 41:A11 43:F01.145.544 85:G02.111.087.225 158:D23.101 183:G04.299.233.750 515:C04.588.274.623 715:D03.383.663.283.266.450.260.222  |ES| 2:1 7:1 19:1 94:1 103:1 131:1 162:1 299:1 419:1 435:1 438:1 451:1 491:1 534:1 658:1 836:1 1331:1 2430:1 2541:1 2695:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (DNA))(NN (methylation))(NN (alteration)))(VP (VBD (detected))(SBAR (S (NP (NN (zebrafish))(NN (liver))(NN (tumor)))(VP (VBD (induced))(NP (NP (JJ (environmental))(NN (carcinogen))(CD (7)))(, (,))(NP (JJ (12-dimethylbenz))(-LRB- (-LRB-))(-RRB- (-RRB-))(NN (anthracene))))))))) |ET|  |BS| 366:G02.111.087.029.538.161 515:C04.588.274.623 572:B01.050.150.900.493.200.244.828 977:D27.888.569.100.125  |ES| 2:1 7:1 10:1 14:1 19:1 81:1 412:1 666:1 836:1 951:1 988:1 1007:1 2017:1 2125:1 3446:1 3447:1 3448:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (S (NP (NNP (Lycopene)))(VP (VBZ (modulates))(SBAR (S (NP (NN (initiation))(NN (N-nitrosodiethylamine)))(VP (VBD (induced))(NP (NN (hepatocarcinogenesis))))))))(: (:))(S (NP (NP (NN (study))(JJ (chromosomal))(NN (abnormality)))(, (,))(NP (NN (membrane))(NN (fluidity))(JJ (antioxidant))(NN (defense))(NN (system)))))) |ET|  |BS| 554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260  |ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Inhibition))(JJ (retinoic))(NN (acid))(NN (hepatocarcinogenesis)))(VP (VBD (induced))(NP (NN (N-nitrosomorpholine))(NN (expression))(NN (myc))(NN (oncogene))(NN (protein))(JJ (Sprague-Dawley))(NN (rat))))) |ET|  |BS| 43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500  |ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1  |EV| 
4.520134953427480617449418787146  |BT| (S (VP (PRP$ (Our))(S (VP (VBP (result))(VP (VBP (demonstrate))(S (NP (JJ (potential))(JJ (therapeutic))(NN (role))(NN (panobinostat)))(VP (VBG (targeting))(NP (JJ (aggressive))(JJ (triple-negative))(NN (breast))(NN (cancer))(NN (cell))(NN (type)))))))))) |ET|  |BS| 15:F01.829.316.616 41:A11 52:E02 160:C04.588.180.788 162:F01.145.126.125  |ES| 18:1 19:1 23:1 26:1 31:1 94:1 101:1 502:1 538:1 541:1 543:1 616:1 658:1 827:1 3348:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (PRP$ (Our))(VP (VBP (result))(NP (NP (NN (show))(NNS (HCCs)))(VP (VBG (developing))(FRAG (X (SYM (AOX)))(: (-))(NP (NP (: (/))(: (-))(NN (mouse))(NN (share))(NN (number)))(VP (VBN (deregulated))(FRAG (-LRB- (-LRB-))(NP (RP (up))(: (-))(VBN (down-regulated))(-RRB- (-RRB-))(NN (gene))(JJ (ciprofibrate-induced))(NN (liver))(NN (tumor))))))))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 142:I01.880.604 351:A17.360 515:C04.588.274.623  |ES| 7:1 9:1 10:1 14:1 19:1 52:1 101:1 429:1 590:1 646:1 658:1 836:1 1132:1 1283:1 1965:1 4321:1 4322:1 4323:1 4324:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Caveolin-1)))(VP (VBZ (enhances))(NP (JJ (resveratrol-mediated))(NN (cytotoxicity))(NN (transport))(JJ (hepatocellular))(NN (carcinoma))(NN (model))))) |ET|  |BS| 104:C04.557.470.200.025.255 945:D12.644.360.024.264 946:D27.888.569.213 947:G03.495.166  |ES| 19:1 72:1 303:1 304:1 1356:1 3315:1 3316:1 3317:1 3318:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NN (5-Fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NP (NP (CD (one))(JJ (common))(JJ (chemotherapeutic))(NN (agent)))(VP (VBN (used))(NP (NP (NN (treatment))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))) |ET|  |BS| 52:E02 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 660:D27.505.954.248  |ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 655:1 728:1 1010:1 1762:1 2308:1 2404:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NP (NN (Beta-catenin/T-cell))(NN (factor)))(PRN (-LRB- (-LRB-))(NP (NN (Tcf)))(-RRB- (-RRB-))))(NN (signaling)))(NP (RB (constitutively))(JJ (active))(NN (majority))(JJ (human))(JJ (colorectal))(NN (cancer)))(, (,))(VP (VBG (accompanying))(NP (NN (change))(NN (Bcl-2))(NN (expression))))) |ET|  |BS| 4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Embelin)))(VP (VBZ (inhibits))(NP (NP (NN (chemical))(JJ (carcinogen-induced))(NN (colon))(NN (carcinogenesis)))(, (,))(NP (NP (NN (effect)))(ADJP (RB (partially))(JJ (dependent)))(NN (presence))(JJ (functional))(NN (PPARgamma)))(, (,))(NP (NP (VBG (indicating))(NN (PPARgamma))(JJ (necessary))(NN (signaling))(NN (pathway)))(VBN (involved))(NN (antitumor))(NN (activity))(JJ (normal))(NN (organism)))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 279:D27.888.569.100 719:D12.776.826.239.588  |ES| 2:1 19:1 75:1 113:1 118:1 195:1 207:1 321:1 346:1 383:1 399:1 415:1 615:1 774:1 1351:1 2124:1 2236:1 2244:1 2421:1 2587:1 2588:1 2589:1 2590:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Forkhead))(NN (box))(NN (transcription))(NN (factor))(NN (FOXO3a)))(VP (VBZ (suppresses))(NP (JJ (estrogen-dependent))(NN (breast))(NN (cancer))(NN (cell))(NN (proliferation))(NN (tumorigenesis))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 166:D12.776.930 183:G04.299.233.750 889:D27.505.696.399.472.277  |ES| 18:1 19:1 23:1 78:1 94:1 185:1 299:1 487:1 686:1 1918:1 3361:1 3363:1 3494:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NNS (data))(NN (pterostilbene)))(VP (VBG (suppressing))(NP (NP (NN (colon))(NN (tumorigenesis)))(, (,))(NP (NN (cell))(NN (proliferation)))(NP (ADJP (RB (well))(JJ (key)))(JJ (inflammatory))(NN (marker))))(ADVP (FW (vivo))(FW (vitro)))(VP (VBP (suggest))(NP (JJ (potential))(NN (use))(NN (pterostilbene))(NN (colon))(NN (cancer))(NN (prevention)))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 158:D23.101 183:G04.299.233.750  |ES| 2:1 18:1 19:1 78:1 94:1 113:1 159:1 216:1 299:1 378:1 534:1 658:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NP (JJ (Aldo-keto))(NN (reductase))(NN (family))(CD (1))(NN (B10)))(PRN (-LRB- (-LRB-))(NP (NN (AKR1B10)))(-RRB- (-RRB-))))(, (,))(NP (NN (member))(JJ (aldo-keto))(NN (reductase))(NN (superfamily)))(, (,)))(VP (VP (VBN (overexpressed))(NP (JJ (human))(JJ (hepatocellular))(NN (carcinoma))))(, (,))(NP (NN (lung))(JJ (squamous))(NN (cell))(NN (carcinoma))(NN (lung))(NN (adenocarcinoma))))) |ET|  |BS| 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 182:A04.411 929:C04.557.470.200.400  |ES| 2:1 10:1 14:1 19:1 25:1 36:1 94:1 95:1 96:1 97:1 98:1 99:1 255:1 303:1 304:1 328:1 769:1 1067:1 3275:1 3276:1 3277:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Inhibition))(JJ (retinoic))(NN (acid))(NN (hepatocarcinogenesis)))(VP (VBD (induced))(NP (NN (N-nitrosomorpholine))(NN (expression))(NN (myc))(NN (oncogene))(NN (protein))(JJ (Sprague-Dawley))(NN (rat))))) |ET|  |BS| 43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500  |ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Cyclooxygenase))(CD (2))(NN (play))(JJ (critical))(NN (role))(NN (development))(JJ (gastrointestinal))(NN (cancer)))(NP (JJ (human))(NN (animal))(NN (model))))) |ET|  |BS| 15:F01.829.316.616 24:D08.811.600.720.750 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 285:E05.598  |ES| 18:1 19:1 31:1 35:1 36:1 46:1 72:1 148:1 183:1 238:1 825:1 3432:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Glycyrrhizic))(NN (Acid)))(NP (VBN (used))(NN (treat))(JJ (chronic))(NN (hepatitis))))(, (,))(S (VP (VBG (inhibiting))(NP (NN (penetration))(NN (hepatitis))(NN (A))(NN (virus))(NNS (hepatocytes)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 122:C14.280.383 262:A11.436.348 734:D02.455.849.919.530.466 735:B04.450.420.410 736:C06.552.380.350  |ES| 2:1 19:1 69:1 476:1 880:1 894:1 1090:1 1422:1 1790:1 2048:1 2625:1 2626:1 2627:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Cyclooxygenase-2))(NN (inhibitor)))(VP (VBP (down-regulate))(NP (NN (osteopontin))(NN (Nr4A2-new))(JJ (therapeutic))(NN (target))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360  |ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Antagonistic))(NN (effect))(NN (selenium))(NN (lipid))(NN (peroxide)))(NN (growth))(NN (control))(JJ (early))(JJ (hepatocellular))(NN (carcinoma)))) |ET|  |BS| 45:G07.700.320.249 104:C04.557.470.200.025.255 934:D01.248.497.158.685.750.637 935:D01.268.185.850  |ES| 19:1 75:1 102:1 289:1 303:1 304:1 1128:1 2401:1 3196:1 3283:1 3284:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (JJ (Conditional))(NN (beta-catenin))(NN (loss))(NN (mouse)))(VP (VBZ (promotes))(NP (NP (NN (chemical))(NN (hepatocarcinogenesis)))(: (:))(NP (NN (role))(NP (ADJP (JJ (oxidative))(NN (stress))(JJ (platelet-derived)))(NN (growth))(NN (factor))(NN (receptor))(NN (alpha/phosphoinositide))(NN (3-kinase)))(NN (signaling)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 69:G02.111.087.800 578:D08.811.913.696.620.550 716:G03.495.710 965:D08.811.913.696.620.682.725.400.900  |ES| 19:1 31:1 32:1 52:1 60:1 102:1 104:1 185:1 186:1 195:1 298:1 900:1 2124:1 2522:1 2583:1 3391:1 3392:1 3393:1 3394:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (Evolution))(JJ (genomic))(NN (instability))(JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 1191:C23.550.362 1192:G05.355.044  |ES| 19:1 52:1 900:1 910:1 1299:1 2732:1 4158:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Expression))(NP (JJ (ets-related))(JJ (transcriptional))(NN (factor)))(NN (E1AF))(VBN (associated))(NN (tumor))(NN (progression))(NN (over-expression))(NN (matrilysin)))(NP (JJ (human))(JJ (gastric))(NN (cancer))))) |ET|  |BS| 8:C04 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 166:D12.776.930 937:D08.811.277.656.300.480.525.700.250  |ES| 7:1 18:1 19:1 36:1 48:1 86:1 169:1 185:1 316:1 559:1 1013:1 3289:1 3483:1 3484:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Bortezomib)))(VP (VBZ (induces))(SBAR (S (NP (NP (JJ (tumor-specific))(NN (cell))(NN (death)))(NN (growth))(NN (inhibition))(JJ (hepatocellular))(NN (carcinoma)))(VP (VBZ (improves))(NP (NN (liver))(NN (fibrosis)))))))) |ET|  |BS| 8:C04 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 134:G04.299.139 675:D01.029.260.110.500 676:C06.552.630  |ES| 19:1 94:1 102:1 103:1 214:1 303:1 304:1 411:1 836:1 949:1 2460:1 2463:1 2464:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Correlation))(NN (Wnt-2))(NN (expression))(NN (beta-catenin))(JJ (intracellular))(NN (accumulation))(JJ (Chinese))(JJ (gastric))(NN (cancer)))(: (:))(NP (NN (relevance))(NN (tumour))(NN (dissemination)))) |ET|  |BS| 8:C04 23:D12.776.091.249 924:A11.284.430.214  |ES| 18:1 19:1 60:1 86:1 104:1 115:1 795:1 1011:1 2120:1 2763:1 3252:1 3324:1 3413:1 3414:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (NNS (Mice)))(VP (VBG (developing))(NP (NP (JJ (diethylnitrosamine-induced))(JJ (hepatocellular))(NN (carcinoma)))(VP (VBN (subjected))(NP (JJ (hydrodynamic))(NN (gene))(NN (delivery)))))))(VP (VBP (overexpress))(NP (NN (Gas1))(NN (liver))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 242:A03.620 554:D02.654.442.200 1229:E04.520.252 1230:G01.342  |ES| 9:1 19:1 303:1 304:1 583:1 590:1 836:1 2513:1 2732:1 3267:1 4311:1 4312:1 4313:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NN (5-Fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NP (NP (CD (one))(ADJP (RB (commonly))(VBN (used)))(JJ (chemotherapeutic))(NN (agent))(NN (colon))(NN (cancer))(NN (treatment)))(, (,))(NP (JJ (narrow))(JJ (therapeutic))(NN (index))(JJ (limited))(NN (toxicity)))))) |ET|  |BS| 46:A03.556.124.526.356 52:E02 560:D03.383.742.698.875.404 660:D27.505.954.248  |ES| 2:1 10:1 14:1 15:1 18:1 19:1 113:1 476:1 541:1 546:1 721:1 728:1 1010:1 1762:1 2131:1 2308:1 2404:1 2405:1 2406:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Loss))(NN (caspase-8)))(VP (VBZ (protects))(SBAR (S (NP (NN (mouse))(JJ (inflammation-related))(NN (hepatocarcinogenesis)))(VP (VBZ (induces))(NP (JJ (non-apoptotic))(NN (liver))(NN (injury)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 242:A03.620 525:C23.550.470 1034:D08.811.277.656.262.500.126.550.800  |ES| 19:1 52:1 214:1 836:1 900:1 1788:1 1863:1 2416:1 3612:1 3613:1 3614:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Chronic))(NN (ethanol))(NN (feeding)))(VP (VBZ (accelerates))(NP (JJ (hepatocellular))(NN (carcinoma))(NN (progression))(JJ (sex-dependent))(NN (manner)))(NP (NN (mouse))(NN (model))(NN (hepatocarcinogenesis))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 751:D02.033.375 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810  |ES| 19:1 48:1 52:1 72:1 303:1 304:1 529:1 900:1 1668:1 2942:1 3440:1 3967:1 4105:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (study))))(, (,))(NP (NP (VBN (investigated))(NN (role))(NN (progastrin)))(VP (VBG (regulating))(NP (NNP (CSC))(NN (phenotype)))))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 80:G05.695 556:C11.768.175  |ES| 2:1 17:1 18:1 19:1 31:1 131:1 236:1 244:1 403:1 671:1 997:1 2869:1 3577:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBD (sought))(VP (VB (examine))(SBAR (S (NP (NN (effectiveness))(NN (honokiol))(VBG (inhibiting))(NP (NN (migration))(NN (invasion))(NN (breast))(NN (cancer))(NN (cell))))(VP (VBP (elucidate))(S (VP (VBG (underlying))(NP (JJ (molecular))(NN (mechanism))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 122:C14.280.383  |ES| 2:1 18:1 19:1 23:1 94:1 131:1 161:1 162:1 219:1 244:1 435:1 514:1 620:1 880:1 960:1 1307:1 1697:1 3573:1 3574:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (S (NP (NP (NN (Ethanol)))(VBD (diminished))(JJ (hepatic))(NN (function)))(VP (VBD (increased))(NP (NN (liver))(NN (damage)))))(, (,))(S (NP (NP (NN (ethanol)))(ADVP (RB (alone))))(VP (VBP (induce))(NP (JJ (hepatic))(NN (foci/HCC))(NN (formation)))))) |ET|  |BS| 20:G03.495 104:C04.557.470.200.025.255 242:A03.620 751:D02.033.375  |ES| 2:1 19:1 33:1 43:1 47:1 241:1 243:1 836:1 838:1 1848:1 3178:1 3440:1 4156:1 4157:1  |EV| 
4.520134953427480617449418787146  |BT| (S (VP (VBN (Dysregulated))(SBAR (S (NP (JJ (Kruppel-like))(NN (factor))(CD (4))(NN (vitamin))(NN (D))(NN (receptor))(NN (signaling)))(VP (VBP (contribute))(NP (NN (progression))(JJ (hepatocellular))(NN (carcinoma)))))))) |ET|  |BS| 16:C23.550.291.656 69:G02.111.087.800 104:C04.557.470.200.025.255 982:D12.776.826.535  |ES| 19:1 48:1 185:1 186:1 195:1 303:1 304:1 318:1 319:1 450:1 2591:1 2592:1 3460:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NP (JJ (Pre-operative))(NN (5-fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(: (-))(NP (VBN (based))(NN (chemoradiotherapy)))(ADVP (RB (locally)))(VP (VBD (advanced))(SBAR (S (NP (NP (JJ (rectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (UICC-II/III)))(-RRB- (-RRB-))))(VP (MD (may))(ADVP (RB (significantly)))(VP (VB (reduce))(NP (JJ (local))(NN (tumour))(NN (mass))))))))) |ET|  |BS| 8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404  |ES| 10:1 14:1 18:1 19:1 124:1 491:1 997:1 1011:1 1985:1 1986:1 1989:1 2307:1 2308:1 2361:1 2804:1 2894:1 2895:1 2896:1 2897:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (study))))(, (,))(VP (VBD (investigated))(SBAR (S (NP (NP (NP (JJ (chemopreventive))(NN (efficacy))(NN (PEITC))(NN (DBM))(NN (azoxymethane)))(PRN (-LRB- (-LRB-))(NP (NN (AOM)))(-RRB- (-RRB-))))(PRN (: (-))(VP (VBN (initiated))(NP (NP (NN (dextran))(NN (sodium))(NN (sulfate)))(PRN (-LRB- (-LRB-))(NP (NN (DSS)))(-RRB- (-RRB-)))))(: (-))))(VP (VBD (promoted))(SBAR (S (NP (NN (colon))(NN (cancer))(NN (mouse))(NN (model)))(VP (VBP (compare))(NP (NP (JJ (potential))(FW (vivo))(NN (mechanism)))(VP (VBG (leading))(NP (NN (chemoprevention))))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 86:D01.268.556.435 131:D09.698.365.272.300 132:D02.172.080 253:E02.319.162  |ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 113:1 131:1 162:1 244:1 378:1 403:1 406:1 407:1 639:1 827:1 870:1 1946:1 1993:1 1994:1 2304:1 3300:1 3306:1 4024:1 4029:1 4245:1 4246:1 4247:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Expression))(NN (protein))(NN (kinase))(NN (C)))(VP (NNS (isoenzymes))(NP (JJ (colorectal))(NN (cancer))(NN (tissue))(JJ (differential))(NN (activation))(JJ (different))(NN (bile))(NN (acid))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 98:A10 992:D08.811.913.696.620.682.700.725 993:D08.811.348 994:D04.808.105  |ES| 4:1 17:1 18:1 19:1 225:1 272:1 316:1 414:1 470:1 1275:1 1621:1 1677:1 1955:1 3486:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Protein))(NN (kinase))(NN (Cbeta)))(NP (JJ (effective))(NN (target))(NN (chemoprevention))(NN (colon))(NN (cancer))))) |ET|  |BS| 12:Z01.542.049 253:E02.319.162 867:D08.811.913.696.620.682.700.725.049  |ES| 18:1 19:1 113:1 160:1 470:1 870:1 1639:1 2911:1 3721:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NP (NNP (UNLABELLED))(: (:))(NN (Activation))(NN (beta-catenin)))(, (,))(NP (NP (JJ (central))(NN (effector))(JJ (canonical))(NN (Wnt))(NN (pathway)))(VP (VBD (recognized))(NP (NP (NN (oncogene)))(, (,))(NP (VBN (implicated))(JJ (hepatocellular))(NN (carcinoma)))))))) |ET|  |BS| 9:G05.360.340.024.340.375.500 23:D12.776.091.249 104:C04.557.470.200.025.255 105:G02.149.115.800.925  |ES| 2:1 19:1 24:1 60:1 87:1 104:1 303:1 304:1 383:1 570:1 877:1 977:1 2266:1 3235:1 3236:1 3237:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(S (NP (NP (JJ (Hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(ADVP (RB (rapidly)))(VP (VBG (increasing))(NP (NP (NN (cancer)))(WHNP (WHNP (WP$ (whose))(JJ (known))(NN (risk))(NN (factor)))(NP (JJ (chronic))(NN (ethanol))(NN (abuse))))(, (,))(NP (JJ (viral))(NN (hepatitis))(NN (infection)))(, (,))(NP (NN (aflatoxin))(NN (exposure))))))) |ET|  |BS| 104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 1137:D03.383.663.283.119 1138:C02.440.420 1139:C25.775.100.250 1140:C06.552.380 1141:C02  |ES| 2:1 10:1 14:1 18:1 19:1 104:1 171:1 185:1 304:1 441:1 556:1 715:1 919:1 1046:1 1790:1 1953:1 2048:1 2151:1 2214:1 2362:1 3424:1 3440:1 3969:1 3974:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (PURPOSE)))(: (:))(S (NP (JJ (Recent))(NN (study)))(VP (VBD (revealed))(S (NP (NP (JJ (branched-chain))(NN (amino))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (BCAA)))(-RRB- (-RRB-))))(VP (VB (reduce))(NP (NP (NP (NN (development))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NN (patient))(NN (obesity))(NN (hepatitis))(NN (C))(NN (virus))(NN (infection))(S (VP (VBG (improving))(NP (NP (NN (insulin))(NN (resistance)))(PRN (-LRB- (-LRB-))(NP (NN (IR)))(-RRB- (-RRB-)))))))))))) |ET|  |BS| 50:M01.643 104:C04.557.470.200.025.255 550:B04.450.410 564:C18.654.726.500 637:D06.472.699.587.200.500.625 638:C02.440.440 639:D12.125.070  |ES| 10:1 14:1 19:1 35:1 104:1 120:1 131:1 275:1 303:1 304:1 441:1 687:1 1094:1 1275:1 1422:1 1955:1 2010:1 2048:1 2189:1 2358:1 2359:1 2360:1 2361:1 2362:1 2363:1 2364:1 2365:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(NNS (data)))(ADVP (RB (thus)))(VP (VBP (establish))(SBAR (S (NP (NN (EPLE))(JJ (novel))(NN (inhibitor))(NN (Wnt))(NN (signaling)))(VP (VBP (hold))(NP (JJ (great))(NN (promise))(JJ (potential))(NN (candidate))(JJ (preclinical))(NN (evaluation))(NN (CRC))(NN (treatment)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 69:G02.111.087.800 225:E05.337 259:D12.776.395.240.150.500  |ES| 19:1 195:1 220:1 245:1 380:1 546:1 658:1 793:1 827:1 877:1 891:1 1243:1 1334:1 1494:1 2489:1 2503:1 2825:1 2826:1 2827:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NP (NN (Expression))(NN (analysis))(NN (group))(NN (IIA))(JJ (secretory))(NN (phospholipase))(NN (A)))(PRN (-LRB- (-LRB-))(NP (CD (2)))(-RRB- (-RRB-))))(NN (mouse))(JJ (differential))(NN (susceptibility))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 192:D08.811.277.352.100.680.750.937.750 401:C23.550.291.687 829:M01.686  |ES| 10:1 14:1 19:1 52:1 69:1 78:1 113:1 148:1 316:1 643:1 644:1 661:1 1353:1 1677:1 2222:1 2300:1 2533:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (ADVP (RB (Moreover)))(, (,))(NP (NP (NN (mouse))(NN (model))(JJ (azoxymethane-induced))(NN (colon))(NN (carcinogenesis)))(, (,))(S (NP (NN (rimonabant)))(ADVP (RB (significantly)))(VP (VBD (decreased))(NP (NP (NP (JJ (aberrant))(NN (crypt))(NN (focus)))(PRN (-LRB- (-LRB-))(NP (NN (ACF)))(-RRB- (-RRB-))))(NN (formation)))))(, (,)))(VP (VBZ (precedes))(NP (JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 20:G03.495 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 824:C04.834.020  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 72:1 113:1 124:1 202:1 207:1 622:1 1431:1 1725:1 2533:1 2831:1 2913:1 2914:1 4318:1  |EV| 
4.520134953427480617449418787146  |BT| (S (IN (Although))(, (,))(NP (NP (NN (NLK))(VBN (known))(NN (tumor))(NN (suppressor))(NN (Wnt/beta-catenin))(NN (signaling))(NN (pathway))(NN (colon))(NN (cancer)))(, (,))(NP (NN (event))(VBG (occurring))(NP (JJ (downstream))(NN (NLK))(NN (pathway))(NN (type))(NN (cancer)))))(VP (VBP (remain))(ADJP (JJ (unclear))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249  |ES| 2:1 7:1 18:1 19:1 107:1 113:1 195:1 205:1 302:1 383:1 443:1 543:1 556:1 560:1 700:1 1737:1 2181:1 3280:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (JJ (Aberrant))(NN (methylation))(NN (histone))(NN (deacetylation))(NN (cyclooxygenase))(CD (2))(JJ (gastric))(NN (cancer)))) |ET|  |BS| 24:D08.811.600.720.750 36:G02.111.087.029.538 399:D12.776.660.470  |ES| 18:1 19:1 80:1 81:1 86:1 148:1 503:1 3180:1 3256:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (S (NP (NP (NNS (Mice)))(VP (VBG (lacking))(NP (NP (NN (methionine))(NN (adenosyltransferase))(NN (1A)))(PRN (-LRB- (-LRB-))(NP (NN (MAT1A)))(-RRB- (-RRB-))))))(VP (VBD (reduced))(NP (NN (PHB1))(NN (expression)))))(, (,))(JJ (impaired))(JJ (mitochondrial))(NN (function)))(, (,))(VP (ADVP (RB (spontaneously)))(VB (develop))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650  |ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Natural))(NNS (polyphenols)))(VP (VBP (facilitate))(NP (NP (NN (elimination))(NN (HT-29))(JJ (colorectal))(NN (cancer))(NN (xenograft))(NN (chemoradiotherapy)))(: (:))(NP (NP (NN (Bcl-2)))(: (-))(NP (NN (superoxide))(NN (dismutase))(JJ (2-dependent))(NN (mechanism))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 56:D02.455.426.559.389.657.715 59:E02.186.079 92:E04.936.764 93:A01.941.875 792:A11.251.210.190.475  |ES| 17:1 18:1 19:1 104:1 146:1 147:1 154:1 156:1 162:1 265:1 1989:1 2780:1 2781:1 2782:1 2783:1 2784:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Altered))(NN (gene))(NN (expression))(NN (DNA))(NN (repair)))(: (-))(NP (NP (NN (cell))(JJ (proliferation-associated))(NNS (proteins/enzymes)))(VP (VBN (examined))(NP (NN (process))(JJ (tamoxifen-induced))(NN (hepatocarcinogenesis))(JJ (female))(JJ (Sprague-Dawley))(NN (rat))))))) |ET|  |BS| 155:G05.355.310 640:D02.455.426.559.389.150.700.900 642:M01.975 730:D08.811 769:B01.050.150.900.649.865.635.505.700.750 1134:G02.111.087.219 1135:D12.776.543  |ES| 9:1 19:1 94:1 115:1 324:1 638:1 666:1 849:1 900:1 971:1 1404:1 2707:1 3963:1 3964:1 3965:1 3966:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NP (NN (Cyclooxygenase-2)))(PRN (-LRB- (-LRB-))(NP (NN (COX-2)))(-RRB- (-RRB-))))(ADVP (RB (constitutively)))(VP (VBD (expressed))(NP (NP (NN (variety))(NN (tumor)))(PP (VBG (including))(NP (JJ (colorectal))(NN (cancer))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 24:D08.811.600.720.750  |ES| 6:1 7:1 10:1 14:1 17:1 18:1 19:1 76:1 196:1 561:1 952:1 1158:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Loss))(NN (hepatocyte))(NN (growth))(NN (factor/c-Met))(NN (signaling))(NN (pathway)))(VP (VBZ (accelerates))(SBAR (S (NP (JJ (early))(NN (stage))(NN (N-nitrosodiethylamine)))(VP (VBD (induced))(NP (NN (hepatocarcinogenesis)))))))) |ET|  |BS| 45:G07.700.320.249 69:G02.111.087.800 126:G02.111.087.800 262:A11.436.348 554:D02.654.442.200  |ES| 19:1 102:1 195:1 383:1 412:1 529:1 900:1 1128:1 1129:1 1788:1 1909:1 2602:1 4289:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (NNP (Bromelain)))(VP (VBZ (exerts))(NP (NP (JJ (antiproliferative))(JJ (proapoptotic))(NN (effect)))(JJ (colorectal))(NN (carcinoma))(NN (cell))(JJ (chemopreventive))(NN (action))(NN (colon))(NN (carcinogenesis)))(FW (vivo))))) |ET|  |BS| 5:C04.588.274.476.411.307 33:C04.697.098 41:A11 46:A03.556.124.526.356 679:D08.811.277.656.262.500.096  |ES| 17:1 19:1 75:1 94:1 104:1 113:1 207:1 304:1 378:1 1882:1 1885:1 1946:1 1977:1 2013:1 3120:1 3359:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Honokiol)))(VP (VP (VBZ (activates))(NP (JJ (AMP-activated))(NN (protein))(NN (kinase))(NN (breast))(NN (cancer))(NN (cell)))(PP (IN (via))(NP (JJ (LKB1-dependent))(NN (pathway)))))(VP (VBZ (inhibits))(NP (NN (breast))(NN (carcinogenesis)))))) |ET|  |BS| 10:A01.236 33:C04.697.098 41:A11 122:C14.280.383 1009:D08.811.913.696.620.682.700.085  |ES| 4:1 18:1 19:1 23:1 94:1 207:1 301:1 383:1 470:1 596:1 615:1 3533:1 3534:1 3535:1  |EV| 
-4.1182648571045206153939943760633  |BT| (S (NP (NP (NNP (Alternol)))(, (,))(NP (JJ (natural))(NN (compound)))(, (,)))(VP (VBZ (exerts))(NP (NP (JJ (anti-tumour))(NN (effect))(NN (osteosarcoma)))(VP (VBG (modulating))(NP (NN (STAT3))(NN (ROS/MAPK))(NN (signalling))(NN (pathway))))))) |ET|  |BS| 12:Z01.542.049 38:Z01.058.290.120.180 40:Z01.542.248.700 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650 666:G02.111.087.800.560  |ES| 2:1 19:1 75:1 251:1 383:1 1562:1 1977:1 2333:1 2432:1 2433:1 2434:1 2435:1 2436:1 2437:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (BACKGROUND))(: (:)))(NP (NP (JJ (Epidermal))(NN (growth))(NN (factor))(JJ (receptor-tyrosine))(NN (kinase))(NN (inhibitor)))(PRN (-LRB- (-LRB-))(NP (NN (EGFR-TKIs)))(-RRB- (-RRB-))))(VP (VBD (approved))(NP (NP (NN (patient)))(JJ (recurrent))(NP (NP (JJ (non-small))(NN (cell))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-))))))) |ET|  |BS| 50:M01.643 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 496:C23.550.291.937 634:D12.125.072.050.875  |ES| 10:1 14:1 18:1 19:1 94:1 102:1 104:1 120:1 185:1 328:1 329:1 380:1 470:1 694:1 1046:1 1753:1 2340:1 2343:1 3297:1 3298:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Down-regulation))(NN (tumor))(NN (suppressor))(NN (A))(NN (kinase))(NN (anchor))(NN (protein))(CD (12))(JJ (human))(NN (hepatocarcinogenesis))(JJ (epigenetic))(NN (mechanism)))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 206:G05.360.340.024.340.375.249 671:G05.355.315.203 823:D08.811.913.696.620.682.700.150.125  |ES| 4:1 7:1 19:1 36:1 69:1 162:1 470:1 700:1 900:1 1120:1 1603:1 3458:1 3459:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (DT (A))(JJ (diethylnitrosamine-induced))(NN (liver))(NN (cancer))(NN (model)))(VP (VBD (used))(VP (VB (evaluate))(NP (NN (role))(NN (Myc))(NN (hepatocarcinogenesis)))))) |ET|  |BS| 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 554:D02.654.442.200  |ES| 18:1 19:1 31:1 69:1 72:1 476:1 836:1 890:1 900:1 1786:1 2732:1  |EV| 
4.520134953427480617449418787146  |BT| (S (PP (IN (For))(NP (NN (example))))(, (,))(NP (NP (NN (gene))(VBN (involved))(NN (inflammation))(NN (matrix))(NN (protease))(NN (cell))(NN (cycle))(NN (regulator))(NN (gene)))(, (,))(NP (NN (cyclin))(NN (D2)))(, (,)))(ADVP (RB (highly)))(VP (VBN (expressed))(NP (NN (colon))(NN (cancer))))) |ET|  |BS| 6:G05.360.340.024.340 525:C23.550.470 995:D12.644.360.262.150.200 996:G05.360.340.024.340.220 997:D08.811.277.656.300 998:D08.811.277.656  |ES| 2:1 6:1 9:1 18:1 19:1 94:1 113:1 235:1 601:1 626:1 743:1 774:1 3064:1 3489:1 3490:1 3491:1 3492:1 3493:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (JJ (Inhibitory))(NN (effect))(JJ (oleanolic))(NN (acid))(JJ (hepatocellular))(NN (carcinoma)))(PP (IN (via))(NP (NP (JJ (ERK-p53-mediated))(NN (cell))(NN (cycle))(NN (arrest)))(NP (JJ (mitochondrial-dependent))(NN (apoptosis))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 772:D02.455.849.919.530.733 773:G04.299.134.109  |ES| 19:1 75:1 89:1 94:1 303:1 304:1 596:1 601:1 602:1 1275:1 2713:1 2714:1 2715:1 2716:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (ADJP (RB (Orally))(VBN (administered)))(NN (lycopene)))(VP (VBZ (attenuates))(NP (NP (JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(NN (rat)))(VP (VBG (modulating))(NP (NP (NN (Nrf-2)))(: (/))(NP (NN (HO-1))(NN (Akt/mTOR))(NN (pathway)))))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534  |ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (DT (The))(JJ (objective))(NN (study)))(VP (VBD (determine))(SBAR (S (NP (NP (NP (NP (JJ (chemopreventive))(NN (activity))(JJ (Korean))(JJ (red))(NN (ginseng))(NN (extract)))(PRN (-LRB- (-LRB-))(NP (NN (KRG)))(-RRB- (-RRB-))))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(VP (VBD (induced))(NP (NN (hepatocarcinogenesis))(NN (rat)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 415:F01.658.500 554:D02.654.442.200 1162:B01.650.940.800.575.100.087.500  |ES| 10:1 14:1 19:1 74:1 131:1 399:1 412:1 691:1 849:1 900:1 1634:1 1875:1 1946:1 1952:1 2496:1 2916:1 4014:1 4015:1 4016:1  |EV| 
4.520134953427480617449418787146  |BT| (S (S (VP (VBG (Mounting))(NP (NN (evidence)))))(VP (VBP (underline))(NP (NP (NP (NP (NP (NP (NN (role))(JJ (inducible))(JJ (nitric))(NN (oxide))(NN (synthase)))(PRN (-LRB- (-LRB-))(NP (NN (iNOS)))(-RRB- (-RRB-))))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))(NN (development)))(, (,))(NP (JJ (functional))(NN (interaction))(NN (pathway))))(VP (VBN (involved))(NP (NNP (HCC))(NN (progression)))))(VP (VBP (remain))(ADJP (JJ (uninvestigated)))))) |ET|  |BS| 15:F01.829.316.616 16:C23.550.291.656 22:D08.811.682.664.500.772.500 104:C04.557.470.200.025.255  |ES| 2:1 10:1 14:1 19:1 31:1 35:1 38:1 48:1 63:1 64:1 65:1 66:1 67:1 303:1 304:1 383:1 415:1 441:1 618:1 774:1 2181:1 3207:1 3208:1 3209:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (Overexpression))(NN (5-lipoxygenase))(NN (colon))(NN (polyp))(NN (cancer))(NN (effect))(NN (5-LOX))(NN (inhibitor))(NN (vitro))(JJ (murine))(NN (model)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 548:D08.811.682.664.500.848 1055:D08.811.682.690.416.583.625 1056:C23.300.825.411.235  |ES| 18:1 19:1 72:1 75:1 113:1 216:1 380:1 627:1 647:1 668:1 3390:1 3684:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (ADVP (RB (Hence)))(, (,))(NP (NN (chloroform)))(VP (VBD (prevented))(SBAR (S (NP (NN (hypomethylation)))(VP (VBD (increased))(NP (NP (NN (mRNA)))(NN (expression))(NN (c-myc))(NN (gene))(NN (promotion))(NN (liver))(NN (tumor))(NN (DCA)))(, (,))(S (VP (VBG (enhancing))(NP (JJ (DCA-promotion))(NN (kidney))(NN (tumor)))))))))) |ET|  |BS| 111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224  |ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NNP (Chitinase))(JJ (3-like))(CD (1)))(VP (VBZ (promotes))(NP (NN (macrophage))(NN (recruitment))(NN (angiogenesis))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 658:A11.329.372 951:D08.811.277.450.207  |ES| 17:1 18:1 19:1 98:1 298:1 2402:1 2502:1 3325:1 3326:1 3327:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (PRP$ (Our))(VBP (result)))(VP (VBP (indicate))(SBAR (S (NP (NNP (Lrat))(NNP (KO))(NN (mouse)))(NP (DT (le))(JJ (susceptible))(JJ (DEN-induced))(NN (hepatocarcinogenesis)))(ADVP (RB (due)))(VP (VBD (increased))(NP (ADJP (NP (NN (retinoid))(NN (signaling)))(JJR (higher)))(NN (expression))(NN (p21)))(, (,))(SBAR (S (NP (NP (VBN (accompanied))(JJ (altered))(JJ (hepatic))(NN (level)))(JJ (DEN-activating))(NN (enzyme))(NNP (MGMT))(NNP (Lrat))(NNP (KO))(NN (mouse)))(ADVP (RB (also)))(VP (VBP (contribute))(SBAR (S (NP (VBN (decreased))(NN (cancer))(NN (initiation)))(VP (VBD (suppressed))(NP (NN (liver))(NN (tumor))(NN (development)))))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 515:C04.588.274.623 649:E01.370.225.124.200 711:D02.455.326.271.665.202.495 807:D08.811.913.555.500.800.650  |ES| 2:1 5:1 7:1 18:1 19:1 35:1 47:1 52:1 101:1 115:1 170:1 195:1 202:1 249:1 307:1 450:1 637:1 658:1 693:1 836:1 838:1 899:1 900:1 1135:1 1479:1 2388:1 2573:1 2735:1 2801:1 2848:1 2849:1 2850:1 2851:1 2852:1 2853:1  |EV| 
4.520134953427480617449418787146  |BT| (NP (NP (NN (INTRODUCTION)))(: (:))(S (NP (NN (Protein))(NN (tyrosine))(NN (kinase)))(NP (CD (6))(-LRB- (-LRB-))(NN (PTK6))(-RRB- (-RRB-))(JJ (non-receptor))(NN (tyrosine))(NN (kinase)))(ADVP (RB (highly)))(VBD (expressed))(NP (NP (JJ (Human))(NNP (Epidermal))(NN (Growth))(NN (Factor))(CD (2)))(PRN (-LRB- (-LRB-))(CC (+))(-RRB- (-RRB-))))(-LRB- (-LRB-))(NP (NP (NN (Her2))(PRN (-LRB- (-LRB-))(CC (+))(-RRB- (-RRB-))(-RRB- (-RRB-)))(NN (breast))(NN (cancer)))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 923:D06.472.317.350 987:D08.811.913.696.620.682.725.400  |ES| 6:1 10:1 14:1 18:1 19:1 23:1 104:1 148:1 444:1 470:1 535:1 626:1 1041:1 1044:1 1219:1 2340:1 2341:1 2911:1 3059:1 3529:1 3608:1 3609:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (DT (The))(JJ (present))(NN (study)))(VP (VBN (designed))(VP (VB (determine))(SBAR (IN (whether))(S (NP (NN (alteration))(NN (expression))(NN (RXRalpha))(NN (retinoid))(NN (receptor))(NN (RARalpha))(NN (RARbeta)))(VP (VBN (involved))(NP (NP (NN (hepatocarcinogenesis)))(VP (VBG (using))(NP (NP (NP (CD (3))('' ('))(: (-))(NN (methyl-4-dimethylaminoazobenzene))(-LRB- (-LRB-))(CD (3))('' ('))(: (-)))(NP (NN (MeDAB))(-RRB- (-RRB-))(: (-))))(VP (VBN (induced))(NP (NN (rat))(NN (liver))(NN (carcinogenesis))(NN (model))))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1163:D02.092.146.325.500 1164:D12.776.826.701  |ES| 10:1 14:1 19:1 72:1 74:1 115:1 131:1 186:1 207:1 221:1 350:1 409:1 691:1 774:1 836:1 849:1 900:1 951:1 1307:1 1683:1 2573:1 4017:1 4018:1 4019:1 4020:1 4021:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NP (NN (Glutathione))(NN (S-transferase))(JJ (placental))(-LRB- (-LRB-))(NN (GST-P))(-RRB- (-RRB-)))(: (-))(NP (NP (JJ (negative))(JJ (hepatocellular))(JJ (altered))(NN (focus)))(PRN (-LRB- (-LRB-))(NP (NN (HAF)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (hepatocellular))(NN (adenoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCA)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(VP (VBD (generated))(NP (NP (NP (NP (CD (two))(JJ (initiation-promotion))(NN (model))(NN (N-nitrosodiethylamine)))(PRN (-LRB- (-LRB-))(NP (NN (NDEN)))(-RRB- (-RRB-))))(NP (NN (peroxisome))(NNS (proliferators))))(, (,))(NP (NN (Wy-14,643))(NN (clofibrate))))))) |ET|  |BS| 104:C04.557.470.200.025.255 554:D02.654.442.200 780:D08.811.913.225.500 783:A16.710 910:D02.241.081.114.968.500.500.195 912:D27.888.569.100.675 1194:C04.557.470.035.120  |ES| 2:1 10:1 14:1 19:1 42:1 72:1 73:1 303:1 304:1 441:1 693:1 933:1 1431:1 1887:1 2446:1 2602:1 2743:1 2745:1 3058:1 3200:1 4167:1 4168:1 4169:1 4170:1 4171:1 4172:1 4173:1  |EV| 
4.520134953427480617449418787146  |BT| (S (NP (NN (Histone))(NN (deacetylase))(CD (6))(NN (function))(NN (tumor))(NN (suppressor)))(VP (VBG (activating))(NP (NN (c-Jun))(JJ (NH2-terminal))(JJ (kinase-mediated))(NN (beclin))(JJ (1-dependent))(JJ (autophagic))(NN (cell))(NN (death))(NN (liver))(NN (cancer))))) |ET|  |BS| 206:G05.360.340.024.340.375.249 771:D08.811.913.696.620.682.700.567.374 1007:G04.299.139.399 1008:D08.811.277.087.520  |ES| 7:1 18:1 19:1 33:1 94:1 411:1 504:1 700:1 836:1 1686:1 1958:1 2140:1 2708:1 3528:1 3529:1 3530:1 3531:1 3532:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (ADJP (RB (Orally))(VBN (administered)))(NN (lycopene)))(VP (VBZ (attenuates))(NP (NP (JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(NN (rat)))(VP (VBG (modulating))(NP (NP (NN (Nrf-2)))(: (/))(NP (NN (HO-1))(NN (Akt/mTOR))(NN (pathway)))))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534  |ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (NN (Colon))(NN (cancer))(NN (cell))(JJ (treated))(NNS (SDs)))(VP (VBD (exhibited))(NP (VBN (reduced))(NN (Wnt))(JJ (transcriptional))(NN (activity)))(, (,))(VP (ADVP (RB (well)))(VBN (reduced)))(NP (JJ (nuclear))(NN (beta-catenin))(NN (localization))(JJ (subsequent))(NN (reduction))(NN (active-beta-catenin))(NN (level))))) |ET|  |BS| 23:D12.776.091.249 41:A11 52:E02 175:J01.897.280.500.269 209:G02.111.087.847  |ES| 2:1 18:1 19:1 60:1 94:1 249:1 370:1 399:1 452:1 559:1 609:1 787:1 877:1 1099:1 1256:1 1319:1 2482:1 2483:1 2484:1 2485:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (PP (IN (In))(NP (NN (addition))))(, (,))(NP (NN (alpha-mangostin)))(VP (MD (may))(VP (VB (chemopreventive))(NP (NP (NN (benefit)))(CC (and/or))(VP (VB (prove))(NP (NP (JJ (useful))(JJ (adjuvant))(NN (therapy)))(, (,))(NP (JJ (complementary))(NN (alternative))(NN (medicine))(NN (treatment))(NN (breast))(NN (cancer))))))))) |ET|  |BS| 52:E02 685:D27.505.696.477.067 687:D26.650.064 750:E02.190  |ES| 2:1 18:1 19:1 23:1 130:1 149:1 244:1 468:1 491:1 546:1 1036:1 1946:1 2246:1 2327:1 2479:1 2619:1 2669:1 2670:1 2671:1  |EV| 
-4.520134953427480617449418787146  |BT| (S (NP (JJ (Anthocyanin-containing))(JJ (purple-fleshed))(NN (potato)))(VP (VBP (suppress))(NP (NP (NN (colon))(NN (tumorigenesis)))(PP (IN (via))(NP (NN (elimination))(NN (colon))(NN (cancer))(NN (stem))(NN (cell))))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 308:A11.872 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087  |ES| 18:1 19:1 78:1 94:1 113:1 156:1 596:1 1106:1 2438:1 2439:1 2440:1 2441:1  |EV| 
-4.520134953427480617449418787146  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(NP (DT (These))(VBP (result))(NP (VBN (suggested))(NN (TFA))(VBD (protected))(ADJP (NN (mouse))(JJ (CCl4-induced))(ADJP (NN (liver))(NN (injury))(JJ (antioxidant)))(NN (stress))(JJ (antiinflammatory)))(NN (effect))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217  |ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1  |EV| 
-0.79218617459662254987051710486412  |BT| (S (ADVP (RB (Moreover)))(, (,))(S (VP (VBG (using))(NP (NP (NN (mouse))(NN (xenograft))(NN (model)))(, (,))(NP (NN (show))(NN (treatment))(JJ (specific))(NNP (PPOX))(NN (inhibitor))(NN (acifluorfen))))))(ADVP (RB (significantly)))(VP (VBD (reduced))(NP (NP (NP (NP (NN (growth))(CD (three))(CD (seven)))(PRN (-LRB- (-LRB-))(NP (CD (42.8))(NN (%)))(-RRB- (-RRB-))))(NN (colon))(NN (cancer))(NN (line)))(NP (VBN (investigated)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875  |ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 102:1 113:1 124:1 264:1 265:1 350:1 369:1 380:1 403:1 429:1 452:1 482:1 540:1 546:1 622:1 1733:1 2770:1 2771:1 2772:1  |EV| 
-0.019631721498328147390566300600767  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NP (NP (NN (dioscin))(NN (show))(JJ (excellent))(JJ (protective))(NN (effect)))(JJ (ethanol-induced))(NN (liver))(NN (injury)))(S (VP (VBG (ameliorating))(NP (NP (JJ (ethanol-induced))(JJ (oxidative))(NN (stress)))(, (,))(NP (JJ (mitochondrial))(NN (function)))(, (,)))(NP (NP (JJ (inflammatory))(NP (NN (cytokine)))(NN (production)))(, (,))(NP (NN (apoptosis))(NN (liver))(NN (steatosis)))(, (,))))))(VP (VBD (developed))(NP (JJ (new))(NN (drug))(NN (treatment))(JJ (ethanol-induced))(NN (liver))(NN (injury))(NN (future))))) |ET|  |BS| 39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241  |ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1  |EV| 
-0.0011892817603325056552421301603317  |BT| (S (NP (NN (Hepatocarcinogenesis)))(VP (VBD (induced))(ADJP (JJ (diethylnitrosamine/phenobarbital))(PRN (-LRB- (-LRB-))(NP (NN (DEN/PB)))(-RRB- (-RRB-)))))) |ET|  |BS| 554:D02.654.442.200 756:D03.383.742.698.253.650  |ES| 10:1 14:1 19:1 412:1 1959:1 4182:1 4183:1  |EV| 
